CUMULATIVE
SUPPLEMENT 7
JULY 2001



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Department of Health and Human Services
Public Health Service
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Information Technology
Division of Data Management and Services

2001

Prepared By
Division of Data Management and Services
Office of Information Technology
Center for Drug Evaluation and Research
Food and Drug Administration

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Cumulative Supplement 7

July 2001

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

CUMULATIVE SUPPLEMENT 7
JULY 2001

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 21st Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of the 21st Edition List will then be added to the "Discontinued Drug Product List" appearing in the 22nd Edition. The current edition Section 2. How To Use The Drug Product Lists describes the layout and usage of the List.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >**A**>. The Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

1.2 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively, to Merck Sharp Dohme or Zenith Labs [New Abbreviated

Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
CAMALL CO INC (CAMALL)	ABC HOLDING CORPORATION (ABC HOLDING)
KNOLL PHARMACEUTICAL COMPANY (KNOLL PHARM)	ABBOTT LABORATORIES PHARMACEUTICAL PRODUCTS (ABBOTT)
MEDEVA AMERICAS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA INC (MEDEVA)	CELLTECH PHARMACEUTICALS INC (CELLTECH PHARMS)
MEDEVA PHARMACEUTICALS CA INC (MEDEVA PHARMS CA)	CELLTECH MANUFACTURING CA INC (CELLTECH MFG CA INC)
MEDEVA PHARMACEUTICALS MA INC (MEDEVA PHARMS MA)	CELLTECH MANUFACTURING INC (CELLTECH MFG)
NOVOPHARM LTD (NOVOPHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM PHARMACEUTICAL CO (NOVOPHARM PHARM)	TEVA PHARMACEUTICALS USA (TEVA)
NOVOPHARM NC INC (NOVOPHARM NC)	TEVA PHARMACEUTICALS USA (TEVA)
ROBERTS LABORATORIES INC (ROBERTS LABS)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)
ROBERTS PHARMACEUTICAL CORP (ROBERTS PHARM)	SHIRE PHARMACEUTICAL DEVELOPMENT INC (SHIRE PHARM)

1.3 AVAILABILITY OF THE EDITION

The 21st Edition of the Orange Book and its monthly cumulative supplements are available by subscription from the Government Printing Office:

Superintendent of Documents
Government Printing Office
P.O. Box 371954
Pittsburgh, PA 15250-7954

The telephone number to charge your subscription is 202-512-1800. The cost is $101.00 annually.

The Approved Drug Products with Therapeutic Equivalence Evaluation (Orange Book) and related drug information is also available on the Internet at the Food and Drug Administration, Center for Drug Evaluation and Research, Drug Info page.

There is an Electronic Orange Book Query (EOB) at http://www.fda.gov/cder/ob. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder or applicant number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. The data is updated concurrently with the publication of the annual edition or monthly cumulative supplements.

The Internet version of the hard copy Orange Book annual edition is at http://www.fda.gov/cder/orange/adp.htm.

The Internet version of the hard copy monthly supplement is at http://www.fda.gov/cder/orange/supplement/cspreface.htm. Changes to the annual edition are listed separately by month.

There are ASCII text files of the Orange Book drug product data at http://www.fda.gov/cder/orange/obreadme.htm. The drug product text files are zipped into zipobtxt.exe. The files are updated concurrently with the publication of the annual edition or monthly cumulative supplements. Appendix A and Appendix B are updated quarterly.

The 21st annual edition of the 2000 Orange Book Patent and Exclusivity List is at http://www.fda.gov/cder/orange/21bookpub.pdf.

The current year Patent and Exclusivity cumulative supplement list that denotes the current month additions is at http://www.fda.gov/cder/orange/supplement/patents.pdf.

The Patent Term Extension and new Patents, Docket Number *95S-0117, is at http://www.fda.gov/cder/orange/docket.pdf. It is updated monthly as soon as available and as otherwise needed.

The Drug Price Competition and Patent Term Restoration Act requires that patent information be filed with all newly submitted Section 505 drug applications. To facilitate industry submission of the information, a patent submission sample format is available in HTML and PDF format at:
http://www.fda.gov/cder/orange/patdecl.pdf
http://www.fda.gov/cder/orange/patdecl.html

The current listing of the Orphan Product Designations and Approvals is available at http://www.fda.gov/orphan/designat/list.htm.

1.4 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2000) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 2000	MAR 2001	JUN 2001	SEP 2001
DRUG PRODUCTS LISTED	10360	10372	10155	
SINGLE SOURCE	2682 (25.9%)	2696 (26.0%)	2665 (26.2%)	
MULTISOURCE	7568 (73.1%)	7566 (72.9%)	7380 (72.7%)	
THERAPEUTICALLY EQUIVALENT	7257 (70.0%)	7263 (70.0%)	7078 (69.7%)	
NOT THERAPEUTICALLY EQUIVALENT	311 (3.0%)	303 (2.9%)	302 (3.0%)	
EXCEPTIONS[1]	110 (1.1%)	110 (1.1%)	110 (1.1%)	
NEW MOLECULAR ENTITIES APPROVED	2	6	3	
NUMBER OF APPLICANTS	594	582	579	

[1]Amino acid-containing products of varying composition (see Introduction, page xx of the List).

1.5 CUMULATIVE SUPPLEMENT LEGEND

The 21st Edition Orange book (OB) Cumulative Supplement (CS) layout has changed. The new format follows the Annual Edition and previous CS format. The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form;Route and then by trade name. The manner of displaying the individual product information has changed.

The individual product record follows the previous format layout for Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Approval number, product number, and approval date. Two new columns have been added to provide more information. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form;route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product throuth the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.
WDAG	Withdrawn. The applicant holder has notified the FDA in writing that the product in no longer being marketed resulting in the product approval being withdrawn by mutual agreement. The product will be listed in the Discontinued Section.
WDRP	Withdrawn. The application approval has been withdrawn for failure to provide Annual Reports. The product will be moved to the Discontinued Section in the next edition.

1.6 CHANGE OF A THERAPEUTIC EQUIVALENT CODE FOR A DRUG ENTITY

Metaxalone tablets were reviewed in the Drug Efficacy Study Implementation program. FDA published a Federal Register notice on August 15, 1974 (39 FR 29396) finding metaxalone tablets to be effective in the treatment of discomfort associated with acute, painful musculo-skeletal conditions. The Federal Register notice did not require the conduct of a bioavailability/bioequivalence study as a condition of marketing.

On March 6, 2001, URL Mutual Pharmaceutical Co. Inc submitted a citizen petition (Docket No. 01P-0117/CP1) asking FDA to reclassify the drug product metaxalone tablets from one not presenting bioequivalence problems to one that requires an in vivo demonstration of bioequivalence as a condition of approval for an ANDA. To support these assertions, the petition included results of two in vivo bioequivalence fasting studies and three separate in vitro dissolution tests. After a careful review of the data submitted by Mutual, the agency agreed that the firm has demonstrated a lack of correlation between in vitro dissolution and in vivo bioequivalence data of oral metaxalone tablets in two bioequivalence studies. The failure of both Mutual formulations to meet the 90% confidence intervals further supports the lack of in vitro/in vivo correlations.

Therefore, in accordance with our policy as enunciated in Section 1.9 of the Introduction to the 21st Edition of the Orange Book, we are providing a 60 day period in which interested parties may submit comments. The closing date for the comments will be November 30, 2001. The comments should be sent to the Director, Division of Bioequivalence, Office of Generic Drugs, Center for Drug Evaluation and Research, (MPN-2) HFD-650, 7500 Standish Place, Rockville, MD 20855. These comments should include scientific data either supporting or disagreeing with our proposal to change the therapeutic equivalence category for metaxalone tablets from a "non bioproblem" to a "bioproblem" drug.

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE

		@ MIKART	150MG;180MG;15MG	N81095 001	OCT 26, 1990	MAY	DISC
		@	150MG;180MG;60MG	N81097 001	OCT 26, 1990	MAY	DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL

TRIAPRIN

		@ DUNHALL	325MG;50MG	N89268 001	JUL 02, 1987	FEB	WDRP

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

		@ ROBERTS AND HAUCK	325MG;50MG;40MG	N87628 001	OCT 01, 1986	FEB	WDRP

TABLET; ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A>	AB	ABLE	325MG;50MG;40MG	N40390 001	JUL 23, 2001	JUL	NEWA
>A>	AB		500MG;50MG;40MG	N40394 001	JUL 23, 2001	JUL	NEWA

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL; ACETAMINOPHEN; AND CAFFEINE WITH CODEINE PHOSPHATE

	AB	WEST WARD	325MG;50MG;40MG;30MG	N75618 001	MAR 23, 2001	MAR	NEWA

FIORICET W/ CODEINE

	AB	+ NOVARTIS	325MG;50MG;40MG;30MG	N20232 001	JUL 30, 1992	MAR	CFTG

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

TABLET; ORAL

ACETAMINOPHEN, CAFFEINE, AND DIHYDROCODEINE BITARTRATE

		+ MIKART	712.8MG;60MG;32MG	N40316 001	APR 28, 1999	JAN	CTNA

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

	AA	MALLINCKRODT	300MG;15MG	N40419 001	MAY 31, 2001	MAY	NEWA
	AA		300MG;30MG	N40419 002	MAY 31, 2001	MAY	NEWA
	AA		300MG;60MG	N40419 003	MAY 31, 2001	MAY	NEWA

CAPITAL WITH CODEINE

		@ CARNRICK	325MG;30MG	N83643 001	MAY 31, 1974	FEB	WDRP

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION; ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	AA	MALLINCKRODT	500MG/15ML;7.5MG/15ML	N40418 001	JUN 27, 2001	JUN	NEWA
	AA	+ MIKART	500MG/15ML;7.5MG/15ML	N81051 001	AUG 28, 1992	JUN	CDFR
			500MG/15ML;5MG/15ML	N81226 001	OCT 27, 1992	JUN	CDFR
		+	500MG/15ML;5MG/15ML	N89557 001	APR 29, 1992	JUN	CDFR
	AA	PHARM ASSOC	500MG/15ML;7.5MG/15ML	N40182 001	MAR 13, 1998	JUN	CDFR

TABLET; ORAL

>D>	AA	+ WATSON LABS	325MG;7.5MG	N40248 001	APR 28, 2000	JUL	DISC
>A>		+	325MG;7.5MG	N40248 001	APR 28, 2000	JUL	DISC

	+		750MG;10MG	N40094 004	MAR 22, 1999	APR	NEWA
		LORTAB					
	AA	+ WATSON LABS	325MG;5MG	N40099 001	JUN 25, 1997	JAN	CAHN
		NORCO					
>D>	AA	WATSON LABS	325MG;7.5MG	N40148 003	SEP 12, 2000	JUL	CRLD
>A>			325MG;7.5MG	N40148 003	SEP 12, 2000	JUL	CRLD
	AA		325MG;7.5MG	N40148 003	SEP 12, 2000	APR	NEWA
		ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE					
		TABLET; ORAL					
		PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN					
>A>	AB	ABLE	650MG;100MG	N75838 001	JUL 11, 2001	JUL	NEWA
		@ HALSEY	325MG;50MG	N70115 001	JUN 12, 1985	MAY	DISC
		@	650MG;100MG	N70116 001	JUN 12, 1985	MAY	DISC
	AB	MALLINCKRODT	650MG;100MG	N75738 001	FEB 02, 2001	FEB	NEWA
	AB	VINTAGE PHARMS	325MG;50MG	N74843 002	FEB 15, 2001	FEB	NEWA
		ACYCLOVIR SODIUM					
		INJECTABLE; INJECTION					
		ACYCLOVIR					
	AP	GENSIA SICOR PHARMS	EQ 50MG BASE/ML	N75627 001	MAR 28, 2001	MAR	NEWA
		ALBUTEROL					
		AEROSOL, METERED; INHALATION					
		ALBUTEROL					
	AB	ARMSTRONG PHARMS	0.09MG/INH	N72273 001	AUG 14, 1996	JUN	CAHN
		ALBUTEROL SULFATE					
		AEROSOL, METERED; INHALATION					
		VENTOLIN HFA					
	+	GLAXO	EQ 0.09MG BASE/INH	N20983 001	APR 19, 2001	APR	NEWA
>D>		CAPSULE; INHALATION					
>D>		VENTOLIN ROTACAPS					
>D>	+	GLAXO WELLCOME	EQ 0.2MG BASE	N19489 001	MAY 04, 1988	JUL	DISC
>A>		@	EQ 0.2MG BASE	N19489 001	MAY 04, 1988	JUL	DISC
		SOLUTION; INHALATION					
		ACCUNEB					
	+	DEY	EQ 0.021% BASE	N20949 002	APR 30, 2001	APR	NEWA
	+		EQ 0.042% BASE	N20949 001	APR 30, 2001	APR	NEWA
		ALBUTEROL SULFATE					
	AN	NEPHRON	EQ 0.5% BASE	N75664 001	JUN 26, 2001	JUN	NEWA
	AN +	@ ROXANE	EQ 0.083% BASE	N75129 001	FEB 13, 2001	FEB	NEWA
>D>		VENTOLIN					
>D>	AN +	GLAXO WELLCOME	EQ 0.083% BASE	N19773 001	APR 23, 1992	JUL	DISC
>A>		@	EQ 0.083% BASE	N19773 001	APR 23, 1992	JUL	DISC
>D>	AN +		EQ 0.5% BASE	N19269 002	JAN 16, 1987	JUL	DISC
>A>		@	EQ 0.5% BASE	N19269 002	JAN 16, 1987	JUL	DISC
		TABLET; ORAL					
		@ GLAXO WELLCOME	EQ 2MG BASE	N19112 001	JUL 10, 1986	JUN	DISC
		@	EQ 4MG BASE	N19112 002	JUL 10, 1986	JUN	DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

DUONEB

+	DEY	EQ 0.083% BASE;0.017%	N20950 001	MAR 21, 2001	MAR	NEWA

ALLOPURINOL

TABLET; ORAL

ZYLOPRIM

AB	PROMETHEUS LABS	100MG	N16084 001	AUG 19, 1966	MAY	CAHN
AB +		300MG	N16084 002	JAN 14, 1974	MAY	CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL

AXERT

	PHARMACIA AND UPJOHN	EQ 6.25MG BASE	N21001 001	MAY 07, 2001	MAY	NEWA
+		EQ 12.5MG BASE	N21001 002	MAY 07, 2001	MAY	NEWA

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

	@ ABBOTT	EQ 250MG BASE/ML	N63265 001	NOV 30, 1994	APR	DISC
	@	EQ 250MG BASE/ML	N63266 001	OCT 31, 1994	APR	DISC
	@	EQ 250MG BASE/ML	N64099 001	JUN 20, 1995	MAY	DISC
	@ ELKINS SINN	EQ 250MG BASE/ML	N63275 001	MAY 18, 1992	APR	DISC

AMINOCAPROIC ACID

TABLET; ORAL

AMICAR

AB +	IMMUNEX	500MG	N15197 001	JUN 03, 1964	MAY	CFTG

AMINOCAPROIC

AB	MIKART	500MG	N75602 001	MAY 24, 2001	MAY	NEWA

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HCL

AB	BARR	200MG	N75389 001	JAN 25, 2001	JAN	NEWA
AB	TARO	200MG	N75424 001	MAR 30, 2001	MAR	NEWA

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HCL

>D>	AB	TEVA	75MG	N85030 001	NOV 22, 1976	JUL	DISC
>A>		@	75MG	N85030 001	NOV 22, 1976	JUL	DISC

AMOXICILLIN

CAPSULE; ORAL

AMOXICILLIN

	@ LABS ATRAL	250MG	N62528 001	AUG 07, 1985	FEB	WDRP
	@	500MG	N62528 002	AUG 07, 1985	FEB	WDRP
	@ MYLAN	250MG	N62067 001	AUG 14, 1980	APR	DISC
	@	500MG	N62067 002	AUG 14, 1980	APR	DISC
	@ TEVA	250MG	N63030 001	FEB 28, 1989	APR	DISC

@	500MG	N63031 001	FEB 28, 1989	APR	DISC	
TRIMOX						
@ APOTHECON	250MG	N63099 001	MAR 20, 1992	APR	DISC	
@	500MG	N63099 002	MAR 20, 1992	APR	DISC	
WYMOX						
@ WYETH AYERST	250MG	N62120 001	APR 28, 1978	APR	DISC	
@	500MG	N62120 002	APR 28, 1978	APR	DISC	
FOR SUSPENSION; ORAL						
TRIMOX						
@ APOTHECON	50MG/ML	N61886 001	DEC 09, 1974	MAY	DISC	
@	125MG/5ML	N61886 002	DEC 09, 1974	MAY	DISC	
@	250MG/5ML	N61886 003	DEC 09, 1974	MAY	DISC	
AMOXICILLIN; CLAVULANATE POTASSIUM						
FOR SUSPENSION; ORAL						
AUGMENTIN ES-600						
+ GLAXOSMITHKLINE	600MG/5ML;EQ 42.9MG BASE/5ML	N50755 001	JUN 22, 2001	JUN	NEWA	
AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE						
TABLET; ORAL						
ADDERALL 7.5						
SHIRE LABS	1.875MG;1.875MG;1.875MG;1.875MG	N11522 011	AUG 31, 2000	APR	CTEC	
AMPHOTERICIN B						
INJECTABLE; INJECTION						
AMPHOTERICIN B						
@ ABBOTT	50MG/VIAL	N64141 001	DEC 23, 1996	MAY	DISC	
INJECTABLE, LIPID COMPLEX; INJECTION						
AMPHOTEC						
+ INTERMUNE PHARMS	50MG/VIAL	N50729 001	NOV 22, 1996	FEB	CAHN	
+	100MG/VIAL	N50729 002	NOV 22, 1996	FEB	CAHN	
AMPICILLIN SODIUM						
INJECTABLE; INJECTION						
AMPICILLIN SODIUM						
@ ELKINS SINN	EQ 125MG BASE/VIAL	N62692 001	JUN 24, 1986	MAY	DISC	
@	EQ 250MG BASE/VIAL	N62692 002	JUN 24, 1986	MAY	DISC	
@	EQ 500MG BASE/VIAL	N62692 003	JUN 24, 1986	MAY	DISC	
@	EQ 1GM BASE/VIAL	N62692 004	JUN 24, 1986	MAY	DISC	
@	EQ 2GM BASE/VIAL	N62692 005	JUN 24, 1986	MAY	DISC	
@	EQ 10GM BASE/VIAL	N62692 006	JUN 24, 1986	MAY	DISC	
@ HANFORD GC	EQ 125MG BASE/VIAL	N63143 001	APR 15, 1993	APR	DISC	
@	EQ 250MG BASE/VIAL	N63145 001	APR 15, 1993	APR	DISC	
@	EQ 500MG BASE/VIAL	N63146 001	APR 15, 1993	APR	DISC	
@	EQ 500MG BASE/VIAL	N63147 001	APR 15, 1993	APR	DISC	
@	EQ 1GM BASE/VIAL	N62772 001	APR 15, 1993	MAY	DISC	
@	EQ 1GM BASE/VIAL	N63139 001	APR 15, 1993	APR	DISC	
@	EQ 2GM BASE/VIAL	N63140 001	APR 15, 1993	APR	DISC	
@	EQ 2GM BASE/VIAL	N63141 001	APR 15, 1993	APR	DISC	
@	EQ 10GM BASE/VIAL	N63142 001	APR 15, 1993	APR	DISC	

	@ IBI	EQ 125MG BASE/VIAL	N62797 001	JUL 12, 1993	MAY	DISC
	@	EQ 2GM BASE/VIAL	N62797 002	JUL 12, 1993	MAY	DISC
>D> AP	MARSAM	EQ 10GM BASE/VIAL	N62994 001	SEP 15, 1988	JUL	DISC
>A>	@	EQ 10GM BASE/VIAL	N62994 001	SEP 15, 1988	JUL	DISC
	OMNIPEN-N					
	@ WYETH AYERST	EQ 125MG BASE/VIAL	N62718 001	DEC 16, 1986	MAY	DISC
	@	EQ 250MG BASE/VIAL	N62718 002	DEC 16, 1986	MAY	DISC
	@	EQ 500MG BASE/VIAL	N62718 003	DEC 16, 1986	MAY	DISC
	@	EQ 1GM BASE/VIAL	N62718 004	DEC 16, 1986	MAY	DISC
	@	EQ 2GM BASE/VIAL	N62718 005	DEC 16, 1986	MAY	DISC
	TOTACILLIN-N					
>D> AP	SMITHKLINE BEECHAM	EQ 10GM BASE/VIAL	N60677 006	MAY 04, 1976	JUL	CTEC
>A>		EQ 10GM BASE/VIAL	N60677 006	MAY 04, 1976	JUL	CTEC

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

AMPICILLIN TRIHYDRATE						
@ BIOCHEMIE	EQ 250MG BASE	N64082 001	AUG 29, 1995	MAY	DISC
@	EQ 500MG BASE	N64082 002	AUG 29, 1995	MAY	DISC

FOR SUSPENSION; ORAL

@ MYLAN	EQ 125MG BASE/5ML	N61829 002	JUL 29, 1974	MAY	DISC
@	EQ 250MG BASE/5ML	N61829 001	JUL 29, 1974	MAY	DISC
TOTACILLIN					
@ SMITHKLINE BEECHAM	EQ 125MG BASE/5ML	N60666 001	MAY 07, 1970	FEB	WDRP
@	EQ 250MG BASE/5ML	N60666 002	MAY 07, 1970	FEB	WDRP

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

FOR SUSPENSION; ORAL

PROBAMPACIN						
@ TEVA	EQ 3.5GM BASE/BOT;1GM/BOT	N61741 001	OCT 10, 1973	MAY	DISC

ARBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

GENESA						
@ GENSIA AUTOMEDICS	0.05MG/ML	N20420 001	SEP 12, 1997	MAR	DISC

ARDEPARIN SODIUM

INJECTABLE; INJECTION

NORMIFLO						
>A> @ PHARMACIA AND UPJOHN	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	JUL	CAHN
>A> @	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	JUL	CAHN
>D> @ WYETH AYERST	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	JUL	CAHN
@	5,000 UNITS/0.5ML	N20227 002	MAY 23, 1997	MAY	DISC
>D> @	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	JUL	CAHN
@	10,000 UNITS/0.5ML	N20227 001	MAY 23, 1997	MAY	DISC

ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K

INJECTABLE; IV (INFUSION)

INFUVITE PEDIATRIC		
+ SABEX	80MG/VIAL;0.02MG/VIAL;400 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14MG/VIAL;17MG/VIAL;	

			1MG/VIAL;1.4MG/VIAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL	N21265 001	FEB 21, 2001	FEB	NEWA
		ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PHYTONADIONE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E					
		FOR SOLUTION; IV (INFUSION)					
		M.V.I. PEDIATRIC					
	+	ASTRAZENECA	80MG/VIAL;0.02MG/VIAL;0.001MG/VIAL;5MG/VIAL;0.01MG/VIAL;0.14MG/VIAL;17MG/VIAL;0.2MG/VIAL;1MG/VIAL;1.4MG/VIAL;EQ 1.2MG BASE/VIAL;0.7MG/VIAL;7MG/VIAL	N18920 001	SEP 21, 2000	FEB	NEWA
		ASPIRIN; BUTALBITAL; CAFFEINE					
		TABLET; ORAL					
>D>		LANORINAL					
>D>	AB	LANNETT	325MG;50MG;40MG	N86986 002	OCT 18, 1985	JUL	DISC
>A>		@	325MG;50MG;40MG	N86986 002	OCT 18, 1985	JUL	DISC
		ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE					
		TABLET; ORAL					
		INVAGESIC					
	AB	GENEVA PHARMS TECH	385MG;30MG;25MG	N74817 001	NOV 27, 1996	JAN	CAHN
		INVAGESIC FORTE					
	AB	GENEVA PHARMS TECH	770MG;60MG;50MG	N74817 002	NOV 27, 1996	JAN	CAHN
		ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE					
		CAPSULE; ORAL					
		PROPOXYPHENE COMPOUND 65					
		@ EON	389MG;32.4MG;65MG	N80044 002	SEP 16, 1983	MAY	DISC
		PROPOXYPHENE COMPOUND-65					
		@ GENEVA PHARMS	389MG;32.4MG;65MG	N83101 002	JUN 24, 1985	MAY	DISC
		ATENOLOL					
		TABLET; ORAL					
		ATENOLOL					
>D>	AB	GENPHARM	25MG	N74126 003	AUG 26, 1998	JUL	DISC
>A>		@	25MG	N74126 003	AUG 26, 1998	JUL	DISC
>D>	AB		50MG	N74126 001	MAR 23, 1994	JUL	DISC
>A>		@	50MG	N74126 001	MAR 23, 1994	JUL	DISC
>D>	AB		100MG	N74126 002	MAR 23, 1994	JUL	DISC
>A>		@	100MG	N74126 002	MAR 23, 1994	JUL	DISC
		ATORVASTATIN CALCIUM					
		TABLET; ORAL					
		LIPITOR					
		PFIZER	EQ 10MG BASE	N20702 001	DEC 17, 1996	MAR	CAHN
			EQ 20MG BASE	N20702 002	DEC 17, 1996	MAR	CAHN
			EQ 40MG BASE	N20702 003	DEC 17, 1996	MAR	CAHN
	+		EQ 80MG BASE	N20702 004	APR 07, 2000	MAR	CAHN

ATROPINE SULFATE
INJECTABLE; IM-IV-SC
ATROPINE SULFATE

>A>	+ ABBOTT	0.05MG/ML	N21146 002	JUL 09, 2001	JUL	NEWA
>A>		0.1MG/ML	N21146 001	JUL 09, 2001	JUL	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE
TABLET; ORAL
DIPHENOXYLATE HCL AND ATROPINE SULFATE

	@ INWOOD LABS	0.025MG;2.5MG	N85509 001	MAR 09, 1978	FEB	WDRP
	@ R AND S PHARMA	0.025MG;2.5MG	N85035 001	JUL 05, 1977	MAY	DISC
>D> AA	WEST WARD	0.025MG;2.5MG	N87765 001	MAR 15, 1982	JUL	DISC
>A>	@	0.025MG;2.5MG	N87765 001	MAR 15, 1982	JUL	DISC

DIPHENOXYLATE HCL W/ ATROPINE SULFATE

	@ PVT FORM	0.025MG;2.5MG	N85766 001	DEC 22, 1978	MAY	DISC

AURANOFIN
CAPSULE; ORAL
RIDAURA

	+ PROMETHEUS LABS	3MG	N18689 001	MAY 24, 1985	MAY	CAHN

AZATHIOPRINE
TABLET; ORAL
IMURAN

	@ PROMETHEUS LABS	25MG	N16324 002	MAR 21, 1980	MAY	CAHN
AB	+	50MG	N16324 001	MAR 20, 1968	MAY	CAHN

AZITHROMYCIN DIHYDRATE; TROVAFLOXACIN MESYLATE
FOR SUSPENSION; TABLET; ORAL
TROVAN/ZITHROMAX COMPLIANCE PAK

	@ PFIZER	EQ 1GM BASE;EQ 100MG BASE	N50762 001	DEC 18, 1998	MAY	DISC

BACITRACIN ZINC
POWDER; FOR RX COMPOUNDING
ZIBA-RX

	@ PHARMA TEK	500,000 UNITS/BOT	N61737 001	APR 26, 1973	MAY	DISC

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT; OPHTHALMIC
NEO-POLYCIN

	@ DOW PHARM	500 UNITS/GM;EQ 3.5MG BASE/GM;10,000 UNITS/GM	N60647 001	APR 19, 1954	FEB	WDRP

BENZQUINAMIDE HYDROCHLORIDE
INJECTABLE; INJECTION
EMETE-CON

	+ PFIZER	EQ 50MG BASE/VIAL	N16820 001	MAR 20, 1974	MAY	CAHN

BETAMETHASONE DIPROPIONATE
CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE

	@ CLAY PARK	EQ 0.05% BASE	N74579 001	NOV 26, 1997	APR	DISC

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	ALTANA	EQ 0.05% BASE;1%	N75502 001	JUN 05, 2001	JUN	NEWA
AB	TARO	EQ 0.05% BASE;1%	N75673 001	MAY 29, 2001	MAY	NEWA

LOTRISONE

AB	+ SCHERING	EQ 0.05% BASE;1%	N18827 001	JUL 10, 1984	MAY	CFTG

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HCL

AT	BAUSCH AND LOMB	EQ 0.5% BASE	N75630 001	APR 12, 2001	APR	NEWA

BETHANECHOL CHLORIDE

TABLET; ORAL

DUVOID

	@ WELLSPRING PHARM	10MG	N86262 001	MAR 22, 1978	JUN	CAHN
	@	25MG	N86263 001	MAR 22, 1978	JUN	CAHN
	@	50MG	N85882 003	MAR 22, 1978	JUN	CAHN

BIMATOPROST

SOLUTION/DROPS; OPHTHALMIC

LUMIGAN

	+ ALLERGAN	0.03%	N21275 001	MAR 16, 2001	MAR	NEWA

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

	+ PROMETHEUS LABS	262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	MAY	DISC
	+	262.4MG;250MG;500MG	N50719 001	AUG 15, 1996	JUN	DISC

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

AB	COPLEY PHARM	5MG	N75644 001	JUN 26, 2001	JUN	NEWA
AB		10MG	N75644 002	JUN 26, 2001	JUN	NEWA

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE

	@ APOTHECON	2.5MG;6.25MG	N75642 002	DEC 27, 2000	JUN	DISC
	@	5MG;6.25MG	N75642 001	DEC 27, 2000	JUN	DISC
	@	10MG;6.25MG	N75642 003	DEC 27, 2000	JUN	DISC
AB	TEVA	2.5MG;6.25MG	N75686 001	JAN 19, 2001	JAN	NEWA
AB		5MG;6.25MG	N75686 002	JAN 19, 2001	JAN	NEWA
AB		10MG;6.25MG	N75686 003	JAN 19, 2001	JAN	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS; OPHTHALMIC

ALPHAGAN

	@ ALLERGAN	0.5%	N20490 001	MAR 13, 1997	APR	DISC

ALPHAGAN P

BRIMONIDINE TARTRATE
SOLUTION/DROPS; OPHTHALMIC
ALPHAGAN P
\+ ALLERGAN — 0.15% — N21262 001 MAR 16, 2001 MAR NEWA

BUPIVACAINE HYDROCHLORIDE
INJECTABLE; SPINAL
MARCAINE
AP + ABBOTT — 0.75% — N18692 001 MAY 04, 1984 JUN CAHN

BUPRENORPHINE HYDROCHLORIDE
INJECTABLE; INJECTION
BUPRENEX
>D> AP + RECKITT AND COLMAN — EQ 0.3MG BASE/ML — N18401 001 DEC 29, 1981 JUL CAHN
>A> AP + RECKITT BENCKISER — EQ 0.3MG BASE/ML — N18401 001 DEC 29, 1981 JUL CAHN

BUPROPION HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
WELLBUTRIN SR
GLAXO WELLCOME — 50MG — N20358 001 OCT 04, 1996 APR CTEC
100MG — N20358 002 OCT 04, 1996 APR CTEC

BUSPIRONE HYDROCHLORIDE
TABLET; ORAL
BUSPAR
AB BRISTOL MYERS SQUIBB — 5MG — N18731 001 SEP 29, 1986 MAR CFTG
AB — 10MG — N18731 002 SEP 29, 1986 MAR CFTG
AB — 15MG — N18731 003 APR 22, 1996 MAR NEWA
AB + — 30MG — N18731 004 APR 22, 1996 JUN CFTG
BUSPIRONE HCL
AB DANBURY PHARMA — 5MG — N74253 001 MAR 28, 2001 MAR NEWA
AB — 10MG — N74253 002 MAR 28, 2001 MAR NEWA
AB MYLAN — 15MG — N75272 003 MAR 28, 2001 MAR NEWA
AB MYLAN TECHNOLOGIES — 30MG — N76008 001 JUN 28, 2001 JUN NEWA
AB PAR PHARM — 7.5MG — N75467 002 MAR 28, 2001 MAR NEWA

BUTABARBITAL SODIUM
TABLET; ORAL
BUTISOL SODIUM
\+ WALLACE LABS — 15MG — N00793 002 JUN 05, 1939 MAY CTEC
SODIUM BUTABARBITAL
@ LANNETT — 15MG — N85849 001 AUG 21, 1978 MAY DISC
@ — 30MG — N85866 001 JUL 20, 1978 MAY DISC

CALCITONIN, SALMON
INJECTABLE; INJECTION
CALCITONIN-SALMON
@ ASTRAZENECA — 200 IU/ML — N73690 001 APR 14, 1995 JUN DISC

CALCIUM ACETATE
CAPSULE; ORAL
PHOSLO
BRAINTREE — EQ 84.5MG CALCIUM — N21160 001 APR 02, 2001 APR NEWA

	+		EQ 169MG CALCIUM	N21160 002	APR 02, 2001	APR	NEWA
	CAPTOPRIL						
	TABLET; ORAL						
	CAPTOPRIL						
	AB	GENEVA PHARMS TECH	12.5MG	N74481 001	FEB 13, 1996	JAN	CAHN
	AB		25MG	N74481 002	FEB 13, 1996	JAN	CAHN
	AB		50MG	N74481 003	FEB 13, 1996	JAN	CAHN
	AB		100MG	N74481 004	FEB 13, 1996	JAN	CAHN
	CARBACHOL						
	SOLUTION; INTRAOCULAR						
	CARBASTAT						
	AT	NOVARTIS	0.01%	N73677 001	APR 28, 1995	FEB	CAHN
	CARBAMAZEPINE						
	TABLET, CHEWABLE; ORAL						
	CARBAMAZEPINE						
>A>	AB	CARACO	100MG	N75712 001	JUL 05, 2001	JUL	NEWA
	TABLET, EXTENDED RELEASE; ORAL						
	TEGRETOL-XR						
>D>	+	NOVARTIS	100MG	N20234 001	MAR 25, 1996	JUL	CRLD
>A>			100MG	N20234 001	MAR 25, 1996	JUL	CRLD
>D>	+		200MG	N20234 002	MAR 25, 1996	JUL	CRLD
>A>			200MG	N20234 002	MAR 25, 1996	JUL	CRLD
	CARBIDOPA; LEVODOPA						
	TABLET; ORAL						
	CARBIDOPA AND LEVODOPA						
	@ SCS		10MG;100MG	N74080 001	MAR 25, 1994	FEB	WDRP
	@		25MG;100MG	N74080 002	MAR 25, 1994	FEB	WDRP
	@		25MG;250MG	N74080 003	MAR 25, 1994	FEB	WDRP
	CARISOPRODOL						
	TABLET; ORAL						
	CARISOPRODOL						
	AA	ABLE	350MG	N40421 001	JUN 21, 2001	JUN	NEWA
	CASPOFUNGIN ACETATE						
	INJECTABLE; IV (INFUSION)						
	CANCIDAS						
	+	MERCK RES	50MG/VIAL	N21227 001	JAN 26, 2001	JAN	NEWA
	+		70MG/VIAL	N21227 002	JAN 26, 2001	JAN	NEWA
	CEFACLOR						
	CAPSULE; ORAL						
	CECLOR						
	AB	CEPH INTL	EQ 250MG BASE	N62205 001	JUL 28, 1979	JUN	CAHN
	AB		EQ 500MG BASE	N62205 002	JUL 28, 1979	JUN	CAHN
	FOR SUSPENSION; ORAL						
	CEFACLOR						
	@ ZENITH GOLDLINE		EQ 125MG BASE/5ML	N64087 001	APR 28, 1995	MAY	DISC
	@		EQ 187MG BASE/5ML	N64086 001	APR 28, 1995	MAY	DISC

	@	EQ 250MG BASE/5ML	N64085 001	APR 28, 1995	MAY	DISC	
	TABLET, EXTENDED RELEASE; ORAL						
	CECLOR CD						
	LILLY	EQ 375MG BASE	N50673 001	JUN 28, 1996	APR	CTEC	
AB	+	EQ 500MG BASE	N50673 002	JUN 28, 1996	JAN	CFTG	
	CEFACLOR						
AB	ZENITH GOLDLINE	EQ 500MG BASE	N65057 001	JAN 05, 2001	JAN	NEWA	
	CEFADROXIL/CEFADROXIL HEMIHYDRATE						
	TABLET; ORAL						
	CEFADROXIL						
	@ ZENITH GOLDLINE	EQ 1GM BASE	N62774 001	APR 08, 1987	MAY	DISC	
	CEFAMANDOLE NAFATE						
	INJECTABLE; INJECTION						
	MANDOL						
	@ LILLY	EQ 1GM BASE/VIAL	N62560 001	SEP 10, 1985	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N62560 002	SEP 10, 1985	MAY	DISC	
	CEFAZOLIN SODIUM						
	INJECTABLE; INJECTION						
	CEFAZOLIN SODIUM						
	@ TEVA	EQ 250MG BASE/VIAL	N63016 001	MAR 14, 1989	APR	DISC	
	@	EQ 500MG BASE/VIAL	N63016 002	MAR 14, 1989	APR	DISC	
	@	EQ 1GM BASE/VIAL	N63016 003	MAR 14, 1989	APR	DISC	
	KEFZOL						
	@ LILLY	EQ 500MG BASE/VIAL	N62557 001	SEP 10, 1985	MAY	DISC	
	@	EQ 1GM BASE/VIAL	N62557 002	SEP 10, 1985	MAY	DISC	
	CEFONICID SODIUM						
	INJECTABLE; INJECTION						
	MONOCID						
	@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N63295 001	JUL 26, 1993	APR	DISC	
	CEFOPERAZONE SODIUM						
	INJECTABLE; INJECTION						
	CEFOBID						
	@ PFIZER	EQ 1GM BASE/VIAL	N63333 001	MAR 31, 1995	MAY	DISC	
	@	EQ 2GM BASE/VIAL	N63333 002	MAR 31, 1995	MAY	DISC	
	CEFORANIDE						
	INJECTABLE; INJECTION						
	PRECEF						
	@ APOTHECON	500MG/VIAL	N62579 001	NOV 26, 1984	MAY	DISC	
	@	1GM/VIAL	N62579 002	NOV 26, 1984	MAY	DISC	
	@	2GM/VIAL	N62579 003	NOV 26, 1984	MAY	DISC	
	@	10GM/VIAL	N62579 004	NOV 26, 1984	MAY	DISC	
	@	20GM/VIAL	N62579 005	NOV 26, 1984	MAY	DISC	
	CEFOXITIN SODIUM						
	INJECTABLE; INJECTION						
>D>	MEFOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	+ MERCK	EQ 20MG BASE/ML	N50581 003	SEP 20, 1984	JUL	DISC	

>A>		@	EQ 20MG BASE/ML	N50581 003	SEP 20, 1984	JUL	DISC
>D>		+	EQ 40MG BASE/ML	N50581 004	SEP 20, 1984	JUL	DISC
>A>		@	EQ 40MG BASE/ML	N50581 004	SEP 20, 1984	JUL	DISC
		CEFTAZIDIME					
		INJECTABLE; INJECTION					
		TAZICEF					
	AP	ABBOTT	500MG/VIAL	N62662 001	MAR 06, 1986	JAN	CAHN
	AP		1GM/VIAL	N62662 002	MAR 06, 1986	JAN	CAHN
	AP		1GM/VIAL	N64032 001	OCT 31, 1993	JAN	CAHN
	AP		2GM/VIAL	N62662 003	MAR 06, 1986	JAN	CAHN
	AP		2GM/VIAL	N64032 002	OCT 31, 1993	JAN	CAHN
	AP		6GM/VIAL	N62662 004	MAR 06, 1986	JAN	CAHN
		TAZIDIME IN PLASTIC CONTAINER					
		@ LILLY	1GM/VIAL	N62739 001	JUL 10, 1986	MAY	DISC
		@	2GM/VIAL	N62739 002	JUL 10, 1986	MAY	DISC
		CEFUROXIME SODIUM					
		INJECTABLE; IM-IV					
		CEFUROXIME					
	AB	AM PHARM PARTNERS	EQ 750MG BASE/VIAL	N65001 001	MAY 30, 2001	MAY	NEWA
	AB	TEVA	EQ 750MG BASE/VIAL	N64192 002	APR 16, 1998	MAY	CDFR
		CEFUROXIME SODIUM					
	AB	HANFORD GC	EQ 750MG BASE/VIAL	N64125 001	MAY 30, 1997	MAY	CDFR
		KEFUROX					
	AB	LILLY	EQ 750MG BASE/VIAL	N62591 001	JAN 10, 1986	MAY	CDFR
		ZINACEF					
	AB +	GLAXO WELLCOME	EQ 750MG BASE/VIAL	N50558 002	OCT 19, 1983	MAY	CDFR
		INJECTABLE; INJECTION					
		CEFUROXIME					
	AP	AM PHARM PARTNERS	EQ 1.5GM BASE/VIAL	N65001 002	MAY 30, 2001	MAY	NEWA
		CEFUROXIME AND DEXTROSE IN DUPLEX CONTAINER					
	+	B BRAUN	EQ 15MG BASE/ML	N50780 001	FEB 21, 2001	FEB	NEWA
	+		EQ 30MG BASE/ML	N50780 002	FEB 21, 2001	FEB	NEWA
		KEFUROX IN PLASTIC CONTAINER					
		@ LILLY	EQ 1.5GM BASE/VIAL	N62590 002	JAN 10, 1986	MAY	DISC
		INJECTABLE; INTRAVENOUS					
		@ LILLY	EQ 750MG BASE/VIAL	N62590 001	JAN 10, 1986	MAY	DISC
		CEPHALEXIN					
		CAPSULE; ORAL					
		CEPHALEXIN					
>D>	AB	STEVENS J	EQ 500MG BASE	N62869 001	MAR 17, 1988	JUL	DISC
>A>		@	EQ 500MG BASE	N62869 001	MAR 17, 1988	JUL	DISC
		@ TEVA	EQ 500MG BASE	N62823 001	FEB 05, 1988	MAY	DISC
		KEFLEX					
	AB	CEPH INTL	EQ 250MG BASE	N62118 001	MAR 27, 1978	JUN	CAHN
	AB		EQ 500MG BASE	N62118 002	MAR 27, 1978	JUN	CAHN
		FOR SUSPENSION; ORAL					
		CEPHALEXIN					
		@ BARR	EQ 125MG BASE/5ML	N62778 001	AUG 06, 1987	MAY	DISC
>A>	AB	RANBAXY	EQ 125MG BASE/5ML	N65081 001	JUL 27, 2001	JUL	NEWA
>A>	AB		EQ 250MG BASE/5ML	N65081 002	JUL 27, 2001	JUL	NEWA

CEPHALEXIN
FOR SUSPENSION; ORAL
KEFLEX
\+ CEPH INTL — EQ 100MG BASE/ML — N62117 001 MAR 27, 1978 JUN CAHN
AB — EQ 125MG BASE/5ML — N62117 002 MAR 27, 1978 JUN CAHN
AB + — EQ 250MG BASE/5ML — N62117 003 MAR 27, 1978 JUN CAHN
TABLET; ORAL
KEFLET
>D> AB LILLY — EQ 250MG BASE — N62745 001 DEC 01, 1986 JUL DISC
>A> @ — EQ 250MG BASE — N62745 001 DEC 01, 1986 JUL DISC
>D> AB — EQ 500MG BASE — N62745 002 DEC 01, 1986 JUL DISC
>A> @ — EQ 500MG BASE — N62745 002 DEC 01, 1986 JUL DISC

CEPHALOTHIN SODIUM
INJECTABLE; INJECTION
KEFLIN IN PLASTIC CONTAINER
@ LILLY — EQ 1GM BASE/VIAL — N62549 001 SEP 10, 1985 APR DISC
@ — EQ 2GM BASE/VIAL — N62549 002 SEP 10, 1985 APR DISC

CHLORAMPHENICOL
CAPSULE; ORAL
CHLORAMPHENICOL
@ ZENITH GOLDLINE — 250MG — N62247 001 APR 28, 1980 MAY DISC
CHLOROMYCETIN
@ PARKEDALE — 50MG — N60591 001 DEC 08, 1950 MAY DISC
@ — 100MG — N60591 003 DEC 08, 1950 MAY DISC
@ — 250MG — N60591 002 DEC 08, 1950 MAY DISC
MYCHEL
\+ ARMENPHARM — 250MG — N60851 001 JUN 20, 1967 MAY CRLD
SOLUTION/DROPS; OPHTHALMIC
CHLORAMPHENICOL
@ AKORN — 0.5% — N62042 001 AUG 31, 1981 FEB WDRP
@ ALCON — 0.5% — N62628 001 SEP 25, 1985 MAY DISC
CHLOROPTIC
\+ ALLERGAN — 0.5% — N50091 001 MAR 20, 1968 MAY CTEC

CHLORDIAZEPOXIDE HYDROCHLORIDE
CAPSULE; ORAL
CHLORDIAZACHEL
@ RACHELLE — 5MG — N85086 001 MAY 11, 1976 FEB WDRP
@ — 10MG — N84639 001 MAY 11, 1976 FEB WDRP
@ — 25MG — N85087 001 MAY 11, 1976 FEB WDRP
CHLORDIAZEPOXIDE HCL
@ FERRANTE — 5MG — N85118 001 SEP 02, 1981 FEB WDRP
@ — 10MG — N85119 001 SEP 02, 1976 FEB WDRP
@ — 25MG — N85120 001 SEP 02, 1976 FEB WDRP
>D> AB GENEVA PHARMS — 5MG — N84678 001 JUN 15, 1976 JUL DISC
>A> @ — 5MG — N84678 001 JUN 15, 1976 JUL DISC
@ — 10MG — N84041 001 JUN 15, 1976 MAY DISC
@ — 25MG — N84679 002 SEP 07, 1976 MAY DISC
>D> AB IMPAX LABS — 5MG — N86213 001 JUL 10, 1979 JUL DISC
>A> @ — 5MG — N86213 001 JUL 10, 1979 JUL DISC
>D> AB — 25MG — N86212 001 JUL 10, 1979 JUL DISC

>A>		@	25MG	N86212 001	JUL 10, 1979	JUL	DISC
		@ ROSEMONT	5MG	N84644 001	FEB 24, 1976	MAY	DISC
>D>	AB		25MG	N84645 001	FEB 24, 1976	JUL	DISC
>A>		@	25MG	N84645 001	FEB 24, 1976	JUL	DISC

CHLOROQUINE PHOSPHATE

TABLET; ORAL

CHLOROQUINE PHOSPHATE

>D>	AA	TEVA	EQ 150MG BASE	N87504 001	JAN 13, 1982	JUL	DISC
>A>		@	EQ 150MG BASE	N87504 001	JAN 13, 1982	JUL	DISC

CHLOROTHIAZIDE

TABLET; ORAL

CHLOROTHIAZIDE

		@ ABC HOLDING	250MG	N85569 001	MAR 08, 1978	MAY	DISC
>D>	AB	CHELSEA LABS	250MG	N86795 001	AUG 15, 1983	JUL	DISC
>A>		@	250MG	N86795 001	AUG 15, 1983	JUL	DISC
		@ DANBURY PHARMA	250MG	N85173 001	NOV 04, 1977	MAY	DISC

CHLORPHENIRAMINE MALEATE

>D>		INJECTABLE; INJECTION					
>D>		CHLORPHENIRAMINE MALEATE					
>D>		+ STERIS	10MG/ML	N86096 001	OCT 09, 1979	JUL	DISC
>A>			10MG/ML	N86096 001	OCT 09, 1979	JUL	DISC
		TABLET; ORAL					
		@ GENEVA PHARMS	4MG	N80961 001	DEC 20, 1972	MAY	DISC
	AA	+ ICN	4MG	N80598 001	FEB 11, 1972	MAY	CRLD
		@ PHARMAVITE	4MG	N85104 001	FEB 11, 1977	FEB	WDRP
		@ WEST WARD	4MG	N83787 001	OCT 18, 1973	FEB	WDRP

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

		@ STERIS	25MG/ML	N80365 001	FEB 13, 1974	MAY	DISC

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

>D>	AB	GENEVA PHARMS	25MG	N87380 001	MAY 01, 1981	JUL	DISC
>A>		@	25MG	N87380 001	MAY 01, 1981	JUL	DISC

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

		@ DANBURY PHARMA	500MG	N81019 001	JUL 29, 1991	MAY	DISC

CIMETIDINE

TABLET; ORAL

CIMETIDINE

	AB	GENEVA PHARMS TECH	200MG	N74506 001	JAN 24, 1996	JAN	CAHN
	AB		300MG	N74506 002	JAN 24, 1996	JAN	CAHN
	AB		400MG	N74506 003	JAN 24, 1996	JAN	CAHN
	AB		800MG	N74506 004	JAN 24, 1996	JAN	CAHN

CINOXACIN
CAPSULE; ORAL
CINOBAC

>D>	AB	LILLY	250MG	N18067 001	JUN 13, 1980	JUL	CTEC
>A>			250MG	N18067 001	JUN 13, 1980	JUL	CTEC
>D>	AB	+	500MG	N18067 002	JUN 13, 1980	JUL	CTEC
>A>		+	500MG	N18067 002	JUN 13, 1980	JUL	CTEC

CINOXACIN

>D>	AB	TEVA	250MG	N73005 001	FEB 28, 1992	JUL	DISC
>A>		@	250MG	N73005 001	FEB 28, 1992	JUL	DISC
>D>	AB		500MG	N73006 001	FEB 28, 1992	JUL	DISC
>A>		@	500MG	N73006 001	FEB 28, 1992	JUL	DISC

CLINDAMYCIN HYDROCHLORIDE
CAPSULE; ORAL
CLEOCIN HCL

AB	+	PHARMACIA AND UPJOHN	EQ 300MG BASE	N50162 003	APR 14, 1988	FEB	CFTG

CLINDAMYCIN HCL

AB		RANBAXY	EQ 150MG BASE	N65061 001	FEB 02, 2001	FEB	NEWA
AB			EQ 300MG BASE	N65061 002	FEB 02, 2001	FEB	NEWA

CLINDAMYCIN PHOSPHATE
INJECTABLE; INJECTION
CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	+	PHARMACIA AND UPJOHN	EQ 18MG BASE/ML	N50639 003	APR 10, 1991	JUN	CFTG

CLINDAMYCIN PHOSPHATE

		@ ABBOTT	EQ 150MG BASE/ML	N62943 001	SEP 29, 1988	MAY	DISC
		@ ELKINS SINN	EQ 150MG BASE/ML	N62806 001	OCT 15, 1987	MAY	DISC
		@	EQ 150MG BASE/ML	N62953 001	APR 21, 1988	MAY	DISC
		@ GENSIA SICOR PHARMS	EQ 150MG BASE/ML	N63041 001	DEC 29, 1989	APR	DISC
		@	EQ 150MG BASE/ML	N63282 001	MAY 29, 1992	APR	DISC
		@ LEDERLE	EQ 150MG BASE/ML	N63068 001	AUG 28, 1989	MAY	DISC

CLINDAMYCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER

AP		ABBOTT	EQ 6MG BASE/ML	N65027 001	JUN 29, 2001	JUN	NEWA
AP			EQ 12MG BASE/ML	N65027 002	JUN 29, 2001	JUN	NEWA
AP			EQ 18MG BASE/ML	N65027 003	JUN 29, 2001	JUN	NEWA

SOLUTION; TOPICAL
CLINDAMYCIN PHOSPHATE

		@ COPLEY PHARM	EQ 1% BASE	N62944 001	JAN 11, 1989	MAY	DISC
		@ TEVA	EQ 1% BASE	N62930 001	JUN 28, 1989	MAY	DISC

CLOBETASOL PROPIONATE
CREAM; TOPICAL
CLOBETASOL PROPIONATE

AB1		STIEFEL	0.05%	N75338 001	FEB 09, 2001	FEB	NEWA

CLOMIPRAMINE HYDROCHLORIDE
CAPSULE; ORAL
ANAFRANIL

AB		TYCO HLTHCARE	25MG	N19906 001	DEC 29, 1989	JUN	CAHN
AB	+		50MG	N19906 002	DEC 29, 1989	JUN	CAHN
AB			75MG	N19906 003	DEC 29, 1989	JUN	CAHN

CLONAZEPAM
TABLET; ORAL
CLONAZEPAM

AB	CARACO	0.5MG	N75423 001	APR 27, 2001	APR	NEWA
AB		1MG	N75423 002	APR 27, 2001	APR	NEWA
AB		2MG	N75423 003	APR 27, 2001	APR	NEWA

CLORAZEPATE DIPOTASSIUM
CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

	@ ABLE	3.75MG	N71777 001	JUL 14, 1987	JAN	DISC
	@	7.5MG	N71778 001	JUL 14, 1987	JAN	DISC
	@	15MG	N71779 001	JUL 14, 1987	JAN	DISC

TABLET; ORAL

>D>	AB	GENEVA PHARMS	3.75MG	N72512 001	MAY 11, 1990	JUL	DISC
>A>		@	3.75MG	N72512 001	MAY 11, 1990	JUL	DISC

CORTISONE ACETATE
TABLET; ORAL
CORTISONE ACETATE

	@ CHELSEA LABS	25MG	N85884 001	MAY 15, 1978	MAY	DISC

CROMOLYN SODIUM
SOLUTION/DROPS; OPHTHALMIC
CROMOLYN SODIUM

AT	NOVEX	4%	N75615 001	JAN 26, 2001	JAN	NEWA

SPRAY, METERED; NASAL

>A>		ALPHARMA	5.2MG/INH	N74800 001	JUL 26, 2001	JUL	NEWA

CYCLACILLIN
TABLET; ORAL
CYCLACILLIN

	@ TEVA	250MG	N62895 001	AUG 04, 1988	MAY	DISC
	@	500MG	N62895 002	AUG 04, 1988	MAY	DISC

CYPROHEPTADINE HYDROCHLORIDE
TABLET; ORAL
CYPROHEPTADINE HCL

>D>	AA	GENEVA PHARMS	4MG	N86808 001	FEB 24, 1981	JUL	DISC
>A>		@	4MG	N86808 001	FEB 24, 1981	JUL	DISC

DACARBAZINE
INJECTABLE; INJECTION
DACARBAZINE

AP	BEDFORD	200MG/VIAL	N75812 001	JUN 15, 2001	JUN	NEWA

DESERPIDINE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
ORETICYL 25

	@ ABBOTT	0.125MG;25MG	N12148 001	DEC 14, 1959	MAR	DISC

ORETICYL 50

	@ ABBOTT	0.125MG;50MG	N12148 003	DEC 14, 1959	MAR	DISC

DESERPIDINE; HYDROCHLOROTHIAZIDE
TABLET; ORAL
ORETICYL FORTE
@ ABBOTT — 0.25MG;25MG — N12148 002 DEC 14, 1959 MAR DISC

DESONIDE
OINTMENT; TOPICAL
DESONIDE
AB ALTANA — 0.05% — N75751 001 MAR 12, 2001 MAR NEWA

DEXAMETHASONE
TABLET; ORAL
DEXAMETHASONE
@ DANBURY PHARMA — 0.75MG — N80968 001 MAY 03, 1973 MAY DISC

DEXAMETHASONE SODIUM PHOSPHATE
INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE
@ DELL LABS — EQ 4MG PHOSPHATE/ML — N83161 001 JUN 06, 1978 FEB WDRP
@ GENSIA SICOR PHARMS — EQ 4MG PHOSPHATE/ML — N81125 001 AUG 31, 1990 MAY DISC
OINTMENT; OPHTHALMIC
DECADRON
@ MERCK — EQ 0.05% PHOSPHATE — N11977 001 SEP 02, 1959 MAY DISC
MAXIDEX
+ ALCON — EQ 0.05% PHOSPHATE — N83342 001 OCT 23, 1973 MAY CTEC
SOLUTION/DROPS; OTIC
DEXAMETHASONE SODIUM PHOSPHATE
@ AKORN — EQ 0.1% PHOSPHATE — N84855 001 JUN 29, 1976 FEB WDRP

DEXAMETHASONE SODIUM PHOSPHATE; NEOMYCIN SULFATE
SOLUTION/DROPS; OPHTHALMIC
NEODECADRON
+ MERCK — EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML — N50322 001 JUL 06, 1959 MAY CTEC
NEOMYCIN SULFATE-DEXAMETHASONE SODIUM PHOSPHATE
@ ALCON UNIVERSAL — EQ 0.1% PHOSPHATE;EQ 3.5MG BASE/ML — N62714 001 JUL 21, 1986 MAY DISC

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE
OINTMENT; OPHTHALMIC
DEXACIDIN
AT NOVARTIS — 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM — N62566 001 FEB 22, 1985 FEB CAHN
@ — 0.1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM — N62566 001 FEB 22, 1985 MAY DISC
SUSPENSION/DROPS; OPHTHALMIC
AT NOVARTIS — 0.1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML — N62544 001 OCT 29, 1984 FEB CAHN

DEXTROAMPHETAMINE SULFATE
TABLET; ORAL
DEXTROAMPHETAMINE SULFATE
AA BARR — 5MG — N40361 001 JAN 31, 2001 JAN NEWA

	AA		10MG	N40361 002	JAN 31, 2001	JAN	NEWA
		DEXTROSTAT					
	AA +	SHIRE RICHWOOD	10MG	N84051 002	MAY 29, 1975	JAN	CFTG
		DIAZEPAM					
		GEL; RECTAL					
		DIASTAT					
>D>	+	ELAN PHARMS	2.5MG/0.5ML	N20648 001	JUL 29, 1997	JUL	CAHN
>D>			5MG/ML	N20648 002	JUL 29, 1997	JUL	CAHN
>D>			10MG/2ML	N20648 003	JUL 29, 1997	JUL	CAHN
>D>			15MG/3ML	N20648 004	JUL 29, 1997	JUL	CAHN
>D>	+		20MG/4ML	N20648 005	JUL 29, 1997	JUL	CAHN
>A>	+	XCEL PHARMS	2.5MG/0.5ML	N20648 001	JUL 29, 1997	JUL	CAHN
>A>			5MG/ML	N20648 002	JUL 29, 1997	JUL	CAHN
>A>			10MG/2ML	N20648 003	JUL 29, 1997	JUL	CAHN
>A>			15MG/3ML	N20648 004	JUL 29, 1997	JUL	CAHN
>A>	+		20MG/4ML	N20648 005	JUL 29, 1997	JUL	CAHN
		DICLOFENAC POTASSIUM					
		TABLET; ORAL					
		DICLOFENAC POTASSIUM					
	AB	EON	50MG	N75582 001	FEB 23, 2001	FEB	NEWA
		DICLOFENAC SODIUM					
		GEL; TOPICAL					
		SOLARAZE					
	+	BIOGLAN PHARMA PLC	3%	N21005 001	OCT 16, 2000	MAR	CAHN
		DICLOXACILLIN SODIUM					
		CAPSULE; ORAL					
		DYCILL					
		@ SMITHKLINE BEECHAM	EQ 250MG BASE	N62238 001	DEC 31, 1979	APR	DISC
		@	EQ 500MG BASE	N62238 002	DEC 31, 1979	APR	DISC
		DICYCLOMINE HYDROCHLORIDE					
		CAPSULE; ORAL					
		DICYCLOMINE HCL					
		@ HALSEY	10MG	N84505 001	OCT 21, 1986	MAY	DISC
		INJECTABLE; INJECTION					
>D>		DICYCLOMINE HCL					
>D>	AP	STERIS	10MG/ML	N80614 001	FEB 11, 1986	JUL	DISC
>A>		@	10MG/ML	N80614 001	FEB 11, 1986	JUL	DISC
		DIETHYLPROPION HYDROCHLORIDE					
		TABLET, EXTENDED RELEASE; ORAL					
		TENUATE DOSPAN					
>D>	BC +	AVENTIS PHARMS	75MG	N12546 001	NOV 07, 1960	JUL	CTEC
>A>	+		75MG	N12546 001	NOV 07, 1960	JUL	CTEC
>D>		TEPANIL TEN-TAB					
>D>	BC	3M	75MG	N17956 001	MAY 25, 1977	JUL	DISC
>A>		@	75MG	N17956 001	MAY 25, 1977	JUL	DISC

DILTIAZEM HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
DILTIAZEM HCL

AB2	MYLAN	120MG	N75124 002	MAR 18, 1998	MAR	CTEC

DIPHENHYDRAMINE HYDROCHLORIDE
CAPSULE; ORAL
DIPHENHYDRAMINE HCL

@	CHELSEA LABS	50MG	N85083 001	JUN 29, 1976	MAY	DISC
@	NEWTRON PHARMS	25MG	N86543 001	FEB 08, 1979	FEB	WDRP
@		50MG	N86544 001	FEB 08, 1979	FEB	WDRP

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL PRESERVATIVE FREE

>D>	AP	AM PHARM PARTNERS	50MG/ML	N80586 002	JAN 10, 1973	JUL	DISC
>A>		@	50MG/ML	N80586 002	JAN 10, 1973	JUL	DISC

DISULFIRAM
TABLET; ORAL
ANTABUSE

	ODYSSEY PHARMS	250MG	N88482 001	DEC 08, 1983	JAN	CAHN
+		500MG	N88483 001	DEC 08, 1983	JAN	CAHN
@	SIDMAK LABS	250MG	N07883 003	NOV 03, 1970	MAR	CAHN
@		500MG	N07883 002	JUN 01, 1953	MAR	CAHN

DOXAZOSIN MESYLATE
TABLET; ORAL
DOXAZOSIN MESYLATE

AB	SIDMAK LABS	EQ 1MG BASE	N75750 001	JUN 08, 2001	JUN	NEWA
AB		EQ 2MG BASE	N75750 002	JUN 08, 2001	JUN	NEWA
AB		EQ 4MG BASE	N75750 003	JUN 08, 2001	JUN	NEWA
AB		EQ 8MG BASE	N75750 004	JUN 08, 2001	JUN	NEWA
AB	TEVA	EQ 1MG BASE	N75353 001	JAN 12, 2001	JAN	NEWA
AB		EQ 2MG BASE	N75353 002	JAN 12, 2001	JAN	NEWA
AB		EQ 4MG BASE	N75353 003	JAN 12, 2001	JAN	NEWA
AB		EQ 8MG BASE	N75353 004	JAN 12, 2001	JAN	NEWA

DOXYCYCLINE
FOR SUSPENSION; ORAL
DOXYCHEL

@	RACHELLE	EQ 25MG BASE/5ML	N61720 001	JUN 18, 1973	FEB	WDRP

VIBRAMYCIN

+	PFIZER	EQ 25MG BASE/5ML	N50006 001	DEC 06, 1967	FEB	CTEC

DOXYCYCLINE HYCLATE
CAPSULE; ORAL
DOXY-LEMMON

@	TEVA	EQ 50MG BASE	N62497 001	AUG 23, 1984	APR	DISC
@		EQ 100MG BASE	N62497 002	JUN 15, 1984	APR	DISC

DOXYCYCLINE HYCLATE

@	CHELSEA LABS	EQ 50MG BASE	N62142 001	AUG 12, 1981	APR	DISC
@		EQ 100MG BASE	N62142 002	AUG 12, 1981	APR	DISC
AB	HALSEY	EQ 50MG BASE	N61717 001	JUL 17, 1973	JUN	CAHN

	@	EQ 50MG BASE	N62418 001	JAN 28, 1983	APR	DISC	
AB		EQ 100MG BASE	N61717 002	JUL 17, 1973	JUN	CAHN	
	@	EQ 100MG BASE	N62418 002	JAN 28, 1983	APR	DISC	
	CAPSULE, COATED PELLETS; ORAL						
	@ SIDMAK LABS NJ	EQ 100MG BASE	N63187 001	JUN 30, 1992	MAY	DISC	
	INJECTABLE; INJECTION						
	DOXYCHEL HYCLATE						
	@ RACHELLE	EQ 100MG BASE/VIAL	N61953 001	SEP 10, 1980	FEB	WDRP	
	DOXYCYCLINE						
	@ BEDFORD	EQ 100MG BASE/VIAL	N62569 001	MAR 09, 1988	MAY	DISC	
	@	EQ 200MG BASE/VIAL	N62569 002	MAR 09, 1988	MAY	DISC	
	@ ELKINS SINN	EQ 100MG BASE/VIAL	N62450 001	OCT 27, 1983	APR	DISC	
	@	EQ 200MG BASE/VIAL	N62450 002	OCT 27, 1983	APR	DISC	
	DOXYCYCLINE HYCLATE						
	@ LEDERLE	EQ 100MG BASE/VIAL	N62992 001	FEB 16, 1989	MAY	DISC	
	@	EQ 200MG BASE/VIAL	N62992 002	FEB 16, 1989	MAY	DISC	
	TABLET; ORAL						
	DOXY-LEMMON						
	@ TEVA	EQ 100MG BASE	N62581 001	MAR 15, 1985	MAY	DISC	
	DOXYCYCLINE HYCLATE						
AB	HALSEY	EQ 100MG BASE	N62269 001	SEP 03, 1980	JUN	CAHN	
AB		EQ 100MG BASE	N62269 002	NOV 08, 1982	JUN	CAHN	
	@	EQ 100MG BASE	N62391 001	SEP 30, 1982	APR	DISC	
	DOXYCYCLINE HYLATE						
	@ HALSEY	EQ 50MG BASE	N62269 003	SEP 03, 1980	JUN	CAHN	
	PERIOSTAT						
+	COLLAGENEX PHARMS	20MG	N50783 001	FEB 02, 2001	FEB	NEWA	
	DROPERIDOL; FENTANYL CITRATE						
	INJECTABLE; INJECTION						
	FENTANYL CITRATE AND DROPERIDOL						
>D> AP	ASTRAZENECA	2.5MG/ML;EQ 0.05MG BASE/ML	N72027 001	APR 13, 1989	JUL	DISC	
>A>	@	2.5MG/ML;EQ 0.05MG BASE/ML	N72027 001	APR 13, 1989	JUL	DISC	
	DROSPIRENONE; ETHINYL ESTRADIOL						
	TABLET; ORAL-28						
	YASMIN						
+	BERLEX LABS	3MG;0.03MG	N21098 001	MAY 11, 2001	MAY	NEWA	
	ENALAPRIL MALEATE						
	TABLET; ORAL						
	ENALAPRIL MALEATE						
AB	TARO	2.5MG	N75657 001	JAN 23, 2001	JAN	NEWA	
AB		5MG	N75657 002	JAN 23, 2001	JAN	NEWA	
AB		10MG	N75657 003	JAN 23, 2001	JAN	NEWA	
AB		20MG	N75657 004	JAN 23, 2001	JAN	NEWA	
AB	TORPHARM	2.5MG	N75178 002	MAR 23, 2001	MAR	NEWA	
AB		5MG	N75178 001	MAR 23, 2001	MAR	NEWA	
AB		10MG	N75178 003	MAR 23, 2001	MAR	NEWA	
AB		20MG	N75178 004	MAR 23, 2001	MAR	NEWA	

ENFLURANE
LIQUID; INHALATION
ENFLURANE

AN	MINRAD	99.9%	N74396	001	JUL 29, 1994	FEB	CAHN

ENOXAPARIN SODIUM
INJECTABLE; SUBCUTANEOUS
LOVENOX

+	AVENTIS	30MG/0.3ML	N20164	001	MAR 29, 1993	APR	CAHN
+		40MG/0.4ML	N20164	002	JAN 30, 1998	APR	CAHN
+		60MG/0.6ML	N20164	003	MAR 27, 1998	APR	CAHN
+		80MG/0.8ML	N20164	004	MAR 27, 1998	APR	CAHN
+		90MG/0.6ML	N20164	006	JUN 02, 2000	APR	CAHN
+		100MG/ML	N20164	005	MAR 27, 1998	APR	CAHN
+		120MG/0.8ML	N20164	007	JUN 02, 2000	APR	CAHN
+		150MG/ML	N20164	008	JUN 02, 2000	APR	CAHN

EPINEPHRINE BITARTRATE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
DURANEST

+	DENTSPLY PHARM	0.005MG/ML;1%	N17751	006	AUG 30, 1976	APR	CAHN
+		0.005MG/ML;1.5%	N17751	007	AUG 30, 1976	APR	CAHN

EPINEPHRINE; ETIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION

@	DENTSPLY PHARM	0.005MG/ML;0.5%	N17751	004	AUG 30, 1976	APR	CAHN

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE
INJECTABLE; INJECTION
LIDOCAINE HCL W/ EPINEPHRINE

>D>	AP	INTL MEDICATION	0.01MG/ML;1%	N86402	001	FEB 04, 1980	JUL	DISC
>A>		@	0.01MG/ML;1%	N86402	001	FEB 04, 1980	JUL	DISC
>D>	AP	STERIS	0.01MG/ML;1%	N80377	003	FEB 20, 1974	JUL	DISC
>D>	AP		0.01MG/ML;2%	N80377	004	FEB 20, 1974	JUL	DISC
>A>		@	0.01MG/ML;1%	N80377	003	FEB 20, 1974	JUL	DISC
>A>		@	0.01MG/ML;2%	N80377	004	FEB 20, 1974	JUL	DISC

LIDOCATON

@	PHARMATON	0.02MG/ML;2%	N84728	001	AUG 17, 1983	FEB	WDRP

ERGOCALCIFEROL
CAPSULE; ORAL
VITAMIN D

@	IMPAX LABS	50,000 IU	N80951	001	JUL 13, 1973	FEB	DISC

ERGOLOID MESYLATES
TABLET; ORAL
ERGOLOID MESYLATES

>D>	AB	DANBURY PHARMA	1MG	N87244	001	AUG 16, 1982	JUL	DISC
>A>		@	1MG	N87244	001	AUG 16, 1982	JUL	DISC

TABLET; SUBLINGUAL

>D>	AA	DANBURY PHARMA	1MG	N87183	001	APR 16, 1981	JUL	DISC
>A>		@	1MG	N87183	001	APR 16, 1981	JUL	DISC

	ERYTHROMYCIN						
	SOLUTION; TOPICAL						
	ERYTHROMYCIN						
	@ CLAY PARK	2%	N63038 001	JAN 11, 1991	APR	DISC	
AT		2%	N63038 001	JAN 11, 1991	MAY	CMFD	
	TABLET, DELAYED RELEASE; ORAL						
	E-BASE						
	@ BARR	333MG	N63028 001	MAY 15, 1990	APR	DISC	
	ILOTYCIN						
	@ DISTA	250MG	N61910 001	FEB 27, 1975	MAY	DISC	
	ERYTHROMYCIN ESTOLATE						
	CAPSULE; ORAL						
	ERYTHROMYCIN ESTOLATE						
	+ BARR	EQ 250MG BASE	N62162 002	JUN 15, 1981	MAY	CTEC	
	@ DANBURY PHARMA	EQ 250MG BASE	N62087 001	JUN 14, 1979	APR	DISC	
	ILOSONE						
	@ LILLY	EQ 125MG BASE	N61897 001	JAN 06, 1975	MAY	DISC	
	@	EQ 250MG BASE	N61897 002	JAN 06, 1975	MAY	DISC	
	FOR SUSPENSION; ORAL						
	@ DISTA	EQ 125MG BASE/5ML	N61893 001	JAN 06, 1975	MAY	DISC	
	SUSPENSION/DROPS; ORAL						
	@ LILLY	EQ 100MG BASE/ML	N61894 003	JAN 07, 1975	APR	DISC	
	TABLET; ORAL						
	@ LILLY	EQ 500MG BASE	N61896 001	JAN 03, 1975	APR	DISC	
	TABLET, CHEWABLE; ORAL						
	@ DISTA	EQ 125MG BASE	N61895 001	JAN 03, 1975	MAY	DISC	
	@	EQ 250MG BASE	N61895 002	JAN 03, 1975	MAY	DISC	
	ERYTHROMYCIN ETHYLSUCCINATE						
	TABLET; ORAL						
	ERYTHROMYCIN ETHYLSUCCINATE						
	@ BARR	EQ 400MG BASE	N62256 001	APR 28, 1980	MAY	DISC	
	ERYTHROMYCIN GLUCEPTATE						
>D>	INJECTABLE; INJECTION						
>D>	ILOTYCIN GLUCEPTATE						
>D>	+ DISTA	EQ 250MG BASE/VIAL	N50370 001	JUN 23, 1964	JUL	DISC	
>A>	@	EQ 250MG BASE/VIAL	N50370 001	JUN 23, 1964	JUL	DISC	
>D>	+	EQ 500MG BASE/VIAL	N50370 002	JUN 23, 1964	JUL	DISC	
>A>	@	EQ 500MG BASE/VIAL	N50370 002	JUN 23, 1964	JUL	DISC	
>D>	+	EQ 1GM BASE/VIAL	N50370 003	JUN 23, 1964	JUL	DISC	
>A>	@	EQ 1GM BASE/VIAL	N50370 003	JUN 23, 1964	JUL	DISC	
	ERYTHROMYCIN STEARATE						
	TABLET; ORAL						
	ERYTHROMYCIN STEARATE						
	@ BARR	EQ 500MG BASE	N63179 001	MAY 15, 1990	MAY	DISC	
	@ ZENITH GOLDLINE	EQ 250MG BASE	N61461 001	SEP 04, 1971	MAY	DISC	
	@	EQ 500MG BASE	N61461 002	APR 11, 1980	MAY	DISC	
	WYAMYCIN S						
	@ WYETH AYERST	EQ 250MG BASE	N61675 001	OCT 06, 1972	APR	DISC	

		@	EQ 500MG BASE	N61675 002	JUL 13, 1973	APR	DISC

ESOMEPRAZOLE MAGNESIUM
CAPSULE, DELAYED REL PELLETS; ORAL
NEXIUM

		+ ASTRAZENECA	EQ 20MG BASE	N21153 001	FEB 20, 2001	FEB	NEWA
		+	EQ 40MG BASE	N21153 002	FEB 20, 2001	FEB	NEWA

ESTRADIOL; NORETHINDRONE ACETATE
FILM, EXTENDED RELEASE; TRANSDERMAL
COMBIPATCH

		NOVARTIS	0.05MG/24HR;0.14MG/24HR	N20870 001	AUG 07, 1998	MAR	CAHN
		+	0.05MG/24HR;0.25MG/24HR	N20870 002	AUG 07, 1998	MAR	CAHN

ESTROGENS, CONJUGATED; MEDROXYPROGESTERONE ACETATE
TABLET; ORAL-28
PREMPRO

		+ WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20527 001	NOV 17, 1995	JAN	CTNA
		+	0.625MG;0.625MG;5MG;5MG	N20527 003	JAN 09, 1998	JAN	CTNA

PREMPRO (PREMARIN;CYCRIN)

		+ WYETH AYERST	0.625MG;0.625MG;2.5MG;2.5MG	N20303 001	DEC 30, 1994	JAN	CTNA

ESTROGENS, ESTERIFIED
TABLET; ORAL
ESTRATAB

>D>	BP	SOLVAY	0.3MG	N86715 001	APR 08, 1981	JUL	DISC
>A>			0.3MG	N86715 001	APR 08, 1981	JUL	DISC
>D>	BP	+	0.625MG	N83209 001	JUN 17, 1977	JUL	DISC
>A>		+	0.625MG	N83209 001	JUN 17, 1977	JUL	DISC

MENEST

>D>	BP	MONARCH PHARMS	0.3MG	N84951 001	SEP 28, 1977	JUL	CTEC
>A>			0.3MG	N84951 001	SEP 28, 1977	JUL	CTEC
>D>	BP		0.625MG	N84948 001	SEP 28, 1977	JUL	CTEC
>A>			0.625MG	N84948 001	SEP 28, 1977	JUL	CTEC

ESTROPIPATE
TABLET; ORAL
ORTHO-EST

	AB	WOMEN FIRST HLTHCARE	0.75MG	N89567 001	FEB 27, 1991	JAN	CAHN
	AB		1.5MG	N89582 001	JUL 17, 1991	JAN	CAHN

ETHINYL ESTRADIOL; LEVONORGESTREL
TABLET; ORAL-21
ALESSE

	AB	+ WYETH AYERST	0.02MG;0.1MG	N20683 001	MAR 27, 1997	APR	CTEC

AVIANE-21

	AB	DURAMED	0.02MG;0.1MG	N75796 002	APR 30, 2001	APR	NEWA

TABLET; ORAL-21, ORAL-28
ENPRESSE-21

>A>	AB	DURAMED	0.03MG,0.04MG,0.03MG;0.05MG, 0.075MG,0.125MG	N75809 001	JUL 16, 2001	JUL	NEWA

		ETHINYL ESTRADIOL; LEVONORGESTREL						
		TABLET; ORAL-28						
		ENPRESSE-21						
		TABLET; ORAL-28						
		ALESSE						
	AB	WYETH AYERST	0.02MG;0.1MG	N20683	002	MAR 27, 1997	APR	CTEC
		AVIANE-28						
	AB	DURAMED	0.02MG;0.1MG	N75796	001	APR 30, 2001	APR	NEWA
		ENPRESSE-28						
>A>	AB	DURAMED	0.03MG,0.04MG,0.03MG;0.05MG, 0.075MG,0.125MG	N75809	002	JUL 16, 2001	JUL	NEWA
		ETHINYL ESTRADIOL; NORETHINDRONE ACETATE						
		TABLET; ORAL-28						
		LOESTRIN FE 1.5/30						
	AB +	PARKE DAVIS	0.03MG;1.5MG	N17355	001	APR 30, 1973	FEB	CFTG
		LOESTRIN FE 1/20						
	AB +	PARKE DAVIS	0.02MG;1MG	N17354	001	APR 30, 1973	FEB	CFTG
		MICROGESTIN FE 1.5/30						
	AB	WATSON LABS	0.03MG;1.5MG	N75548	001	FEB 05, 2001	FEB	NEWA
		MICROGESTIN FE 1/20						
	AB	WATSON LABS	0.02MG;1MG	N75647	001	FEB 05, 2001	FEB	NEWA
		ETHOSUXIMIDE						
		SYRUP; ORAL						
		ZARONTIN						
	AA +	PARKE DAVIS	250MG/5ML	N80258	001	FEB 13, 1974	JAN	CRLD
		ETIDOCAINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		DURANEST						
		@ DENTSPLY PHARM	0.5%	N17751	003	AUG 30, 1976	APR	CAHN
	+		1%	N17751	005	AUG 30, 1976	APR	CAHN
		ETODOLAC						
		TABLET, EXTENDED RELEASE; ORAL						
		ETODOLAC						
	AB	TEVA	400MG	N75665	003	FEB 05, 2001	FEB	NEWA
		ETOPOSIDE PHOSPHATE						
		INJECTABLE; INJECTION						
		ETOPOPHOS PRESERVATIVE FREE						
		@ BRISTOL MYERS SQUIBB	EQ 500MG BASE/VIAL	N20906	001	FEB 27, 1998	JUN	DISC
		@	EQ 1GM BASE/VIAL	N20906	002	FEB 27, 1998	JUN	NEWA
		FAMCICLOVIR						
		TABLET; ORAL						
		FAMVIR						
		NOVARTIS	125MG	N20363	003	DEC 11, 1995	JAN	CAHN
			250MG	N20363	001	APR 26, 1996	JAN	CAHN
	+		500MG	N20363	002	JUN 29, 1994	JAN	CAHN

FAMOTIDINE

INJECTABLE; INJECTION

FAMOTIDINE

AP		AM PHARM PARTNERS	10MG/ML	N75709	001	APR 16, 2001	APR	NEWA
AP		APOTHECON	10MG/ML	N75707	001	APR 16, 2001	APR	NEWA
		@	10MG/ML	N75707	001	APR 16, 2001	MAY	DISC
AP		BEDFORD	10MG/ML	N75651	001	APR 16, 2001	APR	NEWA
AP			10MG/ML	N75684	001	APR 16, 2001	APR	NEWA
AP		ESI LEDERLE	10MG/ML	N75488	001	APR 16, 2001	APR	NEWA
AP		FAULDING	10MG/ML	N75705	001	APR 16, 2001	APR	NEWA

FAMOTIDINE PRESERVATIVE FREE

AP		AM PHARM PARTNERS	10MG/ML	N75813	001	APR 16, 2001	APR	NEWA
AP		APOTHECON	10MG/ML	N75708	001	APR 16, 2001	APR	NEWA
		@	10MG/ML	N75708	001	APR 16, 2001	MAY	DISC
AP		BEDFORD	10MG/ML	N75622	001	APR 16, 2001	APR	NEWA
AP		BEN VENUE	10MG/ML	N75825	001	APR 17, 2001	APR	NEWA
AP		ESI LEDERLE	10MG/ML	N75486	001	APR 16, 2001	APR	NEWA
AP		FAULDING	10MG/ML	N75669	001	APR 16, 2001	APR	NEWA

FAMOTIDINE PRESERVATIVE FREE IN PLASTIC CONTAINER

AP		BAXTER HLTHCARE	0.4MG/ML	N75591	001	MAY 10, 2001	MAY	NEWA

PEPCID

AP	+	MERCK	10MG/ML	N19510	001	NOV 04, 1986	APR	CFTG

PEPCID PRESERVATIVE FREE

AP	+	MERCK	10MG/ML	N19510	004	NOV 04, 1986	APR	CFTG

PEPCID PRESERVATIVE FREE IN PLASTIC CONTAINER

AP	+	MERCK	0.4MG/ML	N20249	001	FEB 18, 1994	MAY	CFTG

TABLET; ORAL

FAMOTIDINE

AB		CARLSBAD	20MG	N75805	001	APR 16, 2001	APR	NEWA
AB			40MG	N75805	002	APR 16, 2001	APR	NEWA
AB		DANBURY PHARMA	20MG	N75062	002	APR 16, 2001	APR	NEWA
AB			40MG	N75062	001	APR 16, 2001	APR	NEWA
AB		DR REDDYS LABS LTD	20MG	N75718	001	APR 16, 2001	APR	NEWA
AB			40MG	N75718	002	APR 16, 2001	APR	NEWA
AB		EON	20MG	N75793	001	APR 16, 2001	APR	NEWA
AB			40MG	N75793	002	APR 16, 2001	APR	NEWA
AB		GENEVA PHARMS	20MG	N75302	001	APR 16, 2001	APR	NEWA
AB			40MG	N75302	002	APR 16, 2001	APR	NEWA
AB		GENPHARM	20MG	N75457	001	APR 18, 2001	APR	NEWA
AB			40MG	N75457	002	APR 18, 2001	APR	NEWA
AB		INVAMED	20MG	N75607	001	MAY 10, 2001	MAY	NEWA
AB			40MG	N75607	002	MAY 10, 2001	MAY	NEWA
AB		MYLAN	20MG	N75704	001	APR 16, 2001	APR	NEWA
AB			40MG	N75704	002	APR 16, 2001	APR	NEWA
AB		TEVA	20MG	N75311	001	APR 16, 2001	APR	NEWA
AB			40MG	N75311	002	APR 16, 2001	APR	NEWA
>A> AB		TORPHARM	20MG	N75611	001	JUL 23, 2001	JUL	NEWA
>A> AB			40MG	N75611	002	JUL 23, 2001	JUL	NEWA
AB		WOCKHARDT	20MG	N75786	001	APR 16, 2001	APR	NEWA
AB			40MG	N75786	002	APR 16, 2001	APR	NEWA
AB		ZENITH GOLDLINE	20MG	N75511	001	APR 16, 2001	APR	NEWA
AB			40MG	N75511	002	APR 16, 2001	APR	NEWA

FAMOTIDINE
TABLET; ORAL
PEPCID
AB MERCK 20MG N19462 001 OCT 15, 1986 APR CFTG
AB + 40MG N19462 002 OCT 15, 1986 APR CFTG

FENTANYL
FILM, EXTENDED RELEASE; TRANSDERMAL
DURAGESIC
ALZA 1.2MG/24HR N19813 003 AUG 07, 1990 MAY CTEC
1.8MG/24HR N19813 002 AUG 07, 1990 MAY CTEC
2.4MG/24HR N19813 001 AUG 07, 1990 MAY CTEC

FENTANYL CITRATE
INJECTABLE; INJECTION
FENTANYL CITRATE PRESERVATIVE FREE
@ MARSAM EQ 0.05MG BASE/ML N74917 001 FEB 03, 1998 JAN DISC

FLECAINIDE ACETATE
TABLET; ORAL
>A> FLECAINIDE ACETATE
>A> AB ALPHAPHARM 50MG N75442 001 JUL 31, 2001 JUL NEWA
>A> AB 100MG N75442 002 JUL 31, 2001 JUL NEWA
>A> AB 150MG N75442 003 JUL 31, 2001 JUL NEWA
>A> TAMBOCOR
>D> 3M 50MG N18830 004 AUG 23, 1988 JUL CFTG
>A> AB 50MG N18830 004 AUG 23, 1988 JUL CFTG
>D> 100MG N18830 001 OCT 31, 1985 JUL CFTG
>A> AB 100MG N18830 001 OCT 31, 1985 JUL CFTG
>D> + 150MG N18830 003 JUN 03, 1988 JUL CFTG
>A> AB + 150MG N18830 003 JUN 03, 1988 JUL CFTG

FLOXURIDINE
INJECTABLE; INJECTION
FLOXURIDINE
AP AM PHARM PARTNERS 500MG/VIAL N75837 001 FEB 22, 2001 FEB NEWA

FLUOCINOLONE ACETONIDE
CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
@ CLAY PARK 0.01% N86810 001 MAR 04, 1982 APR DISC
@ 0.025% N86811 001 MAR 04, 1982 APR DISC

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-SYNALAR
@ MEDICIS 0.025%;EQ 3.5MG BASE/GM N60700 001 JUN 11, 1963 MAY DISC

FLUOROMETHOLONE
SUSPENSION/DROPS; OPHTHALMIC
FLUOR-OP
AB NOVARTIS 0.1% N70185 001 FEB 27, 1986 FEB CAHN

FLUOROURACIL
CREAM; TOPICAL
CARAC
+ DERMIK LABS 0.5% N20985 001 OCT 27, 2000 MAY CTNA

FLUOXETINE HYDROCHLORIDE
CAPSULE, DELAYED REL PELLETS; ORAL
PROZAC WEEKLY
+ LILLY EQ 90MG BASE N21235 001 FEB 26, 2001 FEB NEWA

FLURAZEPAM HYDROCHLORIDE
CAPSULE; ORAL
FLURAZEPAM HCL

>D>	AB	CHELSEA LABS	15MG	N72368 001	MAR 30, 1989	JUL	DISC
>A>		@	15MG	N72368 001	MAR 30, 1989	JUL	DISC
>D>	AB	PUREPAC PHARM	15MG	N71927 001	SEP 09, 1987	JUL	DISC
>A>		@	15MG	N71927 001	SEP 09, 1987	JUL	DISC
>D>	AB		30MG	N71551 001	SEP 09, 1987	JUL	DISC
>A>		@	30MG	N71551 001	SEP 09, 1987	JUL	DISC

FLURBIPROFEN
TABLET; ORAL
FLURBIPROFEN

	AB	CARACO	50MG	N75058 001	APR 27, 2001	APR	NEWA
	AB		100MG	N75058 002	APR 27, 2001	APR	NEWA

FLUVOXAMINE MALEATE
TABLET; ORAL
FLUVOXAMINE MALEATE

	AB	BARR	25MG	N75897 001	JAN 25, 2001	JAN	NEWA
	AB		50MG	N75897 002	JAN 25, 2001	JAN	NEWA
	AB		100MG	N75897 003	JAN 25, 2001	JAN	NEWA
	AB	INVAMED	25MG	N75887 001	JAN 05, 2001	JAN	NEWA
	AB		50MG	N75887 002	JAN 05, 2001	JAN	NEWA
	AB		100MG	N75887 003	JAN 05, 2001	JAN	NEWA
	AB	SYNTHON PHARMS	25MG	N75899 001	JAN 17, 2001	JAN	NEWA
	AB		50MG	N75899 002	JAN 17, 2001	JAN	NEWA
	AB		100MG	N75899 003	JAN 17, 2001	JAN	NEWA
	AB	TORPHARM	25MG	N75902 001	MAY 07, 2001	MAY	NEWA
	AB		50MG	N75902 002	MAY 07, 2001	MAY	NEWA
	AB		100MG	N75902 003	MAY 07, 2001	MAY	NEWA
	AB	WATSON LABS	25MG	N75894 001	APR 18, 2001	APR	NEWA
	AB		50MG	N75894 002	APR 18, 2001	APR	NEWA
	AB		100MG	N75894 003	APR 18, 2001	APR	NEWA
	AB	ZENITH GOLDLINE	25MG	N75898 001	MAR 12, 2001	MAR	NEWA
	AB		50MG	N75898 002	MAR 12, 2001	MAR	NEWA
	AB		100MG	N75898 003	MAR 12, 2001	MAR	NEWA

FORMOTEROL FUMARATE
CAPSULE; INHALATION
FORADIL
+ NOVARTIS 0.012MG/INH N20831 001 FEB 16, 2001 FEB NEWA

	GABAPENTIN						
	CAPSULE; ORAL						
	NEURONTIN						
	PFIZER	100MG	N20235 001	DEC 30, 1993	MAR	CAHN
		300MG	N20235 002	DEC 30, 1993	MAR	CAHN
+		400MG	N20235 003	DEC 30, 1993	MAR	CAHN
	GALANTAMINE HYDROBROMIDE						
	SOLUTION; ORAL						
	REMINYL						
+	JANSSEN	4MG/ML	N21224 001	JUN 22, 2001	JUN	NEWA
	TABLET; ORAL						
	JANSSEN	EQ 4MG BASE	N21169 001	FEB 28, 2001	FEB	NEWA
		EQ 8MG BASE	N21169 002	FEB 28, 2001	FEB	NEWA
+		EQ 12MG BASE	N21169 003	FEB 28, 2001	FEB	NEWA
	GEMFIBROZIL						
	TABLET; ORAL						
	GEMFIBROZIL						
AB	GENEVA PHARMS TECH	600MG	N74615 001	SEP 29, 1995	JAN	CAHN
	GENTAMICIN SULFATE						
	CREAM; TOPICAL						
	GENTAMICIN SULFATE						
	@ BAUSCH AND LOMB	EQ 0.1% BASE	N64056 001	APR 29, 1994	MAY	DISC
	INJECTABLE; INJECTION						
	@ GENSIA SICOR PHARMS	EQ 10MG BASE/ML	N63149 001	NOV 21, 1991	MAY	DISC
	@	EQ 40MG BASE/ML	N63106 002	NOV 21, 1991	APR	DISC
	@ STERIS	EQ 10MG BASE/ML	N62318 002	AUG 20, 1981	APR	DISC
	@	EQ 40MG BASE/ML	N62318 001	JUN 02, 1981	APR	DISC
	U-GENCIN						
	@ PHARMACIA AND UPJOHN	EQ 10MG BASE/ML	N62248 001	MAY 02, 1980	FEB	WDRP
	@	EQ 40MG BASE/ML	N62248 002	MAY 02, 1980	FEB	WDRP
	INJECTABLE; INTRATHECAL						
	GARAMYCIN						
	@ SCHERING	EQ 2MG BASE/ML	N50505 001	OCT 01, 1979	APR	DISC
	OINTMENT; OPHTHALMIC						
	GENTACIDIN						
AT	NOVARTIS	EQ 0.3% BASE	N62501 001	JUL 26, 1984	FEB	CAHN
	@	EQ 0.3% BASE	N62501 001	JUL 26, 1984	MAY	DISC
	OINTMENT; TOPICAL						
	GENTAMICIN SULFATE						
	@ BAUSCH AND LOMB	EQ 0.1% BASE	N64054 001	APR 29, 1994	MAY	DISC
	SOLUTION/DROPS; OPHTHALMIC						
	GENTACIDIN						
AT	NOVARTIS	EQ 0.3% BASE	N62480 001	MAR 30, 1984	FEB	CAHN
	GENTAMICIN SULFATE						
	@ ALCON UNIVERSAL	EQ 0.3% BASE	N62523 001	NOV 25, 1985	APR	DISC

GLIPIZIDE
TABLET; ORAL
GLIPIZIDE

AB	GENEVA PHARMS TECH	5MG	N74542 001	JUN 20, 1995	JAN	CAHN
AB		10MG	N74542 002	JUN 20, 1995	JAN	CAHN
AB	TORPHARM	5MG	N75795 001	JUN 13, 2001	JUN	NEWA
AB		10MG	N75795 002	JUN 13, 2001	JUN	NEWA

GLYCOPYRROLATE
INJECTABLE; INJECTION
GLYCOPYRROLATE

@	GENSIA SICOR PHARMS	0.2MG/ML	N81169 001	SEP 10, 1991	MAY	DISC

GRANISETRON HYDROCHLORIDE
SOLUTION; ORAL
KYTRIL

+	ROCHE	EQ 2MG BASE/10ML	N21238 001	JUN 27, 2001	JUN	NEWA

GRISEOFULVIN, MICROCRYSTALLINE
SUSPENSION; ORAL
GRIFULVIN V

+	J AND J	125MG/5ML	N62483 001	JAN 26, 1984	MAR	CRLD
@	JOHNSON AND JOHNSON	125MG/5ML	N50448 001	MAY 19, 1972	MAR	DISC

GRISEOFULVIN, ULTRAMICROCRYSTALLINE
TABLET; ORAL
GRISACTIN ULTRA

@	WYETH AYERST	125MG	N62178 001	MAR 13, 1980	APR	DISC
@		250MG	N62178 002	MAR 13, 1980	APR	DISC

ULTRAGRIS-165

@	SIDMAK LABS NJ	165MG	N62645 001	JUN 30, 1992	MAY	DISC

ULTRAGRIS-330

@	SIDMAK LABS NJ	330MG	N62646 001	JUN 30, 1992	MAY	DISC

HALOPERIDOL
TABLET; ORAL
HALOPERIDOL

>D>	AB	DANBURY PHARMA	1MG	N70982 001	MAR 06, 1987	JUL	DISC
>A>	@		1MG	N70982 001	MAR 06, 1987	JUL	DISC

HALOPERIDOL LACTATE
INJECTABLE; INJECTION

AP	AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001	MAR 09, 2001	JUN	CTNA
AP	BEDFORD	EQ 5MG BASE/ML	N75858 001	JUN 18, 2001	JUN	NEWA

HALOPERIDOL LACTATE

AP	AM PHARM PARTNERS	EQ 5MG BASE/ML	N75689 001	MAR 09, 2001	MAR	NEWA

HALOTHANE
LIQUID; INHALATION
HALOTHANE

@	BH	99.99%	N84977 001	JUL 14, 1976	JAN	DISC

HEPARIN SODIUM
INJECTABLE; INJECTION
HEPARIN SODIUM
@ ABBOTT 10,000 UNITS/ML N40095 001 JUL 26, 1996 MAY DISC
HEPARIN SODIUM PRESERVATIVE FREE
@ PHARMA SERVE NY 1,000 UNITS/ML N86129 001 FEB 22, 1980 FEB WDRP

HOMATROPINE METHYLBROMIDE
TABLET; ORAL
HOMAPIN-10
>D> + MISSION PHARMA 10MG N86308 001 APR 11, 1979 JUL DISC
>A> @ 10MG N86308 001 APR 11, 1979 JUL DISC
HOMAPIN-5
>D> + MISSION PHARMA 5MG N86309 001 APR 11, 1979 JUL DISC
>A> @ 5MG N86309 001 APR 11, 1979 JUL DISC

HYALURONIDASE
INJECTABLE; INJECTION
WYDASE
>D> + WYETH AYERST 150 UNITS/VIAL N06343 006 MAR 06, 1951 JUL DISC
>A> @ 150 UNITS/VIAL N06343 006 MAR 06, 1951 JUL DISC
>D> + 1,500 UNITS/VIAL N06343 005 MAR 06, 1951 JUL DISC
>A> @ 1,500 UNITS/VIAL N06343 005 MAR 06, 1951 JUL DISC

HYDRALAZINE HYDROCHLORIDE
INJECTABLE; INJECTION
HYDRALAZINE HCL
AP AM PHARM PARTNERS 20MG/ML N40388 001 MAR 13, 2001 MAR NEWA

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
RESERPINE, HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE
@ DANBURY PHARMA 25MG;15MG;0.1MG N85549 001 SEP 29, 1977 MAY DISC

HYDROCHLOROTHIAZIDE
TABLET; ORAL
HYDROCHLOROTHIAZIDE
@ DANBURY PHARMA 50MG N83232 001 JAN 24, 1975 MAY DISC
@ HALSEY 25MG N83972 001 OCT 03, 1974 MAY DISC
@ 50MG N83972 002 OCT 03, 1974 MAY DISC
@ IMPAX LABS 25MG N84029 001 JUL 05, 1977 MAY DISC
@ 50MG N83607 002 JUN 06, 1977 MAY DISC
@ PHARMERAL 25MG N84325 001 JUN 24, 1976 MAY DISC
@ 50MG N84324 001 JUN 24, 1976 MAY DISC
>D> AB PVT FORM 50MG N86597 001 OCT 11, 1978 JUL DISC
>A> @ 50MG N86597 001 OCT 11, 1978 JUL DISC
@ WEST WARD 50MG N84878 001 JAN 31, 1977 MAY DISC

HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
HYDRO-RESERP
@ ABC HOLDING 50MG;0.125MG N84714 002 JUN 29, 1982 MAY DISC

HYDROCHLOROTHIAZIDE; RESERPINE
TABLET; ORAL
HYDROCHLOROTHIAZIDE W/ RESERPINE

		@ DANBURY PHARMA	25MG;0.125MG	N84466 001	JAN 07, 1977	MAY	DISC
		@	50MG;0.125MG	N84467 001	JAN 07, 1977	MAY	DISC
		RESERPINE AND HYDROCHLOROTHIAZIDE-50					
		@ WEST WARD	50MG;0.125MG	N88189 001	MAY 10, 1984	FEB	WDRP

HYDROCORTISONE
CREAM; TOPICAL
HC (HYDROCORTISONE)

		@ C AND M PHARMA	0.5%	N80482 003	MAR 20, 1973	FEB	WDRP
		@	1%	N80482 004	MAR 20, 1973	FEB	WDRP
		HYDROCORTISONE					
		@ TOPIDERM	1%	N89273 001	FEB 17, 1989	FEB	WDRP
		NUTRACORT					
>D>	AT	HEALTHPOINT	1%	N80442 003	APR 04, 1972	JUL	DISC
>A>		@	1%	N80442 003	APR 04, 1972	JUL	DISC
		PROCTOCORT					
		@ MONARCH PHARMS	1%	N83011 001	APR 26, 1973	FEB	DISC

LOTION; TOPICAL
ACTICORT

>D>	AT	BAKER NORTON	1%	N86535 001	FEB 04, 1981	JUL	DISC
>A>		@	1%	N86535 001	FEB 04, 1981	JUL	DISC
		BETA-HC					
		@ BETA DERMAC	1%	N89495 001	JAN 25, 1988	FEB	WDRP
		GLYCORT					
		@ HERAN	1%	N87489 001	OCT 03, 1983	FEB	WDRP
		HYDROCORTISONE					
		@ MERICON	0.5%	N85282 001	JUN 05, 1978	MAY	DISC
		@	1%	N85282 002	FEB 26, 1987	MAY	DISC

OINTMENT; TOPICAL
HC (HYDROCORTISONE)

		@ C AND M PHARMA	1%	N80481 002	MAR 20, 1973	FEB	WDRP

POWDER; FOR RX COMPOUNDING
H-CORT

		@ TORCH	100%	N87834 001	MAR 29, 1982	FEB	WDRP

SOLUTION; TOPICAL
TEXACORT

	AT +	SIRIUS LABS	1%	N80425 001	DEC 22, 1971	JUN	CAHN
	+		2.5%	N81271 001	APR 17, 1992	MAY	CAHN

TABLET; ORAL
HYDROCORTISONE

		@ LANNETT	20MG	N85070 001	MAY 07, 1976	MAY	DISC

HYDROCORTISONE ACETATE
CREAM; TOPICAL
MICORT-HC

		FERNDALE LABS	2.5%	N40396 001	FEB 27, 2001	FEB	NEWA

HYDROCORTISONE ACETATE; NEOMYCIN SULFATE

OINTMENT; TOPICAL

NEO-CORTEF

@ PHARMACIA AND UPJOHN — 1%;EQ 3.5MG BASE/GM — N60751 002 MAY 18, 1965 APR DISC

SUSPENSION/DROPS; OPHTHALMIC

COR-OTICIN

@ AKORN — 1.5%;EQ 3.5MG BASE/ML — N60188 001 OCT 26, 1968 FEB WDRP

HYDROCORTISONE VALERATE

OINTMENT; TOPICAL

HYDROCORTISONE VALERATE

>A> AB ALTANA — 0.2% — N75085 001 JUL 31, 2001 JUL NEWA

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OTIC

NEO-OTOSOL-HC

@ ALCON — 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML — N62423 001 AUG 25, 1983 APR DISC

SUSPENSION/DROPS; OPHTHALMIC

CORTISPORIN

\+ MONARCH PHARMS — 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML — N50169 001 DEC 18, 1964 MAY CTEC

NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE

@ ALCON UNIVERSAL — 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML — N62874 001 MAY 11, 1988 MAY DISC

SUSPENSION/DROPS; OTIC

@ ALCON UNIVERSAL — 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML — N62488 001 NOV 06, 1985 APR DISC

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

>D> AP ABBOTT — 50MG/ML — N86821 001 SEP 05, 1979 JUL DISC

>A> @ — 50MG/ML — N86821 001 SEP 05, 1979 JUL DISC

>D> AP AM PHARM PARTNERS — 25MG/ML — N88184 001 MAR 31, 1983 JUL DISC

>A> @ — 25MG/ML — N88184 001 MAR 31, 1983 JUL DISC

>D> AP — 50MG/ML — N88185 001 MAR 31, 1983 JUL DISC

>A> @ — 50MG/ML — N88185 001 MAR 31, 1983 JUL DISC

@ STERIS — 25MG/ML — N85778 001 OCT 05, 1979 MAY DISC

TABLET; ORAL

>D> AB PAR PHARM — 10MG — N87602 001 JAN 22, 1982 JUL DISC

>A> @ — 10MG — N87602 001 JAN 22, 1982 JUL DISC

>D> AB — 25MG — N87603 001 JAN 22, 1982 JUL DISC

>A> @ — 25MG — N87603 001 JAN 22, 1982 JUL DISC

>D> AB — 50MG — N87604 001 JAN 22, 1982 JUL DISC

>A> @ — 50MG — N87604 001 JAN 22, 1982 JUL DISC

HYDROXYZINE PAMOATE

CAPSULE; ORAL

HYDROXYZINE PAMOATE

@ GENEVA PHARMS — EQ 50MG HCL — N81128 001 JUN 28, 1991 MAY DISC

@ — EQ 100MG HCL — N81129 001 JUN 28, 1991 MAY DISC

@ VANGARD	EQ 50MG HCL	N88393 001	SEP 19, 1983	FEB	WDRP	
IMATINIB MESYLATE						
CAPSULE; ORAL						
GLEEVEC						
NOVARTIS	50MG	N21335 001	MAY 10, 2001	MAY	NEWA	
+	100MG	N21335 002	MAY 10, 2001	MAY	NEWA	
IMIPRAMINE HYDROCHLORIDE						
TABLET; ORAL						
TOFRANIL						
AB TYCO HLTHCARE	10MG	N87844 001	MAY 22, 1984	JUN	CAHN	
AB	25MG	N87845 001	MAY 22, 1984	JUN	CAHN	
AB +	50MG	N87846 001	MAY 22, 1984	JUN	CAHN	
IMIPRAMINE PAMOATE						
CAPSULE; ORAL						
TOFRANIL-PM						
TYCO HLTHCARE	EQ 75MG HCL	N17090 001	MAR 15, 1973	JUN	CAHN	
	EQ 100MG HCL	N17090 004	MAR 08, 1974	JUN	CAHN	
	EQ 125MG HCL	N17090 003	MAR 08, 1974	JUN	CAHN	
+	EQ 150MG HCL	N17090 002	MAR 15, 1973	JUN	CAHN	
INDAPAMIDE						
TABLET; ORAL						
INDAPAMIDE						
AB GENEVA PHARMS TECH	1.25MG	N74594 001	MAY 23, 1996	JAN	CAHN	
AB	2.5MG	N74594 002	MAY 23, 1996	JAN	CAHN	
IPRATROPIUM BROMIDE						
SOLUTION; INHALATION						
IPRATROPIUM BROMIDE						
AN ASLUNG PHARM	0.02%	N75693 001	JAN 26, 2001	JAN	NEWA	
AN NOVEX	0.02%	N75441 001	MAR 28, 2001	MAR	NEWA	
AN WARRICK PHARMS	0.02%	N75507 001	JAN 19, 2001	JAN	NEWA	
ISOFLURANE						
LIQUID; INHALATION						
ISOFLURANE						
AN MINRAD	99.9%	N74416 001	SEP 30, 1994	FEB	CAHN	
ISONIAZID						
SYRUP; ORAL						
ISONIAZID						
+ CAROLINA MEDCL	50MG/5ML	N88235 001	NOV 10, 1983	MAY	CTEC	
@ MIKART	50MG/5ML	N81118 001	JUL 21, 1997	MAY	DISC	
TABLET; ORAL						
@ HALSEY	100MG	N80136 001	NOV 13, 1970	MAY	DISC	
ISOTRETINOIN						
CAPSULE; ORAL						
ACCUTANE						
+ HLR	20MG	N18662 004	MAR 28, 1983	APR	CTEC	

KANAMYCIN SULFATE

INJECTABLE; INJECTION

KANAMYCIN SULFATE

@	LOCH	EQ 75MG BASE/2ML	N63021 001	JUL 31, 1992	MAY	DISC
@		EQ 500MG BASE/2ML	N63022 001	JUL 31, 1992	MAY	DISC
@		EQ 1GM BASE/3ML	N63025 001	JUL 31, 1992	APR	DISC
@	STERIS	EQ 1GM BASE/3ML	N62520 003	MAY 09, 1985	MAY	DISC

KANTREX

+	APOTHECON	EQ 75MG BASE/2ML	N61901 003	MAR 06, 1975	MAY	CTEC
+		EQ 500MG BASE/2ML	N61901 001	MAR 06, 1975	MAY	CTEC
+		EQ 1GM BASE/3ML	N61901 002	MAR 06, 1975	MAY	CTEC

KETOCONAZOLE

CREAM; TOPICAL

NIZORAL

>A>	AB	+	JANSSEN	2%	N19084 001	DEC 31, 1985	JUL	CAHN
>D>	AB	+	MCNEIL CONS	2%	N19084 001	DEC 31, 1985	JUL	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP	APOTEX	15MG/ML	N75631 002	JUN 29, 2001	JUN	NEWA
>A> AP		30MG/ML	N75626 001	JUL 24, 2001	JUL	NEWA
AP		30MG/ML	N75631 001	JUN 29, 2001	JUN	NEWA
@	APOTHECON	15MG/ML	N75348 001	NOV 28, 2000	MAY	DISC
@		30MG/ML	N75348 002	NOV 28, 2000	MAY	DISC

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HCL

@	APOTHECON	5MG/ML	N75355 001	NOV 29, 1999	MAY	DISC

TRANDATE

AP	+	PROMETHEUS LABS	5MG/ML	N19425 001	DEC 31, 1985	MAY	CAHN

LACTULOSE

SOLUTION; ORAL

LACTULOSE

>A>	AA	VINTAGE PHARMS	10GM/15ML	N75993 001	JUL 26, 2001	JUL	NEWA

LAMOTRIGINE

TABLET, CHEWABLE; ORAL

LAMICTAL CD

GLAXO WELLCOME	2MG	N20764 004	SEP 08, 2000	MAR	NEWA

LANSOPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; ORAL

PREVACID

TAP PHARM	15MG/PACKET	N21281 001	MAY 03, 2001	MAY	NEWA
+	30MG/PACKET	N21281 002	MAY 03, 2001	MAY	NEWA

LEUCOVORIN CALCIUM
INJECTABLE; INJECTION
LEUCOVORIN CALCIUM PRESERVATIVE FREE

AP		LUITPOLD	EQ 50MG BASE/VIAL	N40338 001	JAN 31, 2001	JAN	NEWA

LEVOCARNITINE
INJECTABLE; INJECTION
CARNITOR

AP	+	SIGMA TAU	200MG/ML	N20182 001	DEC 16, 1992	MAR	CFTG

LEVOCARNITINE

AP		BEDFORD	200MG/ML	N75567 001	MAR 29, 2001	MAR	NEWA
AP		GENSIA SICOR PHARMS	200MG/ML	N75881 001	MAR 29, 2001	MAR	NEWA
AP		LUITPOLD	200MG/ML	N75861 001	JUN 22, 2001	JUN	NEWA

LEVODOPA
CAPSULE; ORAL
DOPAR

		@ SHIRE LABS	250MG	N16913 001	JUN 04, 1970	MAY	DISC

TABLET; ORAL

		@ SHIRE LABS	250MG	N16913 004	JUL 06, 1972	JUN	DISC
		@	500MG	N16913 005	JUL 06, 1972	JUN	DISC

LARODOPA

		ROCHE	250MG	N16912 003	JUN 04, 1970	JUN	CRLD
	+		500MG	N16912 004	JUN 04, 1970	JUN	CRLD

LEVONORDEFRIN; MEPIVACAINE HYDROCHLORIDE
INJECTABLE; INJECTION
POLOCAINE W/ LEVONORDEFRIN

>D>	AP	ASTRAZENECA	0.05MG/ML;2%	N89517 001	APR 14, 1988	JUL	CAHN
>A>	AP	DENTSPLY PHARM	0.05MG/ML;2%	N89517 001	APR 14, 1988	JUL	CAHN

LEVOTHYROXINE SODIUM
TABLET; ORAL
LEVOXYL

>D>	BX	+	JONES PHARMA	0.025MG	N21301 001	MAY 25, 2001	JUL	CRLD
>A>	BX			0.025MG	N21301 001	MAY 25, 2001	JUL	CRLD
	BX	+		0.025MG	N21301 001	MAY 25, 2001	MAY	NEWA
	BX			0.05MG	N21301 002	MAY 25, 2001	MAY	NEWA
	BX			0.075MG	N21301 003	MAY 25, 2001	MAY	NEWA
	BX			0.088MG	N21301 004	MAY 25, 2001	MAY	NEWA
	BX			0.1MG	N21301 005	MAY 25, 2001	MAY	NEWA
	BX			0.112MG	N21301 006	MAY 25, 2001	MAY	NEWA
	BX			0.125MG	N21301 007	MAY 25, 2001	MAY	NEWA
	BX			0.137MG	N21301 008	MAY 25, 2001	MAY	NEWA
	BX			0.15MG	N21301 009	MAY 25, 2001	MAY	NEWA
	BX			0.175MG	N21301 010	MAY 25, 2001	MAY	NEWA
	BX			0.2MG	N21301 011	MAY 25, 2001	MAY	NEWA
>D>	BX			0.3MG	N21301 012	MAY 25, 2001	JUL	CRLD
>A>	BX	+		0.3MG	N21301 012	MAY 25, 2001	JUL	CRLD
	BX			0.3MG	N21301 012	MAY 25, 2001	MAY	NEWA

UNITHROID

BX		STEVENS J	0.025MG	N21210 001	AUG 21, 2000	MAY	CTEC

	BX		0.05MG	N21210 002	AUG 21, 2000	MAY	CTEC
	BX		0.075MG	N21210 003	AUG 21, 2000	MAY	CTEC
	BX		0.088MG	N21210 004	AUG 21, 2000	MAY	CTEC
	BX		0.1MG	N21210 005	AUG 21, 2000	MAY	CTEC
	BX		0.112MG	N21210 006	AUG 21, 2000	MAY	CTEC
	BX		0.125MG	N21210 007	AUG 21, 2000	MAY	CTEC
	BX		0.15MG	N21210 008	AUG 21, 2000	MAY	CTEC
	BX		0.175MG	N21210 009	AUG 21, 2000	MAY	CTEC
	BX		0.2MG	N21210 010	AUG 21, 2000	MAY	CTEC
	BX +		0.3MG	N21210 011	AUG 21, 2000	MAY	CTEC
	LIDOCAINE HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	LIDOCAINE HCL						
>D>	AP	STERIS	1%	N80377 001	FEB 20, 1974	JUL	DISC
>A>		@	1%	N80377 001	FEB 20, 1974	JUL	DISC
>D>	AP		2%	N80377 002	FEB 20, 1974	JUL	DISC
>A>		@	2%	N80377 002	FEB 20, 1974	JUL	DISC
		LIDOCATON					
		@ PHARMATON	2%	N84727 001	AUG 17, 1983	FEB	WDRP
	LINCOMYCIN HYDROCHLORIDE						
	INJECTABLE; INJECTION						
	LINCOCIN						
	+	PHARMACIA AND UPJOHN	EQ 300MG BASE/ML	N50317 001	DEC 29, 1964	MAY	CTEC
	LINCOMYCIN HCL						
	@ STERIS		EQ 300MG BASE/ML	N63180 001	APR 16, 1991	MAY	DISC
	LISINOPRIL						
	TABLET; ORAL						
	ZESTRIL						
	AB	ASTRAZENECA	10MG	N19777 002	MAY 19, 1988	APR	CTEC
	LITHIUM CARBONATE						
	CAPSULE; ORAL						
	ESKALITH						
	AB	SMITHKLINE BEECHAM	300MG	N16860 001	APR 06, 1970	JUN	CRLD
	LITHIUM CARBONATE						
	+	ROXANE	600MG	N17812 003	JAN 28, 1987	JUN	CRLD
	LOPERAMIDE HYDROCHLORIDE						
	CAPSULE; ORAL						
	LOPERAMIDE HCL						
>D>	AB	ROXANE	2MG	N73080 001	NOV 27, 1991	JUL	DISC
>A>		@	2MG	N73080 001	NOV 27, 1991	JUL	DISC
	LORAZEPAM						
	TABLET; ORAL						
	LORAZEPAM						
>D>	AB	WATSON LABS	0.5MG	N71086 001	MAR 23, 1987	JUL	DISC
>A>		@	0.5MG	N71086 001	MAR 23, 1987	JUL	DISC

		MECLIZINE HYDROCHLORIDE						
		TABLET; ORAL						
		MECLIZINE HCL						
		@ CHELSEA LABS	12.5MG	N85269 001	NOV 11, 1976	MAY	DISC	
		MEGESTROL ACETATE						
		SUSPENSION; ORAL						
>A>		MEGACE						
>D>		+ BRISTOL MYERS SQUIBB	40MG/ML	N20264 001	SEP 10, 1993	JUL	CFTG	
>A>	AB	+	40MG/ML	N20264 001	SEP 10, 1993	JUL	CFTG	
>A>		MEGESTROL ACETATE						
>A>	AB	PAR PHARM	40MG/ML	N75671 001	JUL 25, 2001	JUL	NEWA	
		MELOXICAM						
		TABLET; ORAL						
		MOBIC						
>D>		+ BOEHRINGER INGELHEIM	7.5MG	N20938 001	APR 13, 2000	JUL	CRLD	
>A>			7.5MG	N20938 001	APR 13, 2000	JUL	CRLD	
>A>		+	15MG	N20938 002	AUG 23, 2000	JUL	NEWA	
		MEPERIDINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		MEPERIDINE HCL						
		@ ASTRAZENECA	50MG/ML	N89784 001	MAR 31, 1989	JUN	DISC	
		@	100MG/ML	N89788 001	MAR 31, 1989	JUN	DISC	
		MEPIVACAINE HYDROCHLORIDE						
		INJECTABLE; INJECTION						
		MEPIVACAINE HCL						
>D>	AP	INTL MEDICATION	1%	N87509 001	OCT 05, 1982	JUL	DISC	
>A>		@	1%	N87509 001	OCT 05, 1982	JUL	DISC	
		POLOCAINE						
>D>	AP	ASTRAZENECA	3%	N88653 001	AUG 21, 1984	JUL	CAHN	
>A>	AP	DENTSPLY PHARM	3%	N88653 001	AUG 21, 1984	JUL	CAHN	
		MEPROBAMATE						
		TABLET; ORAL						
		AMOSENE						
		@ FERNDALE LABS	400MG	N84030 001	MAY 10, 1974	FEB	WDRP	
		MEPROBAMATE						
		@ HALSEY	400MG	N80699 002	OCT 16, 1972	MAY	DISC	
		MEQUINOL; TRETINOIN						
		SOLUTION; TOPICAL						
		SOLAGE						
		+ WESTWOOD SQUIBB	2%;0.01%	N20922 001	DEC 10, 1999	JUN	CAHN	
		MESALAMINE						
		SUPPOSITORY; RECTAL						
		CANASA						
		+ AXCAN SCANDIPHARM	500MG	N21252 001	JAN 05, 2001	JAN	NEWA	

MESNA
INJECTABLE; INTRAVENOUS
MESNA

AP		AM PHARM PARTNERS	100MG/ML	N75811 001	APR 26, 2001	APR	NEWA
AP		GENSIA SICOR PHARMS	100MG/ML	N75764 001	APR 27, 2001	APR	NEWA

MESNEX

AP	+	ASTA	100MG/ML	N19884 001	DEC 30, 1988	APR	CFTG

METAPROTERENOL SULFATE
SOLUTION; INHALATION
METAPROTERENOL SULFATE

AN		NOVEX	0.4%	N75402 001	FEB 28, 2001	FEB	NEWA
AN			0.6%	N75403 001	FEB 28, 2001	FEB	NEWA

METHAMPHETAMINE HYDROCHLORIDE
TABLET; ORAL
DESOXYN

>D>	AA	+ ABBOTT	5MG	N05378 002	DEC 31, 1943	JUL	CTEC
>A>		+	5MG	N05378 002	DEC 31, 1943	JUL	CTEC

>D> METHAMPHETAMINE HCL

>D>	AA	REXAR	5MG	N84931 001	JAN 19, 1976	JUL	DISC
>A>		@	5MG	N84931 001	JAN 19, 1976	JUL	DISC
>D>			10MG	N84931 002	AUG 22, 1977	JUL	DISC
>A>		@	10MG	N84931 002	AUG 22, 1977	JUL	DISC

METHAZOLAMIDE
TABLET; ORAL
METHAZOLAMIDE

@ APPLIED ANAL	25MG	N40011 001	JUL 17, 1997	MAY	DISC
@	50MG	N40011 002	JUL 17, 1997	MAY	DISC

METHIMAZOLE
TABLET; ORAL
METHIMAZOLE

AB	EON	5MG	N40411 001	MAR 27, 2001	MAR	NEWA
AB		10MG	N40411 002	MAR 27, 2001	MAR	NEWA
+	GENPHARM	20MG	N40350 003	JUN 07, 2001	JUN	NEWA

METHOTREXATE SODIUM
TABLET; ORAL
TREXALL

BARR	EQ 5MG BASE	N40385 001	MAR 21, 2001	MAR	NEWA
	EQ 7.5MG BASE	N40385 002	MAR 21, 2001	MAR	NEWA
	EQ 10MG BASE	N40385 003	MAR 21, 2001	MAR	NEWA
+	EQ 15MG BASE	N40385 004	MAR 21, 2001	MAR	NEWA

METHSCOPOLAMINE BROMIDE
TABLET; ORAL
METHSCOPOLAMINE BROMIDE

@ PVT FORM	2.5MG	N80970 001	OCT 18, 1976	MAY	DISC
PAMINE					
+	BRADLEY PHARMS	2.5MG	N08848 001	APR 09, 1953	MAY	CTEC

METHYCLOTHIAZIDE
TABLET; ORAL
METHYCLOTHIAZIDE

>D>	AB	PAR PHARM	2.5MG	N89135	001	FEB 12, 1986	JUL	DISC
>A>		@	2.5MG	N89135	001	FEB 12, 1986	JUL	DISC
>D>	AB		5MG	N89136	001	FEB 12, 1986	JUL	DISC
>A>		@	5MG	N89136	001	FEB 12, 1986	JUL	DISC

METHYLDOPA
TABLET; ORAL
METHYLDOPA

		@ LEDERLE	125MG	N70070	003	OCT 15, 1985	MAY	DISC

METHYLPHENIDATE HYDROCHLORIDE
CAPSULE, EXTENDED RELEASE; ORAL
METADATE CD

	+	CELLTECH PHARMS	20MG	N21259	001	APR 03, 2001	APR	NEWA

TABLET; ORAL
METHYLPHENIDATE HCL

AB		ABLE	5MG	N40404	001	MAR 29, 2001	MAR	NEWA
AB			10MG	N40404	002	MAR 29, 2001	MAR	NEWA
AB			20MG	N40404	003	MAR 29, 2001	MAR	NEWA

TABLET, EXTENDED RELEASE; ORAL
METADATE ER

AB		CELLTECH PHARMS	10MG	N40306	001	OCT 20, 1999	APR	CTEC

METHYLPHENIDATE HCL

AB		ABLE	20MG	N76032	001	MAY 09, 2001	MAY	NEWA
AB		DANBURY PHARMA	20MG	N40410	001	FEB 09, 2001	FEB	NEWA

METHYLPREDNISOLONE ACETATE
INJECTABLE; INJECTION
DEPO-MEDROL

		PHARMACIA AND UPJOHN	40MG/ML	N11757	001	APR 27, 1959	MAY	CTEC

METHYLPREDNISOLONE ACETATE

		@ STERIS	40MG/ML	N85600	001	MAR 14, 1979	MAY	DISC

METHYLPREDNISOLONE ACETATE; NEOMYCIN SULFATE
CREAM; TOPICAL
NEO-MEDROL ACETATE

		@ PHARMACIA AND UPJOHN	0.25%;EQ 3.5MG BASE/GM	N60611	002	DEC 07, 1964	MAY	DISC
		@	1%;EQ 3.5MG BASE/GM	N60611	001	DEC 07, 1964	MAY	DISC

METHYLPREDNISOLONE SODIUM SUCCINATE
INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

		@ GENSIA SICOR PHARMS	EQ 500MG BASE/VIAL	N81267	001	NOV 30, 1992	MAY	DISC
		@	EQ 1GM BASE/VIAL	N81268	001	NOV 30, 1992	MAY	DISC

METHYLTESTOSTERONE
TABLET; BUCCAL
ORETON

		@ SCHERING	10MG	N80281	001	AUG 03, 1979	FEB	DISC

METHYLTESTOSTERONE
TABLET; BUCCAL/SUBLINGUAL
METHYLTESTOSTERONE

>D>	BP	IMPAX LABS	10MG	N84287 001	JUL 16, 1974	JUL	DISC
>A>		@	10MG	N84287 001	JUL 16, 1974	JUL	DISC
>D>	BP	+ LILLY	10MG	N80256 001	DEC 22, 1971	JUL	DISC
>A>		@	10MG	N80256 001	DEC 22, 1971	JUL	DISC

TABLET; ORAL

>D>	BP	LILLY	25MG	N80256 002	DEC 22, 1971	JUL	DISC
>A>		@	25MG	N80256 002	DEC 22, 1971	JUL	DISC

METOCLOPRAMIDE HYDROCHLORIDE
INJECTABLE; INJECTION
METOCLOPRAMIDE HCL

		@ ABBOTT	EQ 5MG BASE/ML	N70506 001	JUN 22, 1989	MAY	DISC

SOLUTION; INJECTION
METOCLOPRAMIDE

	AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	JAN	NEWA

SOLUTION; ORAL

	AA	UDL	EQ 5MG BASE/5ML	N75051 001	JAN 26, 2001	MAY	CDFR

TABLET; ORAL
METOCLOPRAMIDE HCL

	AB	GENEVA PHARMS TECH	EQ 5MG BASE	N74478 001	OCT 05, 1995	JAN	CAHN
	AB		EQ 10MG BASE	N74478 002	OCT 05, 1995	JAN	CAHN
>D>	AB	MUTUAL PHARM	EQ 5MG BASE	N71536 002	JAN 16, 1997	JUL	DISC
>A>		@	EQ 5MG BASE	N71536 002	JAN 16, 1997	JUL	DISC
>D>	AB		EQ 10MG BASE	N71536 001	APR 28, 1993	JUL	DISC
>A>		@	EQ 10MG BASE	N71536 001	APR 28, 1993	JUL	DISC

METOPROLOL SUCCINATE
TABLET, EXTENDED RELEASE; ORAL
TOPROL-XL

>D>		+ ASTRAZENECA	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	JUL	CRLD
>A>		+	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	JUL	CRLD
		+	EQ 25MG TARTRATE	N19962 004	FEB 05, 2001	FEB	NEWA
>D>		+	EQ 100MG TARTRATE	N19962 002	JAN 10, 1992	JUL	CRLD
>A>		+	EQ 100MG TARTRATE	N19962 002	JAN 10, 1992	JUL	CRLD

METRONIDAZOLE
INJECTABLE; INJECTION
METRO I.V.

		@ B BRAUN	500MG/100ML	N18674 001	AUG 31, 1982	MAY	DISC

METRONIDAZOLE

		@ ABBOTT	500MG/100ML	N18889 001	NOV 18, 1983	MAY	DISC
		@ ELKINS SINN	500MG/100ML	N18907 001	MAR 30, 1984	MAY	DISC

TABLET; ORAL
PROTOSTAT

		@ JOHNSON RW	250MG	N18871 001	MAR 02, 1983	MAR	DISC
		@	500MG	N18871 002	MAR 02, 1983	MAR	DISC

MEZLOCILLIN SODIUM MONOHYDRATE
INJECTABLE; INJECTION
MEZLIN

@	BAYER	EQ 1GM BASE/VIAL	N62372	005	JAN 13, 1983	MAY	DISC
@		EQ 2GM BASE/VIAL	N62372	001	MAY 13, 1982	MAY	DISC
@		EQ 3GM BASE/VIAL	N62372	002	MAY 13, 1982	MAY	DISC
@		EQ 4GM BASE/VIAL	N62372	003	MAY 13, 1982	MAY	DISC
@		EQ 20GM BASE/VIAL	N62372	004	MAR 02, 1988	MAY	DISC

MIDAZOLAM HYDROCHLORIDE
INJECTABLE; INJECTION
MIDAZOLAM HCL

@	APOTHECON	EQ 1MG BASE/ML	N75620	001	NOV 01, 2000	MAY	DISC
@		EQ 5MG BASE/ML	N75620	002	NOV 01, 2000	MAY	DISC
@		EQ 5MG BASE/ML	N75641	001	OCT 19, 2000	MAY	DISC
@	ASTRAZENECA	EQ 5MG BASE/ML	N75263	001	JUN 26, 2000	MAY	DISC

MINOCYCLINE HYDROCHLORIDE
CAPSULE; ORAL
MINOCIN

AB	LEDERLE	EQ 75MG BASE	N50649	003	FEB 12, 2001	MAR	NEWA
AB +		EQ 100MG BASE	N50649	002	MAY 31, 1990	MAR	CRLD

MINOCYCLINE HCL

AB	DANBURY PHARMA	EQ 100MG BASE	N63065	001	DEC 30, 1991	MAR	CRLD
AB	IMPAX LABS	EQ 75MG BASE	N65005	003	APR 18, 2001	APR	NEWA

VECTRIN

@	MEDICIS	EQ 75MG BASE	N63067	002	SEP 15, 1999	MAY	DISC
@		EQ 100MG BASE	N63067	001	JUL 31, 1990	MAY	DISC

POWDER, EXTENDED RELEASE; DENTAL
ARESTIN

+	ORAPHARMA	EQ 1MG BASE	N50781	001	FEB 16, 2001	FEB	NEWA

MIRTAZAPINE
TABLET, ORALLY DISINTEGRATING; ORAL
REMERON SOLTAB

+	ORGANON INC	15MG	N21208	001	JAN 12, 2001	JAN	NEWA
		30MG	N21208	002	JAN 12, 2001	JAN	NEWA
		45MG	N21208	003	JAN 12, 2001	JAN	NEWA

MORPHINE SULFATE
CAPSULE, EXTENDED RELEASE; ORAL
KADIAN

+	FAULDING PHARMS	20MG	N20616	001	JUL 03, 1996	JUN	CAHN
+		30MG	N20616	004	MAR 09, 2001	JUN	NEWA
+		50MG	N20616	002	JUL 03, 1996	JUN	CAHN
+		60MG	N20616	005	MAR 09, 2001	JUN	NEWA
+		100MG	N20616	003	JUL 03, 1996	JUN	CAHN

TABLET, EXTENDED RELEASE; ORAL
MORPHINE SULFATE

AB	WATSON LABS	100MG	N75656	001	JAN 30, 2001	JAN	NEWA

NADOLOL
TABLET; ORAL
NADOLOL

AB	GENEVA PHARMS TECH	20MG	N74501 001	NOV 09, 1995	JAN	CAHN
AB		40MG	N74501 002	NOV 09, 1995	JAN	CAHN
AB		80MG	N74501 003	NOV 09, 1995	JAN	CAHN

NAFCILLIN SODIUM
INJECTABLE; INJECTION
NAFCILLIN SODIUM

	@ APOTHECON	EQ 500MG BASE/VIAL	N61984 001	APR 29, 1976	MAY	DISC
+		EQ 500MG BASE/VIAL	N62527 001	AUG 02, 1984	MAY	CRLD
	@	EQ 1GM BASE/VIAL	N61984 002	APR 29, 1976	MAY	DISC
	@	EQ 2GM BASE/VIAL	N61984 003	APR 29, 1976	MAY	DISC
	@	EQ 4GM BASE/VIAL	N61984 005	APR 29, 1976	MAY	DISC
	@ MARSAM	EQ 500MG BASE/VIAL	N62844 001	OCT 26, 1988	MAY	DISC
	@	EQ 1GM BASE/VIAL	N62844 002	OCT 26, 1988	MAY	DISN
	@	EQ 1.5GM BASE/VIAL	N62844 003	OCT 26, 1988	MAY	DISC
	@	EQ 2GM BASE/VIAL	N62844 004	OCT 26, 1988	MAY	DISC
	@	EQ 4GM BASE/VIAL	N62844 005	OCT 26, 1988	MAY	DISC
	@	EQ 10GM BASE/VIAL	N63008 001	SEP 29, 1988	MAY	DISC
	NALLPEN					
	@ SMITHKLINE BEECHAM	EQ 500MG BASE/VIAL	N61999 001	JUL 10, 1978	MAY	DISC
	@	EQ 1GM BASE/VIAL	N61999 002	JUL 10, 1978	MAY	DISC
	@	EQ 2GM BASE/VIAL	N61999 003	JUL 10, 1978	MAY	DISC
	@	EQ 10GM BASE/VIAL	N61999 004	JUL 17, 1978	MAY	DISC
	UNIPEN					
	@ WYETH AYERST	EQ 500MG BASE/VIAL	N50320 001	JUN 23, 1970	MAY	DISC
	@	EQ 500MG BASE/VIAL	N62717 001	DEC 16, 1986	MAY	DISC
	@	EQ 1GM BASE/VIAL	N62717 002	DEC 16, 1986	MAY	DISC
	@	EQ 2GM BASE/VIAL	N50320 003	JUN 23, 1970	MAY	DISC
	@	EQ 2GM BASE/VIAL	N62717 004	DEC 16, 1986	MAY	DISC
	@	EQ 4GM BASE/VIAL	N50320 004	JUN 23, 1970	MAY	DISC
	@	EQ 10GM BASE/VIAL	N50320 005	DEC 21, 1978	MAY	DISC
	UNIPEN IN PLASTIC CONTAINER					
	@ WYETH AYERST	EQ 1GM BASE/VIAL	N50320 002	JUN 23, 1970	MAY	DISC

NALBUPHINE HYDROCHLORIDE
INJECTABLE; INJECTION
NALBUPHINE HCL

	@ ASTRAZENECA	10MG/ML	N72070 001	APR 10, 1989	JUN	DISC
	@	20MG/ML	N72073 001	APR 10, 1989	JUN	DISC

NALOXONE HYDROCHLORIDE
INJECTABLE; INJECTION
NALOXONE

	@ WYETH AYERST	0.02MG/ML	N70188 001	SEP 24, 1986	JAN	DISC
	@	0.02MG/ML	N70189 001	SEP 24, 1986	JAN	DISC
	@	0.4MG/ML	N70190 001	SEP 24, 1986	JAN	DISC
	@	0.4MG/ML	N70191 001	SEP 24, 1986	JAN	DISC

NALOXONE HYDROCHLORIDE; PENTAZOCINE HYDROCHLORIDE

TABLET; ORAL

NALOXONE HCL AND PENTAZOCAINE

>A>	AB	AMIDE PHARM	EQ 0.5MG BASE;EQ 50MG BASE	N75735 001	JUL 11, 2001	JUL	NEWA

NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

ALBALON

>D>	AT	ALLERGAN	0.1%	N80248 001	MAR 24, 1972	JUL	CRLD
>A>	AT		0.1%	N80248 001	MAR 24, 1972	JUL	CRLD

>D> NAPHCON FORTE

>D>	AT +	ALCON	0.1%	N80229 001	MAR 06, 1974	JUL	DISC
>A>		@	0.1%	N80229 001	MAR 06, 1974	JUL	DISC

OPCON

>D>	AT	BAUSCH AND LOMB	0.1%	N87506 001	DEC 01, 1981	JUL	DISC
>A>		@	0.1%	N87506 001	DEC 01, 1981	JUL	DISC

VASOCON

	AT	NOVARTIS	0.1%	N80235 002	MAR 24, 1983	FEB	CAHN

NAPROXEN

TABLET, EXTENDED RELEASE; ORAL

NAPROXEN

	AB +	ALPHAPHARM	375MG	N75390 001	APR 19, 2001	APR	NEWA
	AB +		500MG	N75390 002	APR 19, 2001	APR	NEWA

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

	AB	GENEVA PHARMS TECH	EQ 250MG BASE	N74495 001	DEC 05, 1994	JAN	CAHN
	AB		EQ 500MG BASE	N74495 002	DEC 05, 1994	JAN	CAHN

NEFAZODONE HYDROCHLORIDE

TABLET; ORAL

SERZONE

		BRISTOL MYERS SQUIBB	50MG	N20152 001	DEC 22, 1994	APR	CTEC

NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION; IRRIGATION

NEOMYCIN AND POLYMYXIN B SULFATES

		@ STERIS	EQ 40MG BASE/ML;200,000 UNITS/ML	N62664 001	APR 08, 1986	MAY	DISC

NEOSPORIN G.U. IRRIGANT

		MONARCH PHARMS	EQ 40MG BASE/ML;200,000 UNITS/ML	N60707 001	JUN 28, 1966	MAY	CTEC

SOLUTION/DROPS; OPHTHALMIC

STATROL

>D>		ALCON	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N62339 001	NOV 30, 1984	JUL	DISC
>A>		@	EQ 3.5MG BASE/ML;16,250 UNITS/ML	N62339 001	NOV 30, 1984	JUL	DISC

NETILMICIN SULFATE
INJECTABLE; INJECTION
NETROMYCIN
@ SCHERING — EQ 100MG BASE/ML — N50544 003 FEB 28, 1983 MAY DISC

NIFEDIPINE
CAPSULE; ORAL
NIFEDIPINE
@ CHASE LABS NJ — 10MG — N72409 001 JUL 04, 1990 FEB WDRP
@ — 20MG — N73421 001 JUN 19, 1991 FEB WDRP
TABLET, EXTENDED RELEASE; ORAL
ADALAT CC
AB1 BAYER — 30MG — N20198 001 APR 21, 1993 APR CTEC
NIFEDIPINE
AB2 BIOVAIL — 30MG — N75289 002 FEB 06, 2001 FEB NEWA
PROCARDIA XL
AB2 + PFIZER — 30MG — N19684 001 SEP 06, 1989 FEB CTEC

NITROFURAZONE
OINTMENT; TOPICAL
NITROFURAZONE
@ CLAY PARK — 0.2% — N84968 001 JAN 25, 1978 MAY DISC
POWDER; TOPICAL
FURACIN
@ ROBERTS LABS — 0.2% — N83791 001 OCT 17, 1975 FEB WDRP
SOLUTION; TOPICAL
NITROFURAZONE
@ CLAY PARK — 0.2% — N85130 001 NOV 02, 1978 MAY DISC
+ WENDT — 0.2% — N87081 001 JUL 22, 1981 MAY CTEC

NITROGLYCERIN
AEROSOL; SUBLINGUAL
NITROLINGUAL
@ POHL BOSKAMP — 0.4MG/SPRAY — N18705 001 OCT 31, 1985 APR DISC

NORETHINDRONE ACETATE
TABLET; ORAL
NORETHINDRONE ACETATE
AB BARR — 5MG — N75951 001 MAY 25, 2001 MAY NEWA

NORTRIPTYLINE HYDROCHLORIDE
CAPSULE; ORAL
PAMELOR
AB TYCO HLTHCARE — EQ 10MG BASE — N18013 001 AUG 01, 1977 JUN CAHN
AB — EQ 25MG BASE — N18013 002 AUG 01, 1977 JUN CAHN
AB — EQ 50MG BASE — N18013 004 JUN 14, 1979 JUN CAHN
AB + — EQ 75MG BASE — N18013 003 JUN 14, 1979 JUN CAHN
SOLUTION; ORAL
AA TYCO HLTHCARE — EQ 10MG BASE/5ML — N18012 001 AUG 01, 1977 JUN CAHN

		NYSTATIN						
		CREAM; TOPICAL						
		NILSTAT						
		@ LEDERLE	100,000 UNITS/GM	N61445 001	APR 02, 1971	MAY	DISC	
		NYSTATIN						
		@ TEVA	100,000 UNITS/GM	N61966 001	MAY 25, 1976	MAY	DISC	
		OINTMENT; TOPICAL						
		NILSTAT						
		@ LEDERLE	100,000 UNITS/GM	N61444 001	MAR 29, 1971	MAY	DISC	
		NYSTATIN						
	AT +	ALTANA	100,000 UNITS/GM	N62124 002	SEP 23, 1982	MAY	CTEC	
		SUSPENSION; ORAL						
		@ ROXANE	100,000 UNITS/ML	N62832 001	DEC 27, 1991	MAY	DISC	
		@ TEVA	100,000 UNITS/ML	N62670 001	JUN 18, 1987	MAY	DISC	
		@	100,000 UNITS/ML	N62776 001	DEC 17, 1987	MAY	DISC	
>D>	AA	THAMES	100,000 UNITS/ML	N62876 001	FEB 29, 1988	JUL	DISC	
>A>		@	100,000 UNITS/ML	N62876 001	FEB 29, 1988	JUL	DISC	
		TABLET; ORAL						
		@ EON	500,000 UNITS	N62065 001	JUL 22, 1977	MAY	DISC	
		@ ROSEMONT	500,000 UNITS	N62524 001	NOV 26, 1985	MAY	DISC	
		TABLET; VAGINAL						
		KOROSTATIN						
		@ HOLLAND RANTOS	100,000 UNITS	N61718 001	SEP 30, 1974	FEB	WDRP	
		NYSTATIN; TRIAMCINOLONE ACETONIDE						
		OINTMENT; TOPICAL						
		MYCO-TRIACET II						
		@ TEVA	100,000 UNITS/GM;0.1%	N62045 002	NOV 26, 1985	MAY	DISC	
		NYSTATIN AND TRIAMCINOLONE ACETONIDE						
		@ CLAY PARK	100,000 UNITS/GM;0.1%	N62280 002	OCT 10, 1985	MAY	DISC	
		OLANZAPINE						
		TABLET; ORAL						
		ZYPREXA						
		LILLY	15MG	N20592 005	SEP 09, 1997	JUN	CRLD	
	+		20MG	N20592 006	SEP 09, 1997	JUN	CMFD	
		OXACILLIN SODIUM						
		INJECTABLE; INJECTION						
		BACTOCILL						
		@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N62736 001	DEC 19, 1986	FEB	DISC	
		@	EQ 2GM BASE/VIAL	N62736 002	DEC 19, 1986	FEB	DISC	
		OXACILLIN SODIUM						
	AP +	APOTHECON	EQ 1GM BASE/VIAL	N61490 003	APR 08, 1971	FEB	CRLD	
	AP +		EQ 2GM BASE/VIAL	N62737 002	DEC 23, 1986	FEB	CRLD	
		@ IBI	EQ 125MG BASE/VIAL	N62798 003	DEC 11, 1995	MAY	DISC	
		@	EQ 250MG BASE/VIAL	N62798 004	DEC 11, 1995	MAY	DISC	
		@	EQ 500MG BASE/VIAL	N62798 005	DEC 11, 1995	MAY	DISC	
		@	EQ 1GM BASE/VIAL	N62798 001	DEC 11, 1995	MAY	DISC	
		@	EQ 2GM BASE/VIAL	N62798 002	DEC 11, 1995	MAY	DISC	

OXAPROZIN
TABLET; ORAL
DAYPRO
AB + SEARLE 600MG N18841 004 OCT 29, 1992 JAN CFTG
OXAPROZIN
AB DR REDDYS LABS LTD 600MG N75855 001 JAN 31, 2001 JAN NEWA
AB EON 600MG N75845 001 JAN 31, 2001 JAN NEWA
AB GENEVA PHARMS 600MG N75850 001 APR 27, 2001 APR NEWA
AB GENPHARM 600MG N75847 001 FEB 28, 2001 FEB NEWA >D>
AB INVAMED 600MG N75842 001 APR 12, 2001 APR NEWA >A>
AB WATSON LABS 600MG N75848 001 FEB 09, 2001 FEB NEWA >D>
>A>
>D>
>A>

OXAZEPAM
CAPSULE; ORAL
SERAX
AB FAULDING PHARMS 10MG N15539 002 SEP 29, 1966 JUN CAHN
AB 15MG N15539 004 SEP 29, 1966 JUN CAHN
AB + 30MG N15539 006 SEP 29, 1966 JUN CAHN
TABLET; ORAL
+ FAULDING PHARMS 15MG N15539 008 NOV 16, 1967 JUN CAHN

OXCARBAZEPINE
SUSPENSION; ORAL
TRILEPTAL
+ NOVARTIS 300MG/5ML N21285 001 MAY 25, 2001 MAY NEWA

OXYCODONE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL
OXYCONTIN
@ PURDUE PHARMA LP 160MG N20553 005 MAR 15, 2000 JUN DISC

OXYTETRACYCLINE HYDROCHLORIDE
CAPSULE; ORAL
OXYTETRACYCLINE HCL
@ IMPAX LABS EQ 250MG BASE N60760 001 AUG 09, 1967 FEB DISC >A>
@ PROTER EQ 250MG BASE N60869 001 JAN 29, 1964 FEB WDRP >D>
@ WEST WARD EQ 250MG BASE N60770 001 SEP 29, 1967 MAY DISC
TERRAMYCIN
+ PFIZER EQ 250MG BASE N50286 002 SEP 08, 1964 MAY CTEC >D>
>D>
>D>
>A>
>D>
>A>

PACLITAXEL
INJECTABLE; INJECTION
PACLITAXEL
>A> AP BEDFORD 6MG/ML N75190 001 JUL 27, 2001 JUL NEWA >A>
>A> AP MYLAN 6MG/ML N75278 001 JUL 23, 2001 JUL NEWA
AP ZENITH GOLDLINE 6MG/ML N75297 001 MAR 27, 2001 MAR NEWA >D>
>A>

PAMIDRONATE DISODIUM
INJECTABLE; INJECTION
AREDIA
AP + NOVARTIS 30MG/VIAL N20036 001 OCT 31, 1991 APR CFTG
AP + 90MG/VIAL N20036 004 MAY 06, 1993 APR CFTG

PAMIDRONATE DISODIUM
INJECTABLE; INJECTION
PAMIDRONATE DISODIUM

AP	BEDFORD	30MG/VIAL	N75290 001	APR 30, 2001	APR	NEWA
AP		90MG/VIAL	N75290 003	APR 30, 2001	APR	NEWA

PANCURONIUM BROMIDE
INJECTABLE; INJECTION
PANCURONIUM BROMIDE

>D>	AP	ASTRAZENECA	1MG/ML	N72210 001	MAR 31, 1988	JUL	DISC
>A>		@	1MG/ML	N72210 001	MAR 31, 1988	JUL	DISC
>D>	AP		2MG/ML	N72211 001	MAR 31, 1988	JUL	DISC
>A>		@	2MG/ML	N72211 001	MAR 31, 1988	JUL	DISC
>D>	AP		2MG/ML	N72213 001	MAR 31, 1988	JUL	DISC
>A>		@	2MG/ML	N72213 001	MAR 31, 1988	JUL	DISC

PANTOPRAZOLE SODIUM
INJECTABLE; IV (INFUSION)
PROTONIX IV

	+	WYETH AYERST	EQ 40MG BASE/VIAL	N20988 001	MAR 22, 2001	MAR	NEWA

TABLET, DELAYED RELEASE; ORAL
PROTONIX

	+	WYETH AYERST	EQ 20MG BASE	N20987 002	JUN 12, 2001	JUN	NEWA

PEMOLINE
TABLET; ORAL
PEMOLINE

AB	MALLINCKRODT	18.75MG	N75726 003	MAR 30, 2001	MAR	NEWA
AB		37.5MG	N75726 002	MAR 30, 2001	MAR	NEWA
AB		75MG	N75726 001	MAR 30, 2001	MAR	NEWA
AB	WATSON LABS	18.75MG	N75287 001	JUN 13, 2001	JUN	NEWA

PENCICLOVIR SODIUM
CREAM; TOPICAL
DENAVIR

>A>	+	NOVARTIS	1%	N20629 001	SEP 24, 1996	JUL	CAHN
>D>	+	SMITHKLINE BEECHAM	1%	N20629 001	SEP 24, 1996	JUL	CAHN

PENICILLIN G POTASSIUM
FOR SOLUTION; ORAL
PENICILLIN
TEVA

>D>			200,000 UNITS/5ML	N60307 002	MAY 27, 1964	JUL	DISC
>A>		@	200,000 UNITS/5ML	N60307 002	MAY 27, 1964	JUL	DISC
>D>			400,000 UNITS/5ML	N60307 004	MAY 27, 1964	JUL	DISC
>A>		@	400,000 UNITS/5ML	N60307 004	MAY 27, 1964	JUL	DISC

PENICILLIN-2
TEVA

>D>			250,000 UNITS/5ML	N60307 003	MAY 27, 1964	JUL	DISC
>A>		@	250,000 UNITS/5ML	N60307 003	MAY 27, 1964	JUL	DISC

TABLET; ORAL
PENICILLIN G POTASSIUM

		@ TEVA	200,000 UNITS	N60306 001	JUN 01, 1964	MAY	DISC
		@	250,000 UNITS	N60306 002	JUN 01, 1964	MAY	DISC
		@	400,000 UNITS	N60306 003	JUN 01, 1964	MAY	DISC

		@	500,000 UNITS	N60306 004	JUN 26, 1979	MAY	DISC
		PENICILLIN G PROCAINE					
		INJECTABLE; INJECTION					
		PENICILLIN G PROCAINE					
		@ PFIZER	300,000 UNITS/VIAL	N60099 001	NOV 10, 1948	MAY	DISC
		@	1,500,000 UNITS/VIAL	N60099 002	NOV 10, 1948	MAY	DISC
		PFIZERPEN-AS					
		@ PFIZER	300,000 UNITS/ML	N60286 001	NOV 01, 1950	MAY	DISC
		@	600,000 UNITS/ML	N60286 002	NOV 01, 1950	MAY	DISC
		WYCILLIN					
	+	KING PHARMS	300,000 UNITS/ML	N60101 002	APR 26, 1948	MAY	CTEC
	+		600,000 UNITS/ML	N60101 001	APR 26, 1948	MAY	CTEC
		PENICILLIN G SODIUM					
		INJECTABLE; IM-IV					
		PENICILLIN G SODIUM					
	+	BIOCHEMIE	5,000,000 UNITS/VIAL	N65068 001	FEB 26, 2001	FEB	NEWA
		@ MARSAM	5,000,000 UNITS/VIAL	N63014 001	SEP 13, 1988	FEB	DISC
		PENICILLIN V POTASSIUM					
		FOR SOLUTION; ORAL					
		PENICILLIN V POTASSIUM					
		@ MYLAN	EQ 125MG BASE/5ML	N61624 002	AUG 07, 1972	MAY	DISC
		@	EQ 250MG BASE/5ML	N61624 001	JUN 05, 1972	MAY	DISC
		V-CILLIN K					
		@ LILLY	EQ 125MG BASE/5ML	N60004 001	AUG 21, 1958	MAY	DISC
		@	EQ 250MG BASE/5ML	N60004 002	APR 07, 1967	MAY	DISC
		TABLET; ORAL					
		PEN-VEE K					
	AB +	WYETH AYERST	EQ 500MG BASE	N60006 003	JAN 13, 1958	MAY	CRLD
		PENICILLIN V POTASSIUM					
	AB +	BIOCHEMIE	EQ 500MG BASE	N64071 002	NOV 30, 1995	MAY	CTEC
		@ MYLAN	EQ 250MG BASE	N61530 001	NOV 18, 1971	MAY	DISC
		@	EQ 500MG BASE	N61530 002	MAR 20, 1972	MAY	DISC
		V-CILLIN K					
		@ LILLY	EQ 125MG BASE	N60003 001	SEP 17, 1957	MAY	DISC
		@	EQ 250MG BASE	N60003 002	SEP 17, 1957	MAY	DISC
		@	EQ 500MG BASE	N60003 003	SEP 17, 1957	MAY	DISC
		PENTOBARBITAL					
>D>		ELIXIR; ORAL					
>D>		NEMBUTAL					
>D>	+	ABBOTT	18.2MG/5ML	N83244 001	JAN 08, 1975	JUL	DISC
>A>		@	18.2MG/5ML	N83244 001	JAN 08, 1975	JUL	DISC
		PENTOBARBITAL SODIUM					
		CAPSULE; ORAL					
		NEMBUTAL SODIUM					
>D>	AA +	ABBOTT	50MG	N84093 001	JAN 14, 1975	JUL	DISC
>A>		@	50MG	N84093 001	JAN 14, 1975	JUL	DISC

		PENTOBARBITAL SODIUM							
>D>		SUPPOSITORY; RECTAL							
>D>		NEMBUTAL							
>D>		+ ABBOTT	30MG	N83247	001	JAN 25, 1982	JUL	DISC	
>A>		@	30MG	N83247	001	JAN 25, 1982	JUL	DISC	
>D>		+	60MG	N83247	002	JAN 25, 1982	JUL	DISC	
>A>		@	60MG	N83247	002	JAN 25, 1982	JUL	DISC	
>D>		+	120MG	N83247	003	JAN 25, 1982	JUL	DISC	
>A>		@	120MG	N83247	003	JAN 25, 1982	JUL	DISC	
>D>		+	200MG	N83247	004	JAN 25, 1982	JUL	DISC	
>A>		@	200MG	N83247	004	JAN 25, 1982	JUL	DISC	
>A>		PERFLUTREN							
>A>		INJECTABLE; INTRAVENOUS							
>A>		DEFINITY							
>A>		+ DUPONT PHARMS	6.52MG/ML	N21064	001	JUL 31, 2001	JUL	NEWA	
		PERPHENAZINE							
		CONCENTRATE; ORAL							
		PERPHENAZINE							
		+ PHARM ASSOC	16MG/5ML	N40360	001	MAY 25, 2001	MAY	NEWA	
		TRILAFON							
		@ SCHERING	16MG/5ML	N11557	001	DEC 12, 1958	MAR	DISC	
		PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM							
		TABLET; ORAL							
		SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PENAZOPYRIDINE HCL							
		+ ABLE	200MG;800MG;160MG	N21105	001	JUN 26, 2001	JUN	NEWA	
		PHENDIMETRAZINE TARTRATE							
		CAPSULE; ORAL							
		PHENDIMETRAZINE TARTRATE							
>D>	AA	+ EON	35MG	N85633	001	JUL 13, 1978	JUL	DISC	
>A>		@	35MG	N85633	001	JUL 13, 1978	JUL	DISC	
		@	35MG	N85694	001	JUN 05, 1978	MAY	DISC	
>D>	AA		35MG	N85702	001	JUN 07, 1978	JUL	DISC	
>A>		@	35MG	N85702	001	JUN 07, 1978	JUL	DISC	
		X-TROZINE							
>D>	AA	SHIRE RICHWOOD	35MG	N87394	001	SEP 22, 1982	JUL	CRLD	
>A>	AA	+	35MG	N87394	001	SEP 22, 1982	JUL	CRLD	
		CAPSULE, EXTENDED RELEASE; ORAL							
		BONTRIL							
>D>	BC	MALLINCKRODT	105MG	N88021	001	SEP 21, 1982	JUL	CRLD	
>A>	BC	+	105MG	N88021	001	SEP 21, 1982	JUL	CRLD	
		PHENDIMETRAZINE TARTRATE							
>D>	BC	+ GENEVA PHARMS	105MG	N87378	001	NOV 03, 1981	JUL	DISC	
>A>		@	105MG	N87378	001	NOV 03, 1981	JUL	DISC	
		TABLET; ORAL							
		PHENAZINE-35							
		@ ABC HOLDING	35MG	N85512	001	MAY 06, 1977	MAY	DISC	
		PHENDIMETRAZINE TARTRATE							
		@ EON	35MG	N85402	001	MAY 19, 1978	MAY	DISC	
		@	35MG	N85497	001	AUG 19, 1977	MAY	DISC	

>D>	AA	MIKART	35MG	N89452 001	OCT 30, 1991	JUL	DISC
>A>		@	35MG	N89452 001	OCT 30, 1991	JUL	DISC
		@ ROSEMONT	35MG	N84399 001	MAY 28, 1981	MAY	DISC
>D>		STATOBEX					
>D>	AA	TEVA	35MG	N86013 001	DEC 16, 1977	JUL	DISC
>A>		@	35MG	N86013 001	DEC 16, 1977	JUL	DISC
		X-TROZINE					
>D>	AA	SHIRE RICHWOOD	35MG	N86550 001	SEP 16, 1981	JUL	DISC
>A>		@	35MG	N86550 001	SEP 16, 1981	JUL	DISC
>D>	AA		35MG	N86551 001	SEP 16, 1981	JUL	DISC
>A>		@	35MG	N86551 001	SEP 16, 1981	JUL	DISC
>D>	AA		35MG	N86552 001	SEP 16, 1981	JUL	DISC
>A>		@	35MG	N86552 001	SEP 16, 1981	JUL	DISC
		PHENTERMINE HYDROCHLORIDE					
		CAPSULE; ORAL					
>D>		OBY-TRIM					
>D>	AA	SHIRE RICHWOOD	30MG	N87764 001	MAR 18, 1982	JUL	DISC
>A>		@	30MG	N87764 001	MAR 18, 1982	JUL	DISC
		PHENTERMINE HCL					
		@ ABC HOLDING	30MG	N85411 001	SEP 10, 1980	MAY	DISC
		@ ROSEMONT	30MG	N84487 001	APR 09, 1982	MAY	DISC
		TABLET; ORAL					
		+ EON	30MG	N88605 001	SEP 28, 1987	MAY	CMFD
		PHENYTOIN					
		SUSPENSION; ORAL					
		PHENYTOIN					
	AB	UDL	125MG/5ML	N40342 001	JAN 31, 2001	JAN	NEWA
		PIPERAZINE CITRATE					
		SYRUP; ORAL					
		PIPERAZINE CITRATE					
		@ LANNETT	EQ 500MG BASE/5ML	N80963 001	JUL 25, 1974	MAY	DISC
		TABLET; ORAL					
		@ IMPAX LABS	EQ 250MG BASE	N80874 001	JUL 19, 1973	MAY	DISC
		PIPOBROMAN					
>D>		TABLET; ORAL					
>D>		VERCYTE					
>D>		+ ABBOTT	25MG	N16245 002	JUL 01, 1966	JUL	DISC
>A>		@	25MG	N16245 002	JUL 01, 1966	JUL	DISC
		POTASSIUM CHLORIDE					
		TABLET, EXTENDED RELEASE; ORAL					
		K-DUR 10					
	AB	KEY PHARMS	10MEQ	N19439 002	JUN 13, 1986	APR	CTEC
		PRAZOSIN HYDROCHLORIDE					
		CAPSULE; ORAL					
		PRAZOSIN HCL					
>D>	AB	PUREPAC PHARM	EQ 1MG BASE	N72991 001	MAY 16, 1989	JUL	DISC
>A>		@	EQ 1MG BASE	N72991 001	MAY 16, 1989	JUL	DISC

>D>	AB		EQ 2MG BASE	N72921 001	MAY 16, 1989	JUL	DISC	
>A>		@	EQ 2MG BASE	N72921 001	MAY 16, 1989	JUL	DISC	
>D>	AB		EQ 5MG BASE	N72992 001	MAY 16, 1989	JUL	DISC	
>A>		@	EQ 5MG BASE	N72992 001	MAY 16, 1989	JUL	DISC	

PREDNICARBATE
OINTMENT; TOPICAL
DERMATOP

	+	AVENTIS PHARMS	0.1%	N19568 001	SEP 23, 1991	MAR	CMFD	

PREDNISOLONE
TABLET; ORAL
PREDNISOLONE

		@ CHELSEA LABS	5MG	N85085 002	FEB 23, 1977	MAY	DISC	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM
OINTMENT; OPHTHALMIC
VASOCIDIN

AT		NOVARTIS	0.5%;10%	N88791 001	OCT 05, 1984	FEB	CAHN	

SUSPENSION/DROPS; OPHTHALMIC
METIMYD

	+	SCHERING	0.5%;10%	N10210 001	FEB 24, 1956	FEB	CTEC	

PREDAMIDE

		@ AKORN	0.5%;10%	N88059 001	JUL 29, 1983	FEB	WDRP	

SULPHRIN

		@ BAUSCH AND LOMB	0.5%;10%	N88089 001	DEC 28, 1982	FEB	WDRP	

PREDNISOLONE SODIUM PHOSPHATE
SOLUTION/DROPS; OPHTHALMIC
INFLAMASE FORTE

AT	+	NOVARTIS	EQ 0.9% PHOSPHATE	N80751 002	DEC 19, 1973	FEB	CAHN	

INFLAMASE MILD

AT	+	NOVARTIS	EQ 0.11% PHOSPHATE	N80751 001	DEC 19, 1973	FEB	CAHN	

PREDNISOLONE SODIUM PHOSPHATE

		@ AKORN	EQ 0.11% PHOSPHATE	N83358 001	AUG 21, 1974	FEB	WDRP	
		@	EQ 0.9% PHOSPHATE	N83358 002	AUG 21, 1974	FEB	WDRP	
		@ ALCON UNIVERSAL	EQ 0.11% PHOSPHATE	N81043 001	OCT 24, 1991	MAY	DISC	
		@	EQ 0.9% PHOSPHATE	N81044 001	OCT 24, 1991	MAY	DISC	

PREDNISONE
TABLET; ORAL
PREDNISONE

		@ CHELSEA LABS	5MG	N85084 002	DEC 15, 1981	MAY	DISC	
		@ GENEVA PHARMS	5MG	N80336 002	JUL 29, 1976	MAY	DISC	
>D>	AB	HALSEY	10MG	N86595 001	APR 10, 1979	JUL	DISC	
>A>		@	10MG	N86595 001	APR 10, 1979	JUL	DISC	
		@ LANNETT	20MG	N84275 001	JUN 27, 1974	MAY	DISC	

PRIMIDONE
SUSPENSION; ORAL
MYSOLINE

>D>	+	ELAN PHARMA	250MG/5ML	N10401 001	JUL 05, 1956	JUL	CAHN	
>A>	+	XCEL PHARMS	250MG/5ML	N10401 001	JUL 05, 1956	JUL	CAHN	

PRIMIDONE
TABLET; ORAL
MYSOLINE

>D>	AB		ELAN PHARMA	50MG	N09170 003	MAR 08, 1954	JUL	CAHN
	AB			50MG	N09170 003	MAR 08, 1954	MAY	CFTG
>D>	AB	+		250MG	N09170 002	MAR 08, 1954	JUL	CAHN
>A>	AB		XCEL PHARMS	50MG	N09170 003	MAR 08, 1954	JUL	CAHN
>A>	AB	+		250MG	N09170 002	MAR 08, 1954	JUL	CAHN
			PRIMIDONE					
	AB		LANNETT	50MG	N84903 002	MAY 24, 2001	MAY	NEWA

PROCHLORPERAZINE
SUPPOSITORY; RECTAL
COMPAZINE

>D>			SMITHKLINE BEECHAM	2.5MG	N11127 003	FEB 09, 1959	JUL	CFTG
>A>	AB			2.5MG	N11127 003	FEB 09, 1959	JUL	CFTG
>D>				5MG	N11127 001	SEP 27, 1957	JUL	CFTG
>A>	AB			5MG	N11127 001	SEP 27, 1957	JUL	CFTG
			PROCHLORPERAZINE					
>A>	AB		ABLE	2.5MG	N40407 001	JUL 11, 2001	JUL	NEWA
>A>	AB			5MG	N40407 002	JUL 11, 2001	JUL	NEWA
>A>	AB			25MG	N40407 003	JUL 11, 2001	JUL	NEWA

PROCHLORPERAZINE EDISYLATE
INJECTABLE; INJECTION
PROCHLORPERAZINE EDISYLATE

>D>	AP		WYETH AYERST	EQ 5MG BASE/ML	N86348 001	JUL 05, 1979	JUL	DISC
>A>			@	EQ 5MG BASE/ML	N86348 001	JUL 05, 1979	JUL	DISC

PROCHLORPERAZINE MALEATE
TABLET; ORAL
PROCHLORPERAZINE MALEATE

	AB		GENEVA PHARMS TECH	EQ 5MG BASE	N40101 001	JUL 19, 1996	JAN	CAHN
	AB			EQ 10MG BASE	N40101 002	JUL 19, 1996	JAN	CAHN
	AB			EQ 25MG BASE	N40101 003	JUL 19, 1996	JAN	CAHN

PROGESTERONE
INJECTABLE; INJECTION
PROGESTERONE

	AO		AM PHARM PARTNERS	50MG/ML	N75906 001	APR 25, 2001	APR	NEWA
	AO	+	STERIS	50MG/ML	N17362 002	MAY 08, 1978	APR	CFTG

PROMETHAZINE HYDROCHLORIDE
SUPPOSITORY; RECTAL
PROMETHACON

			@ POLYMEDICA	50MG	N84902 001	OCT 05, 1981	MAY	DISC

TABLET; ORAL
PHENERGAN

			WYETH AYERST	12.5MG	N07935 002	MAR 29, 1951	MAY	CTEC
			PROMETHAZINE HCL					
			@ LANNETT	12.5MG	N80949 001	JUL 28, 1976	MAY	DISC
			@	25MG	N80949 002	JUN 28, 1976	MAY	DISC

	@	50MG	N80949 003	JUN 28, 1976	MAY	DISC
	@ PVT FORM	25MG	N83658 001	OCT 01, 1976	MAY	DISC
	PROPOXYPHENE HYDROCHLORIDE					
	CAPSULE; ORAL					
	PROPOXYPHENE HCL					
	@ GENEVA PHARMS	65MG	N83125 002	APR 14, 1976	MAY	DISC
	@ IMPAX LABS	65MG	N83317 001	OCT 23, 1973	MAY	DISC
	PROPRANOLOL HYDROCHLORIDE					
	TABLET; ORAL					
	PROPRANOLOL HCL					
	@ LEDERLE	10MG	N70125 001	JUL 30, 1985	MAY	DISC
	@ WATSON LABS	20MG	N70549 001	APR 11, 1986	MAY	DISC
	PROTRIPTYLINE HYDROCHLORIDE					
	TABLET; ORAL					
	PROTRIPTYLINE HCL					
AB	ODYSSEY PHARMS	5MG	N73644 001	AUG 24, 1995	JAN	CAHN
AB		10MG	N73645 001	AUG 24, 1995	JAN	CAHN
	VIVACTIL					
AB	ODYSSEY PHARMS	5MG	N73644 001	AUG 24, 1995	MAR	CTNA
AB +		10MG	N73645 001	AUG 24, 1995	MAR	CTNA
	@ SIDMAK LABS	5MG	N16012 001	SEP 27, 1967	MAR	DISC
	@	10MG	N16012 002	SEP 27, 1967	MAR	DISC
	PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE					
	SYRUP; ORAL					
	TRILITRON					
	@ NEWTRON PHARMS	30MG/5ML;1.25MG/5ML	N88474 001	FEB 12, 1985	FEB	WDRP
	QUINIDINE GLUCONATE					
	TABLET, EXTENDED RELEASE; ORAL					
	QUINAGLUTE					
BX +	BERLEX LABS	324MG	N16647 001	DEC 08, 1969	MAR	CTEC
	QUINIDINE GLUCONATE					
BX	DANBURY PHARMA	324MG	N87810 001	SEP 29, 1982	MAR	CTEC
	@ GENEVA PHARMS	324MG	N89894 001	DEC 15, 1988	MAR	DISC
BX	MUTUAL PHARM	324MG	N89338 001	FEB 11, 1987	MAR	CTEC
	QUINIDINE SULFATE					
	TABLET; ORAL					
	QUINIDINE SULFATE					
	@ IMPAX LABS	200MG	N83347 001	DEC 08, 1976	FEB	DISC
	@ MUTUAL PHARM	300MG	N81031 001	APR 14, 1989	MAY	DISC
	@ WEST WARD	200MG	N83862 001	SEP 02, 1976	MAY	DISC
	RIFAMPIN					
	CAPSULE; ORAL					
	RIFAMPIN					
AB	VERSAPHARM	150MG	N65028 001	MAR 14, 2001	MAR	NEWA
AB		300MG	N65028 002	MAR 14, 2001	MAR	NEWA

RISPERIDONE
TABLET; ORAL
RISPERDAL
JANSSEN

+	0.5MG	N20272 007	JAN 27, 1999	APR	CRLD
	1MG	N20272 001	DEC 29, 1993	APR	CRLD
	4MG	N20272 004	DEC 29, 1993	APR	CRLD

SECOBARBITAL SODIUM
CAPSULE; ORAL
SECOBARBITAL SODIUM
@ ICN

100MG	N85477 001	DEC 10, 1981	FEB	WDRP

SECRETIN
INJECTABLE; INJECTION
SECRETIN-FERRING
@ FERRING

75CU/VIAL	N18290 001	MAY 29, 1981	JUN	DISC

SILVER SULFADIAZINE
DRESSING; TOPICAL
SILDAFLO
@ QUESTCOR PHARMS

1%	N19608 001	NOV 30, 1989	MAY	CTNA

SIMVASTATIN
TABLET; ORAL
ZOCOR
MERCK

5MG	N19766 001	DEC 23, 1991	APR	CTEC

SODIUM POLYSTYRENE SULFONATE
SUSPENSION; ORAL, RECTAL
SPS

AA	+	CAROLINA MEDCL	15GM/60ML	N87859 001	DEC 08, 1982	MAY	CRLD

SODIUM TETRADECYL SULFATE
INJECTABLE; INJECTION
SOTRADECOL

>D>	+	ELKINS SINN	1%	N05970 004	AUG 13, 1946	JUL	DISC
>A>	@		1%	N05970 004	AUG 13, 1946	JUL	DISC
>D>	+		3%	N05970 005	AUG 13, 1946	JUL	DISC
>A>	@		3%	N05970 005	AUG 13, 1946	JUL	DISC

SOTALOL HYDROCHLORIDE
TABLET; ORAL
SORINE

AB		UPSHER SMITH	80MG	N75500 001	APR 27, 2001	APR	NEWA
AB			120MG	N75500 004	APR 27, 2001	APR	NEWA
AB			160MG	N75500 002	APR 27, 2001	APR	NEWA
AB			240MG	N75500 003	APR 27, 2001	APR	NEWA

STREPTOMYCIN SULFATE
INJECTABLE; INJECTION
STREPTOMYCIN SULFATE
@ PFIZER

EQ 1GM BASE/VIAL	N60076 001	FEB 18, 1946	MAY	DISC

	@	EQ 5GM BASE/VIAL	N60076 002	FEB 18, 1946	MAY	DISC	
	+ PHARMA TEK	EQ 1GM BASE/VIAL	N64210 001	JUN 30, 1998	MAY	CTEC	
	SULFACETAMIDE SODIUM						
	OINTMENT; OPHTHALMIC						
	BLEPH-10						
	@ ALLERGAN	10%	N84015 001	JAN 07, 1975	MAY	DISC	
	CETAMIDE						
AT	+ ALCON	10%	N80021 001	SEP 27, 1972	MAY	CTEC	
	SODIUM SULAMYD						
	@ SCHERING	10%	N05963 002	NOV 26, 1947	MAY	DISC	
	SOLUTION/DROPS; OPHTHALMIC						
	BLEPH-10						
AT	+ ALLERGAN	10%	N80028 001	MAY 25, 1971	MAY	CRLD	
	BLEPH-30						
AT	+ ALLERGAN	30%	N80028 002	MAY 25, 1971	MAY	CRLD	
	SODIUM SULAMYD						
	@ SCHERING	10%	N05963 001	AUG 01, 1946	MAY	DISC	
	@	30%	N05963 003	NOV 26, 1947	MAY	DISC	
	SULF-10						
	@ NOVARTIS	10%	N80025 001	JUN 03, 1971	FEB	CAHN	
	SULF-15						
AT	NOVARTIS	15%	N89047 001	OCT 31, 1995	FEB	CAHN	
	SULTEN-10						
	@ BAUSCH AND LOMB	10%	N87818 001	FEB 03, 1983	FEB	WDRP	
	SULFAMETHOXAZOLE						
	TABLET; ORAL						
	GANTANOL						
	+ ROCHE	500MG	N12715 002	NOV 17, 1961	MAY	CTEC	
	SULFAMETHOXAZOLE						
	@ GENEVA PHARMS	500MG	N85844 001	MAR 23, 1978	MAY	DISC	
	SULFAMETHOXAZOLE; TRIMETHOPRIM						
	SUSPENSION; ORAL						
	TRIMETH/SULFA						
	@ NASKA	200MG/5ML;40MG/5ML	N72399 001	MAY 23, 1988	FEB	WDRP	
	TABLET; ORAL						
	SULFAMETHOXAZOLE AND TRIMETHOPRIM						
	@ TEVA	400MG;80MG	N18242 001	MAY 19, 1981	MAY	DISC	
	@	800MG;160MG	N18242 002	MAY 19, 1981	MAY	DISC	
	SULFANILAMIDE						
	CREAM; VAGINAL						
	AVC						
AT	+ NOVAVAX	15%	N06530 003	JAN 27, 1987	JAN	CAHN	
	SUPPOSITORY; VAGINAL						
	+ NOVAVAX	1.05GM	N06530 004	JAN 27, 1987	JAN	CAHN	
	SULFISOXAZOLE						
	TABLET; ORAL						
	SULFISOXAZOLE						
>D> AB	GENEVA PHARMS	500MG	N85628 001	JUN 13, 1977	JUL	DISC	

>A>	@		500MG	N85628 001	JUN 13, 1977	JUL	DISC	

TECHNETIUM TC-99M APCITIDE
INJECTABLE; INJECTION
ACUTECT

>D>		BERLEX LABS	N/A					
			N/A	N20887 001	SEP 14, 1998	JUL	CAHN	
>A>		DIATIDE RES LABS	N/A	N20887 001	SEP 14, 1998	MAY	CAHN	
			N/A	N20887 001	SEP 14, 1998	JUL	CAHN	
				N20887 001	SEP 14, 1998	APR	CAHN	

TEMAZEPAM
CAPSULE; ORAL
RESTORIL

		TYCO HLTHCARE						
	AB		7.5MG	N18163 003	OCT 25, 1991	JUN	CAHN	
	AB	+	15MG	N18163 001	FEB 27, 1981	JUN	CAHN	
			30MG	N18163 002	FEB 27, 1981	JUN	CAHN	

TERAZOSIN HYDROCHLORIDE
CAPSULE; ORAL
TERAZOSIN HCL

	AB	TORPHARM						
	AB		EQ 1MG BASE	N75498 001	APR 12, 2001	APR	NEWA	
	AB		EQ 2MG BASE	N75498 002	APR 12, 2001	APR	NEWA	
	AB		EQ 5MG BASE	N75498 003	APR 12, 2001	APR	NEWA	
	AB		EQ 10MG BASE	N75498 004	APR 12, 2001	APR	NEWA	
	AB	ZENITH GOLDLINE	EQ 1MG BASE	N75614 002	JAN 30, 2001	JAN	NEWA	
	AB		EQ 2MG BASE	N75614 001	JAN 30, 2001	JAN	NEWA	
	AB		EQ 5MG BASE	N75614 003	JAN 30, 2001	JAN	NEWA	
	AB		EQ 10MG BASE	N75614 004	JAN 30, 2001	JAN	NEWA	

TERBUTALINE SULFATE
TABLET; ORAL
BRETHINE

	AB	NOVARTIS						
	AB	+	2.5MG	N17849 001	MAY 17, 1976	JUN	CFTG	
			5MG	N17849 002	MAY 17, 1976	JUN	CFTG	
		TERBUTALINE SULFATE						
	AB	IMPAX LABS	2.5MG	N75877 001	JUN 26, 2001	JUN	NEWA	
	AB		5MG	N75877 002	JUN 26, 2001	JUN	NEWA	

TETRACYCLINE HYDROCHLORIDE
CAPSULE; ORAL
PANMYCIN

		@ PHARMACIA AND UPJOHN	250MG	N60347 001	SEP 28, 1954	MAY	DISC	
		ROBITET						
		@ WYETH AYERST	250MG	N61734 001	JUN 06, 1973	MAY	DISC	
		@	500MG	N61734 002	JUN 06, 1973	MAY	DISC	
		TETRACYCLINE HCL						
		@ DANBURY PHARMA	250MG	N62343 001	OCT 02, 1981	MAY	DISC	
		@	500MG	N62343 002	OCT 02, 1981	MAY	DISC	
		@ EON	250MG	N61471 001	OCT 28, 1971	MAY	DISC	
		@ WEST WARD	250MG	N60768 001	AUG 24, 1964	MAY	DISC	
		@	500MG	N60768 002	NOV 07, 1977	MAY	DISC	
>D>	AB	WYETH AYERST	250MG	N61685 001	DEC 11, 1972	JUL	DISC	
>A>		@	250MG	N61685 001	DEC 11, 1972	JUL	DISC	

>D>	AB		500MG	N61685 002	DEC 11, 1972	JUL	DISC
>A>		@	500MG	N61685 002	DEC 11, 1972	JUL	DISC
		THIORIDAZINE HYDROCHLORIDE					
		TABLET; ORAL					
		THIORIDAZINE HCL					
>D>	AB	CHELSEA LABS	10MG	N88561 001	MAY 11, 1984	JUL	DISC
>A>		@	10MG	N88561 001	MAY 11, 1984	JUL	DISC
>D>	AB	TEVA	10MG	N88493 001	MAY 17, 1985	JUL	DISC
>A>		@	10MG	N88493 001	MAY 17, 1985	JUL	DISC
>D>	AB	ZENITH GOLDLINE	50MG	N88194 001	APR 14, 1983	JUL	DISC
>A>		@	50MG	N88194 001	APR 14, 1983	JUL	DISC
		THIOTEPA					
		INJECTABLE; INJECTION					
		THIOPLEX					
	AP +	IMMUNEX	15MG/VIAL	N20058 001	DEC 22, 1994	APR	CFTG
		THIOTEPA					
	AP	BEDFORD	15MG/VIAL	N75547 001	APR 02, 2001	APR	NEWA
	AP	GENSIA SICOR PHARMS	15MG/VIAL	N75730 001	APR 20, 2001	APR	NEWA
	+		30MG/VIAL	N75730 002	APR 20, 2001	APR	NEWA
		@ IMMUNEX	15MG/VIAL	N11683 001	FEB 19, 1959	APR	DISC
		THYROGLOBULIN					
		TABLET; ORAL					
		THYROGLOBULIN					
		@ IMPAX LABS	64.8MG	N80151 001	AUG 07, 1973	FEB	DISC
		TICARCILLIN DISODIUM					
		INJECTABLE; INJECTION					
		TICAR					
		@ SMITHKLINE BEECHAM	EQ 3GM BASE/VIAL	N62690 001	DEC 19, 1986	MAY	DISC
		TOBRAMYCIN					
		SOLUTION/DROPS; OPHTHALMIC					
		TOBRAMYCIN					
		@ ALCON UNIVERSAL	0.3%	N63176 001	MAY 25, 1994	MAY	DISC
		TOBRAMYCIN SULFATE					
		INJECTABLE; INJECTION					
		TOBRAMYCIN SULFATE					
		@ ASTRAZENECA	EQ 40MG BASE/ML	N63121 001	OCT 31, 1994	MAY	DISC
		@ ELKINS SINN	EQ 10MG BASE/ML	N63128 001	NOV 27, 1991	MAY	DISC
		@	EQ 40MG BASE/ML	N63127 001	NOV 27, 1991	MAY	DISC
		@ LEDERLE	EQ 10MG BASE/ML	N63113 001	APR 26, 1991	MAY	DISC
		TOLMETIN SODIUM					
		CAPSULE; ORAL					
		TOLMETIN SODIUM					
>D>	AB	GENEVA PHARMS	EQ 400MG BASE	N73462 001	APR 30, 1992	JUL	DISC
>A>		@	EQ 400MG BASE	N73462 001	APR 30, 1992	JUL	DISC

TOPIRAMATE
TABLET; ORAL
TOPAMAX
+ JOHNSON RW — 25MG — N20505 004 DEC 24, 1996 MAR CRLD
200MG — N20505 002 DEC 24, 1996 MAR CRLD

TRAVOPROST
SOLUTION/DROPS; OPHTHALMIC
TRAVATAN
+ ALCON UNIVERSAL — 0.004% — N21257 001 MAR 16, 2001 MAR NEWA

TRIAMCINOLONE
TABLET; ORAL
TRIAMCINOLONE
@ IMPAX LABS — 4MG — N84340 001 APR 22, 1975 FEB DISC

TRIAMCINOLONE ACETONIDE
CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
@ TARO — 0.025% — N40038 001 OCT 26, 1994 MAY DISC
@ TOPIDERM — 0.025% — N89274 001 FEB 21, 1989 FEB WDRP
@ — 0.1% — N89275 001 FEB 21, 1989 FEB WDRP
@ — 0.5% — N89276 001 FEB 21, 1989 FEB WDRP
>D> DISC; TOPICAL
>D> KENALOG
>D> + APOTHECON — 0.147MG/GM — N12104 001 DEC 24, 1959 JUL CDFR
OINTMENT; TOPICAL
ARISTOCORT
>D> AT FUJISAWA HLTHCARE — 0.5% — N80745 002 MAY 28, 1974 JUL DISC
>A> @ — 0.5% — N80745 002 MAY 28, 1974 JUL DISC
ARISTOCORT A
>D> AT FUJISAWA HLTHCARE — 0.5% — N80745 003 SEP 23, 1975 JUL DISC
>A> @ — 0.5% — N80745 003 SEP 23, 1975 JUL DISC
TRIAMCINOLONE ACETONIDE
>D> AT G AND W LABS — 0.025% — N89795 001 DEC 23, 1988 JUL DISC
>A> @ — 0.025% — N89795 001 DEC 23, 1988 JUL DISC
>D> AT — 0.1% — N89796 001 DEC 23, 1988 JUL DISC
>A> @ — 0.1% — N89796 001 DEC 23, 1988 JUL DISC
AT THAMES — 0.025% — N40374 001 JUN 05, 2001 JUN NEWA
AT — 0.5% — N40386 001 JUN 05, 2001 JUN NEWA
>A> SPRAY; TOPICAL
>A> KENALOG
>A> + APOTHECON — 0.147MG/GM — N12104 001 DEC 24, 1959 JUL CDFR

TRICHLORMETHIAZIDE
TABLET; ORAL
TRICHLOREX
@ LANNETT — 4MG — N83436 001 AUG 11, 1980 MAY DISC
@ — 4MG — N85630 001 MAY 16, 1977 FEB WDRP

TRIFLUOPERAZINE HYDROCHLORIDE
CONCENTRATE; ORAL
TRIFLUOPERAZINE HCL
@ GENEVA PHARMS — EQ 10MG BASE/ML — N85787 001 APR 15, 1982 MAY DISC

TRIFLUOPERAZINE HYDROCHLORIDE
TABLET; ORAL
TRIFLUOPERAZINE HCL
TABLET; ORAL

AB	GENEVA PHARMS TECH	EQ 1MG BASE	N40153 001	OCT 25, 1996	JAN	CAHN
AB		EQ 2MG BASE	N40153 002	OCT 25, 1996	JAN	CAHN
AB		EQ 5MG BASE	N40153 003	OCT 25, 1996	JAN	CAHN
AB		EQ 10MG BASE	N40153 004	OCT 25, 1996	JAN	CAHN

TRIMETHOBENZAMIDE HYDROCHLORIDE
INJECTABLE; INJECTION
TRIMETHOBENZAMIDE HCL

>D> AP	STERIS	100MG/ML	N86577 001	OCT 19, 1982	JUL	DISC
>A>	@	100MG/ML	N86577 001	OCT 19, 1982	JUL	DISC

TRIMETHOPRIM HYDROCHLORIDE
SOLUTION; ORAL
PRIMSOL

@ ASCENT PEDS	EQ 25MG BASE/5ML	N74374 001	JUN 23, 1995	JUN	DISC

TRIPLE SULFA (SULFABENZAMIDE;SULFACETAMIDE;SULFATHIAZOLE)
CREAM; VAGINAL
TRIPLE SULFA

@ FOUGERA	3.7%;2.86%;3.42%	N86424 001	MAY 31, 1979	JUN	DISC

TRIPTORELIN PAMOATE
INJECTABLE; INTRAMUSCULAR
TRELSTAR

+ DEBIO RECHERCHE	11.25MG/VIAL	N21288 001	JUN 29, 2001	JUN	NEWA

TRELSTAR DEPOT

+ DEBIO RECHERCHE	EQ 3.75MG BASE/VIAL	N20715 001	JUN 15, 2000	JUN	CDFR

URACIL MUSTARD
CAPSULE; ORAL
URACIL MUSTARD

@ SHIRE PHARM	1MG	N12892 001	SEP 13, 1962	JUN	DISC

VALGANCICLOVIR HYDROCHLORIDE
TABLET; ORAL
VALCYTE

+ SYNTEX (USA) INC LLC	EQ 450MG BASE	N21304 001	MAR 29, 2001	MAR	NEWA

VALPROIC ACID
CAPSULE; ORAL
VALPROIC ACID

@ PAR PHARM	250MG	N70431 001	FEB 28, 1986	MAY	DISC
>D> AB SCHERER RP	250MG	N70195 001	JUL 02, 1987	JUL	DISC
>A> @	250MG	N70195 001	JUL 02, 1987	JUL	DISC

VALSARTAN
>A> TABLET; ORAL
>A> DIOVAN

>A> NOVARTIS	80MG	N21283 001	JUL 18, 2001	JUL	NEWA

>A>								
>A>	+		160MG	N21283 002	JUL 18, 2001	JUL	NEWA	
			320MG	N21283 003	JUL 18, 2001	JUL	NEWA	
	VANCOMYCIN HYDROCHLORIDE							
	INJECTABLE; INJECTION							
	VANCOMYCIN HCL							
	@ ELKINS SINN		EQ 500MG BASE/VIAL	N62879 001	AUG 02, 1988	MAY	DISC	
	@		EQ 1GM BASE/VIAL	N62879 002	AUG 02, 1988	MAY	DISC	
	VINBLASTINE SULFATE							
	INJECTABLE; INJECTION							
	VELBAN							
	@ LILLY		10MG/VIAL	N12665 001	MAR 06, 1961	MAY	DISC	
	VINBLASTINE SULFATE							
AP	+ BEDFORD		10MG/VIAL	N89395 001	APR 09, 1987	MAY	CRLD	
	VITAMIN A PALMITATE							
	CAPSULE; ORAL							
	VITAMIN A							
	@ WEST WARD		EQ 50,000 UNITS BASE	N80967 001	MAY 04, 1973	FEB	WDRP	
	WARFARIN SODIUM							
	TABLET; ORAL							
	COUMADIN							
>D>	AB + DUPONT MERCK		2.5MG					>D>
>A>	AB		2.5MG	N09218 018	NOV 29, 1961	JUL	CRLD	>A>
>D>	AB +		5MG	N09218 018	NOV 29, 1961	JUL	CRLD	
>A>	AB +		5MG	N09218 007	FEB 17, 1964	JUL	CRLD	
				N09218 007	FEB 17, 1964	JUL	CRLD	
	ZIPRASIDONE HYDROCHLORIDE							
	CAPSULE; ORAL							
	GEODON							
	PFIZER		20MG					
			40MG	N20825 001	FEB 05, 2001	FEB	NEWA	
			60MG	N20825 002	FEB 05, 2001	FEB	NEWA	
	+		80MG	N20825 003	FEB 05, 2001	FEB	NEWA	
				N20825 004	FEB 05, 2001	FEB	NEWA	>D>
								>A>
	ZOLMITRIPTAN							
	TABLET, ORALLY DISINTEGRATING; ORAL							
	ZOMIG-ZMT							
	ASTRAZENECA		2.5MG	N21231 001	FEB 13, 2001	FEB	NEWA	>A>
								>A>

>A>

ACETAMINOPHEN
SUPPOSITORY; RECTAL

	ACETAMINOPHEN						
	ALPHARMA US PHARM	120MG	N18337 003	SEP 12, 1983	MAR	CAHN
		325MG	N18337 002	AUG 21, 1981	MAR	CAHN
+		650MG	N18337 001	APR 22, 1980	MAR	CAHN
	INFANTS' FEVERALL					
	ALPHARMA US PHARM	80MG	N18337 004	AUG 26, 1992	MAR	CAHN

ACETAMINOPHEN; CLEMASTINE FUMARATE; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL

	TAVIST ALLERGY/SINUS/HEADACHE						
+	NOVARTIS	500MG;EQ 0.25MG BASE;30MG	N21082 001	MAR 01, 2001	MAR	NEWA

ALCOHOL; CHLORHEXIDINE GLUCONATE
SOLUTION; TOPICAL

	AVAGARD						
+	3M	61%;1%	N21074 001	JUN 07, 2001	JUN	NEWA

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL

	BROMATAPP						
>D>	COPLEY PHARM	12MG;75MG	N71099 001	JUL 02, 1987	JUL	DISC
>A>	@	12MG;75MG	N71099 001	JUL 02, 1987	JUL	DISC

CLEMASTINE FUMARATE; PHENYLPROPANOLAMINE HYDROCHLORIDE
TABLET, EXTENDED RELEASE; ORAL

	TAVIST-D						
	@ NOVARTIS	1.34MG;75MG	N18298 002	AUG 21, 1992	JAN	DISC
	@	1.34MG;75MG	N20640 001	AUG 09, 1996	JAN	DISC

CLOTRIMAZOLE
CREAM; VAGINAL

	TRIVAGIZOLE 3						
>D>	+ TARO	2%	N21143 001	APR 12, 2000	JUL	CRLD
>A>	+	2%	N21143 001	APR 12, 2000	JUL	CRLD

CROMOLYN SODIUM
SPRAY, METERED; NASAL

>A>	CROMOLYN SODIUM						
>A>	BAUSCH AND LOMB	5.2MG/SPRAY	N75702 001	JUL 03, 2001	JUL	NEWA

FAMOTIDINE
TABLET; ORAL

	FAMOTIDINE						
	TEVA	10MG	N75312 001	MAY 31, 2001	MAY	NEWA
>A>	ZENITH GOLDLINE	10MG	N75512 001	JUL 26, 2001	JUL	NEWA

IBUPROFEN; PSEUDOEPHEDRINE HYDROCHLORIDE
TABLET; ORAL

	IBUPROHM COLD AND SINUS						
	OHM LABS	200MG;30MG	N74567 001	APR 17, 2001	APR	NEWA

INSULIN PURIFIED PORK
INJECTABLE; INJECTION
REGULAR PURIFIED PORK INSULIN
+ NOVO NORDISK 100 UNITS/ML N18381 001 MAR 17, 1980 MAY CTEC

INSULIN RECOMBINANT HUMAN
INJECTABLE; INJECTION
NOVOLIN R
+ NOVO NORDISK 100 UNITS/ML N19938 001 JUN 25, 1991 MAY CTEC

INSULIN RECOMBINANT HUMAN; INSULIN SUSP ISOPHANE RECOMBINANT HUMAN
INJECTABLE; INJECTION
HUMULIN 50/50
+ LILLY 50 UNITS/ML;50 UNITS/ML N20100 001 APR 29, 1992 MAY CTEC
NOVOLIN 70/30
+ NOVO NORDISK 30 UNITS/ML;70 UNITS/ML N19991 001 JUN 25, 1991 MAY CTEC

MICONAZOLE NITRATE
CREAM; TOPICAL
MONISTAT 3 COMBINATION PACK
+ PERSONAL PRODS 2%;4% N21261 001 FEB 02, 2001 FEB NEWA
CREAM; TOPICAL, VAGINAL
+ PERSONAL PRODS 2%;4% N21261 001 FEB 02, 2001 MAY CDFR
CREAM; VAGINAL

MINOXIDIL
SOLUTION; TOPICAL
MINOXIDIL EXTRA STRENGTH (FOR MEN)
PERRIGO 5% N75598 001 JUN 13, 2001 JUN NEWA

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST

CUMULATIVE SUPPLEMENT NUMBER 7 JULY '01

NO JULY 2001 APPROVALS

This data is provided to the Division of Data Management and Services from the Office of Orphan Products Development and it is not edited prior to publication.

Orphan Products Designations and Approvals List
July 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
2-methoxyestradiol TN=Panzem	Treatment of multiple myeloma	EntreMed, Inc. 9640 Medical Center Drive Rockville MD 20850 DD= 7/10/01 MA=
9-nitro-20-(S)-camptothecin TN=Camvirex	Treatment of pediatric HIV infection/AIDS	NovoMed Pharmaceuticals, Inc. P.O. Box 900 Germantown MD 20875-0900 DD= 5/15/01 MA=
Adeno-associated viral vector containing the gene for human coagulation factor IX TN=Coagulin-B	Intrahepatic treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502 DD= 6/13/01 MA=
Adeno-associated viral vector containing the gene for human coagulation factor IX TN=Coagulin-B	Intramuscular treatment of patients with moderate to severe hemophilia	Avigen, Inc. 1301 Harbor Bay Parkway Alameda CA 94502 DD= 6/13/01 MA=
adenovirus-mediated herpes simplex virus-thymidine kinase TN=	Use with gancyclovir in the treatment of malignant glioma	Ark Therapeutics Ltd 6 Warren Mews London W1T6AR UK DD= 7/31/01 MA=
Alendronate disodium TN=Fosamax	Treatment of the bone manifestations of Gaucher disease	Richard J. Wenstrup, M.D. Division of Human Genetics Children's Hospital Research Cincinnati OH 45229-3039 DD= 2/13/01 MA=

Orphan Products Designations and Approvals List
July 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
B Lymphocyte Stimulator TN=BLyS	Treatment of common variable immunodeficiency (CVID)	Human Genome Sciences, Inc. 9410 Key West Avenue Rockville MD 20850 DD= 2/21/01 MA=
Busulfan TN=Spartajet-Busulfan	Intrathecal therapy for neoplastic meningitis	SuperGen, Inc. 4140 Dublin Boulevard Dublin CA 94568 DD= 3/5/01 MA=
Coenzyme Q10 TN=	For the treatrment of Huntington's disease	Vitaline Corporation 385 Williamson Way Ashland OR 97520 DD= 3/5/01 MA=
docosahexanoic acid-paclitaxel TN=Taxoprexin	Treatment of hormone-refractory prostate cancer.	Protarga, Inc. 1100 East Hector Street Suite 450 Conshohocken PA 19428-2377 DD= 3/5/01 MA=
Glatiramer acetate for injection TN=Copaxone	Treatment of primary-progressive multiple sclerosis	TEVA Pharmaceuticals, USA 1090 Horsham Road North Wales PA 19454 DD= 6/5/01 MA=
h5G1.1mAb TN=	Idiopathic membranous glomerular nephropathy	Alexion Pharmaceuticals, Inc. 352 Knotter Drive Cheshire CT 06410 DD= 3/5/01 MA=
Hsp E7 TN=	Treatment of recurrent respiratory papillomatosis (RRP)	StressGen Biotechnologies, Inc. 409 2nd Avenue Suite 201 Collegeville PA 19426-2655 DD= 3/19/01 MA=

Orphan Products Designations and Approvals List
July 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
human gammaglobulin TN=	Treatment for juvenile rheumatoid arthritis	Protein Therapeutics, Inc 9040 S. Rita Rd., Suite 1100 Tucson AZ 84747 DD= 5/25/01 MA=
Imatinib TN=Gleevec	Treatment of chronic myelogenous leukemia	Novartis Pharmaceuticals 59 Route 10 East Hanover NJ 07936-1080 DD= 1/31/01 MA= 5/10/01
INH-A00021 TN=	Reduction (prevention) of nosocomial bacteremia caused by staphylococci in very low birth weight infants.	Inhibitex, Inc. 8995 Westside Parkway Suite 150 Alpharetta GA 30004 DD= 6/13/01 MA=
Interferon-alfa-1b TN=	Treatment of multiple myeloma	Ernest C.Borden Center for Cancer Drud Discovery 9500 Euclid Avenue Clevland OH 44195 DD= 4/17/01 MA=
Intraoral fluoride releasing system TN=IFRS	Prevention of dental caries due to radiation-induced xerostomia in patients with head and neck cancer	Digestive Care, Inc. 1120 Win Drive Bethlehem PA 18017 DD= 7/31/01 MA=
Latrodectus immune F(ab)2 TN=Aracmyn	Treatment of black widow spider envenomations	Rare Disease Therapeutics, Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 6/18/01 MA=
Medroxyprogesterone acetate TN=Hematrol	Treatment of immune thrombocytopenic purpura.	InKine Pharmaceutical Company, 1787 Sentry Parkway West Building 18, Suite 440 Blue Bell PA 19422 DD= 2/22/01 MA=

Orphan Products Designations and Approvals List
July 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
MTC-DOX for Injection TN=	Treatment of hepatocellular carcinoma	FeRx Incorporated 4330 La Jolla Village Drive Suite #250 San Diego CA 92122 DD= 1/3/01 MA=
muramyltripeptide, phosphatidyl-ethanolamine encased in multi-lamellar liposomes TN=	Treatment of children and adolescent osteosarcoma	Jenner Biotherapies, Inc. 541 Kenosa Street Walworth WI 53184 DD= 6/5/01 MA=
Nitroprusside TN=	Treatment and prevention of cerebral vasospasm following subarachnoid hemorrhage.	Thomas, MD, Jeffrey Evan Thomas Jefferson University and 834 Walnut Street, Suite 650 Philadelphia PA 19107-5102 DD= 2/21/01 MA=
Novel Acting Thrombolytic (NAT) TN=	Treatment of peripheral arterial occlusion (PAO)	Amgen, Inc. One Amgen Center Drive Thousand Oaks CA 91320-1799 DD= 1/26/01 MA=
NZ-1002 TN=	Enzyme replacement therapy in patients with all subtypes of Mucopolysaccharidosis I.	Novazyme Pharmaceuticals, Inc. 800 Research Parkway Suite 200 Oklahoma City OK 73104 DD= 4/11/01 MA=
p1-(uridine 5'-)-p4-(2'-deoxycytidine 5'-) tetraphosphate, tetrasodium salt TN=	For the treatment of cystic fibrosis	Inspire Pharmaceuticals, Inc. 4222 Emperor Blvd. Suite 470 Durham NC 27703 DD= 3/7/01 MA=

Orphan Products Designations and Approvals List
July 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
Perflubron TN=LiquiVent	Treatment of acute respiratory distress disease (ARDS) in adults	Alliance Pharmaceutical Corp. 3040 Science Park Road San Diego CA 92191 DD= 4/26/01 MA=
Polyethylene glycol (PEG)-uricase TN=	To control the clinical consequences of hyperuricemia in patients with severe gout in whom conventional therapy is contraindicated or has been ineffective.	Bio-Technology General Corporation 70 Wood Avenue South Iselin NJ 08830 DD= 2/21/01 MA=
Pyruvate TN=	Treatment of interstitial lung disease.	Cellular Sciences, Inc 84 park Avenue P.O. Box 968 Flemington NJ 08822 DD= 2/21/01 MA=
Recombinant Human Alpha-Fetoprotein TN=	Treatment of myasthenia gravis	Atlantic Biopharmaceuticals, Inc. 50 Church Street 5th floor Cambridge MA 02138 DD= 2/22/01 MA=
Reviparin sodium TN=Clivarine	Treatment of deep vein thrombosis which may lead to pulmonary embolism in pediatric patients	Knoll AG Ludwigshafen, Germany DD= 6/18/01 MA=
Reviparin sodium TN=Clivarine	Long-term treatment of acute deep vein trombosis with or without pulmonary embolism in pregnant patients	Knoll AG Ludwigshafen, Germany DD= 6/18/01 MA=

Orphan Products Designations and Approvals List
July 2001

Name: Generic Name TN=Trade Name	Indication Designated:	Sponsor & Address DD=Date Designated MA=Marketing Approval
squalamine lactate TN=	Treatment of ovarian cancer refractory or resistant to standard chemotherapy	Genaera Corporation 5110 Campus Drive Plymouth Meeting PA 19462 DD= 5/11/01 MA=
Synthetic Human Parathyroid Hormone 1-34 TN=	Treatment of hypoparathyroidism	Orphan Pharmaceuticals, U.S., Inc. 1101 Kermit Drive, Suite 608 Nashville TN 37217 DD= 1/26/01 MA=
Unconjugated Chimeric (human-murine) G250 IgG monoclonal antibody TN=	Treatment of renal cell carcinoma.	Wilex Biotechnology GmbH Grillparzerstrasse 10B 81675 Munich Germany DE DD= 3/22/01 MA=
Vasoactive intestinal peptide TN=	Treatment of Acute Respiratory Distress Syndrome.	Sami I. Said, M.D. State University of New York at Health Sciences Center T17, 040 Stony Brook NY 11794-8172 DD= 3/9/01 MA=
Virulizin TN=Virulizin	Treatment of pancreatic cancer.	Lorus Therapeutics Inc. 7100 Woodbine Avenue, Suite 215 Markham, ON L3R 5J2 Canada DD= 2/1/01 MA=

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 2001 ADDITIONS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021205 001	ABACAVIR SULFATE;TRIZIVIR	6180639	JAN 30, 2018	U-248		
	021082 001	ACETAMINOPHEN;TAVIST ALLERGY/SINUS				NC	MAR 01, 2004
	021123 001	ACETAMINOPHEN;ULTRACET	5336691	AUG 09, 2011		NC	AUG 15, 2004
	020760 001	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018			
	020760 002	ALATROFLOXACIN MESYLATE;TROVAN PRESERVATIVE	6194429	JUL 23, 2018		NCE	DEC 18, 2002
	020949 001	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
	020949 002	ALBUTEROL SULFATE;ACCUNEB				NP	APR 30, 2004
	020950 001	ALBUTEROL SULFATE;DUONEB				NP	MAR 21, 2004
	020983 001	ALBUTEROL SULFATE;VENTOLIN HFA	6251368	DEC 04, 2012		I-235	SEP 23, 2001
						I-262	JUN 02, 2002
	021074 001	ALCOHOL;AVAGARD	5897031	JUN 21, 2016		NC	JUN 07, 2004
	020560 001	ALENDRONATE SODIUM;FOSAMAX	6194004	DEC 02, 2012			
	020560 004	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
	020560 005	ALENDRONATE SODIUM;FOSAMAX	6225294	JUL 17, 2018			
>ADD>	021001 001	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
>ADD>	021001 002	ALMOTRIPTAN MALATE;AXERT	5565447	MAR 27, 2014		NCE	MAY 07, 2006
>ADD>	021107 001	ALOSETRON HYDROCHLORIDE;LOTRONEX	6284770	OCT 05, 2018	U-405		
			5360800	FEB 02, 2010			
	021078 001	ATOVAQUONE;MALARONE	6166046	NOV 25, 2013		NC	JUL 14, 2003
			5053432	OCT 01, 2008			
	021078 002	ATOVAQUONE;MALARONE PEDIATRIC	5053432	OCT 01, 2008		NC	JUL 14, 2003
	019408 002	BETAMETHASONE DIPROPIONATE;DIPROLENE	4489070	MAY 13, 2003			
	021056 001	BEXAROTENE;TARGRETIN	5780676	JUL 14, 2015		ODE	DEC 29, 2006
			5962731	OCT 05, 2016			
			5466861	NOV 14, 2012			
	020498 001	BICALUTAMIDE;CASODEX	1712251	SEP 18, 2001	U-391		
			5712251	SEP 18, 2001	U-391		
	021275 001	BIMATOPROST;LUMIGAN	5688819	SEP 21, 2012		NCE	MAR 16, 2006
>ADD>	020613 001	BRIMONIDINE TARTRATE;ALPHAGAN	6194415	JUN 28, 2015	U-394		
>ADD>			6248741	JUN 28, 2015	U-394		
>ADD>	021262 001	BRIMONIDINE TARTRATE;ALPHAGAN P	6194415	JUN 28, 2015	U-395	NP	MAY 16, 2004
>ADD>			6248741	JUN 28, 2015	U-395		
>ADD>			5424078	JUN 13, 2012			
>ADD>			5736165	APR 07, 2015	U-399		
	020816 001	BRINZOLAMIDE;AZOPT	5378703	APR 01, 2012	U-224		
	020358 001	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
	020358 002	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
	020358 003	BUPROPION HYDROCHLORIDE;WELLBUTRIN SR				M-10	JUN 11, 2004
	074253 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	074253 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	075272 003	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 24, 2001
	075467 002	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	SEP 26, 2001
	076008 001	BUSPIRONE HYDROCHLORIDE;BUSPIRONE HCL				PC	JAN 28, 2002
	020524 001	BUTENAFINE HYDROCHLORIDE;MENTAX				I-333	JUN 06, 2004

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	018874 001	CALCITRIOL;CALCIJEX	6274169	AUG 02, 2019			
			4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
>ADD>	018874 002	CALCITRIOL;CALCIJEX	6265392	AUG 02, 2019			
			6274169	AUG 02, 2019			
			4308264	JAN 28, 2001			
			6051567	AUG 02, 2019			
			4308264*PED	JUL 28, 2001			
			6051567*PED	FEB 02, 2020			
	019976 001	CALCIUM ACETATE;PHOSLO	6265392	AUG 02, 2019			
	021160 001	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	021160 002	CALCIUM ACETATE;PHOSLO	4870105	APR 07, 2007	U-381		
	020896 001	CAPECITABINE;XELODA	4870105	APR 07, 2007	U-381		
	020896 002	CAPECITABINE;XELODA				I-323	APR 30, 2004
	021227 001	CASPOFUNGIN ACETATE;CANCIDAS				I-323	APR 30, 2004
			5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
	021227 002	CASPOFUNGIN ACETATE;CANCIDAS	5952300	MAR 28, 2017		NCE	JAN 26, 2006
			5378804	MAR 16, 2013			
			5514650	MAR 16, 2013			
			5792746	MAR 16, 2013			
			6136783	MAR 28, 2017			
	019111 001	CHLORPHENIRAMINE POLISTIREX;TUSSIONEX	4762709	AUG 09, 2005			
>ADD>	021149 001	CHORIOGONADOTROPIN ALFA;OVIDREL	5767251	JUN 16, 2015		NP	SEP 20, 2003
	021022 001	CICLOPIROX;PENLAC	4957730	SEP 18, 2007	U-379		
>ADD>	020839 001	CLOPIDOGREL BISULFATE;PLAVIX	4847265	NOV 17, 2011			
	020705 001	DELAVIRDINE MESYLATE;RESCRIPTOR	6177101	JUN 11, 2018			
	020607 001	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
	020607 002	DICLOFENAC SODIUM;ARTHROTEC	5698225	MAY 03, 2010	U-392		
>ADD>	021005 001	DICLOFENAC SODIUM;SOLARAZE	5639738	JUN 17, 2014	U-402	NP	OCT 16, 2003
>ADD>			5792753	AUG 11, 2015			
>ADD>			5852002	JUN 17, 2014	U-402		
>ADD>			5914322	AUG 11, 2015			
>ADD>			5929048	JUL 27, 2016	U-402		
>ADD>			5985850	NOV 16, 2016			
>ADD>	020154 002	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
>ADD>			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			5880106	JUL 22, 2011			
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>			5616566*PED	MAR 01, 2007	U-180		
>ADD>			5880106*PED	JAN 22, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020154 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
>ADD>			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			5880106	JUL 22, 2011			
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>			5616566*PED	MAR 01, 2007	U-180		
>ADD>			5880106*PED	JAN 22, 2012			
>ADD>	020154 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
>ADD>			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			5880106	JUL 22, 2011			
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>			5616566*PED	MAR 01, 2007	U-180		
>ADD>			5880106*PED	JAN 22, 2012			
>ADD>	020154 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	D-58	OCT 28, 2002
>ADD>			5616566	AUG 29, 2006	U-180	PED	APR 28, 2003
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			5880106	JUL 22, 2011			
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>			5616566*PED	MAR 01, 2007	U-180		
>ADD>			5880106*PED	JAN 22, 2012			
>ADD>	020154 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248	NS	OCT 28, 2002
>ADD>			5254539	AUG 29, 2006	U-248	PED	APR 28, 2003
>ADD>			5880106	JUL 22, 2011			
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>			5616566*PED	MAR 01, 2007	U-180		
>ADD>			5880106*PED	JAN 22, 2012			
>ADD>			5616566	AUG 29, 2006	U-180		
>ADD>	020155 003	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5616566	AUG 29, 2006	U-180		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>			5616566*PED	MAR 01, 2007	U-180		
>ADD>	020155 004	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5616566	AUG 29, 2006	U-180		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>			5616566*PED	MAR 01, 2007	U-180		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020155 005	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5616566	AUG 29, 2006	U-180		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>			5616566*PED	MAR 01, 2007	U-180		
>ADD>	020155 006	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-52		
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>			5616566*PED	MAR 01, 2007	U-180		
>ADD>			5616566	AUG 29, 2006	U-180		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>	020156 001	DIDANOSINE;VIDEX	4861759	AUG 29, 2006	U-248		
>ADD>			5616566	AUG 29, 2006	U-180		
>ADD>			5254539	AUG 29, 2006	U-248		
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>			5616566*PED	MAR 01, 2007	U-180		
>ADD>	021183 001	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
>ADD>			5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>	021183 002	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
>ADD>			5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>	021183 003	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
>ADD>			5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
>ADD>	021183 004	DIDANOSINE;VIDEX EC	4861759	AUG 29, 2006	U-248	NDF	OCT 31, 2003
>ADD>			5254539	AUG 29, 2006	U-248	PED	MAY 01, 2004
>ADD>			4861759*PED	MAR 01, 2007	U-248		
>ADD>			5254539*PED	MAR 01, 2007	U-248		
	020623 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020623 002	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020624 001	DOLASETRON MESYLATE MONOHYDRATE;ANZEMET	4906755	JUL 02, 2011			
	020690 001	DONEPEZIL HYDROCHLORIDE;ARICEPT	6140321	DEC 30, 2016			
			6245911	DEC 01, 2018			
	020690 002	DONEPEZIL HYDROCHLORIDE;ARICEPT	5985864	DEC 30, 2016			
			6140321	DEC 30, 2016			
			6245911	DEC 01, 2018			
	020869 001	DORZOLAMIDE HYDROCHLORIDE;COSOPT	5985864	DEC 30, 2016			
			6248735	APR 17, 2011			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021098 001	DROSPIRENONE;YASMIN				NC	MAY 11, 2004
>ADD>	020706 001	EMEDASTINE DIFUMARATE;EMADINE	4430343	AUG 14, 2005	U-403		
>ADD>			5441958	DEC 08, 2013	U-404		
>ADD>	020668 001	ENALAPRIL MALEATE;LEXXEL	4264611	JUN 19, 2001	U-3		
>ADD>			4803081	APR 03, 2007			
>ADD>			4264611*PED	DEC 19, 2001	U-3		
>ADD>			4803081*PED	OCT 03, 2007			
>ADD>	020668 002	ENALAPRIL MALEATE;LEXXEL	4374829	DEC 30, 2001	U-3		
>ADD>			4472380	SEP 18, 2001			
>ADD>			4703038	OCT 07, 2005	U-3		
>ADD>			4803081	APR 03, 2007			
>ADD>			4264611	JUN 19, 2001	U-3		
>ADD>			4264611*PED	DEC 19, 2001	U-3		
>ADD>			4803081*PED	OCT 03, 2007			
	018998 001	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 002	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 003	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	018998 005	ENALAPRIL MALEATE;VASOTEC				M-7	DEC 13, 2004
	020164 002	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 003	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 004	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 005	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 006	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001			
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 007	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020164 008	ENOXAPARIN SODIUM;LOVENOX	4486420	DEC 04, 2001	U-122		
			4692435	DEC 24, 2004	U-123		
			5389618	FEB 14, 2012			
	020718 001	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
	020718 002	EPTIFIBATIDE;INTEGRILIN				D-66	JUN 08, 2004
>ADD>	019386 001	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	DEC 23, 2008			
>ADD>	019386 002	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	DEC 23, 2008			
>ADD>	019386 003	ESMOLOL HYDROCHLORIDE;BREVIBLOC	5017609	DEC 23, 2008			
>ADD>			4593119	JUN 03, 2003			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
021153 001	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
		4738974	APR 19, 2005	U-373		
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4508905	FEB 20, 2001			
021153 002	ESOMEPRAZOLE MAGNESIUM;NEXIUM	4255431	APR 05, 2001	U-373	NP	FEB 20, 2004
		4738974	APR 19, 2005	U-373		
		4636499	MAY 30, 2005	U-373		
		5900424	MAY 04, 2016	U-373		
		4786505	APR 20, 2007	U-373		
		4853230	APR 20, 2007	U-373		
		5714504	FEB 03, 2015	U-373		
		5877192	MAY 27, 2014	U-373		
		5093342	FEB 02, 2010	U-373		
		5599794	FEB 04, 2014	U-373		
		5629305	FEB 04, 2014	U-373		
		5690960	NOV 25, 2014	U-373		
		6147103	OCT 09, 2018			
		6166213	OCT 09, 2018			
		6191148	OCT 09, 2018			
		4508905	FEB 20, 2001			
020870 001	ESTRADIOL;COMBIPATCH	5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020870 002	ESTRADIOL;COMBIPATCH	6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			
020538 005	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
		6024976	JAN 07, 2014			
		5474783	DEC 12, 2012			
		5656286	AUG 12, 2014			
		5958446	DEC 12, 2012			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020538 006	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 007	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020538 008	ESTRADIOL;VIVELLE-DOT	6024976	JAN 07, 2014			
			5474783	DEC 12, 2012			
			5656286	AUG 12, 2014			
			5958446	DEC 12, 2012			
	020130 002	ETHINYL ESTRADIOL;ESTROSTEP FE	5010070	APR 23, 2008		I-331	JUL 01, 2004
	020130 001	ETHINYL ESTRADIOL;ESTROSTEP 21	5010070	APR 23, 2008		I-331	JUL 01, 2004
	020946 001	ETHINYL ESTRADIOL;PREVEN EMERGENCY CON	6156742	DEC 05, 2020	U-374		
>ADD>	020584 001	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
>ADD>						PED	FEB 11, 2004
>ADD>	020584 002	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
>ADD>						PED	FEB 11, 2004
>ADD>	020584 003	ETODOLAC;LODINE XL				I-321	AUG 11, 2003
>ADD>						PED	FEB 11, 2004
>ADD>	020457 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	RE35524	MAY 17, 2010			
>ADD>	020906 001	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	RE35524	MAY 17, 2010			
			5041424	AUG 20, 2008	U-135		
>ADD>	020906 002	ETOPOSIDE PHOSPHATE;ETOPOPHOS PRESERVATI	RE35524	MAY 17, 2010			
			5041424	AUG 20, 2008	U-135		
	075312 001	FAMOTIDINE;FAMOTIDINE				PC	NOV 28, 2001
	020902 001	FAMOTIDINE;PEPCID AC				D-47	NOV 09, 2001
						PED	MAY 09, 2002
>ADD>	019834 001	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
>ADD>			4803081	APR 03, 2007			
>ADD>			4803081*PED	OCT 03, 2007			
>ADD>			4264611*PED	DEC 19, 2001	U-3		
>ADD>	019834 002	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
>ADD>			4803081	APR 03, 2007			
>ADD>			4264611*PED	DEC 19, 2001	U-3		
>ADD>			4803081*PED	OCT 03, 2007			
>ADD>	019834 004	FELODIPINE;PLENDIL	4264611	JUN 19, 2001	U-3		
>ADD>			4803081	APR 03, 2007			
>ADD>			4264611*PED	DEC 19, 2001	U-3		
>ADD>			4803081*PED	OCT 03, 2007			
	020625 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020872 002	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020872 004	FEXOFENADINE HYDROCHLORIDE;ALLEGRA	6187791	MAY 11, 2012	U-138		
	020786 001	FEXOFENADINE HYDROCHLORIDE;ALLEGRA-D	6187791	MAY 11, 2012	U-138		
	020985 001	FLUOROURACIL;CARAC	4690825	OCT 04, 2005			
>ADD>	021235 001	FLUOXETINE HYDROCHLORIDE;PROZAC WEEKLY	5910319	MAY 29, 2017	U-396	NDF	FEB 26, 2004
>ADD>			5985322	MAY 29, 2017	U-397		
	018936 007	FLUOXETINE HYDROCHLORIDE;SARAFEM				PED	JAN 06, 2004
	021077 001	FLUTICASONE PROPIONATE;ADVAIR DISKUS 100/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 002	FLUTICASONE PROPIONATE;ADVAIR DISKUS 250/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	021077 003	FLUTICASONE PROPIONATE;ADVAIR DISKUS 500/50	5270305	SEP 07, 2010	U-387		
			5290815	MAR 01, 2011	U-386		
	020831 001	FORMOTEROL FUMARATE;FORADIL				NCE	FEB 16, 2006
>ADD>	021279 001	FORMOTEROL FUMARATE;FORADIL				NDF	SEP 25, 2004
>ADD>						NCE	FEB 16, 2006
	021169 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021169 002	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021169 003	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	021224 001	GALANTAMINE HYDROBROMIDE;REMINYL	4663318	JAN 15, 2006		NCE	FEB 28, 2006
	020239 002	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-89		
	021238 001	GRANISETRON HYDROCHLORIDE;KYTRIL	4886808	DEC 29, 2007	U-105	I-264	JUL 27, 2002
	020387 001	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020387 002	HYDROCHLOROTHIAZIDE;HYZAAR	5608075	MAR 04, 2014			
	020402 002	IBUPROFEN POTASSIUM;ADVIL MIGRAINE LIQUI				NP	MAR 16, 2003
	021128 001	IBUPROFEN;CHILDREN'S MOTRIN CO	6211246	JUN 10, 2019			
>ADD>	021335 001	IMATINIB MESYLATE;GLEEVEC				NCE	MAY 10, 2006
>ADD>						ODE	MAY 10, 2008
	021335 002	IMATINIB MESYLATE;GLEEVEC				NCE	MAY 10, 2006
						ODE	MAY 10, 2008
>ADD>	021081 001	INSULIN GLARGINE;LANTUS	5656722*PED	MAR 12, 2015			
			5656722	SEP 12, 2014			
	020394 001	IPRATROPIUM BROMIDE;ATROVENT				I-327	OCT 27, 2003
	018662 002	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	018662 003	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	018662 004	ISOTRETINOIN;ACCUTANE	4464394	AUG 07, 2001			
			4464394*PED	FEB 07, 2002			
	020657 001	ITRACONAZOLE;SPORANOX				I-332	MAY 09, 2004
>ADD>	020966 001	ITRACONAZOLE;SPORANOX	4791111	DEC 23, 2005		I-332	MAY 09, 2004
>ADD>	019700 001	KETOROLAC TROMETHAMINE;ACULAR	4454151	MAR 22, 2002	U-75		
>ADD>			5110493	MAY 05, 2009			
>ADD>			4454151*PED	SEP 22, 2002	U-75		
>ADD>			5110493*PED	NOV 05, 2009	U-75		
					U-75		

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	020811 001	KETOROLAC TROMETHAMINE;ACULAR PRESERVATIVE	4454151	MAR 22, 2002			
>ADD>			4454151*PED	SEP 22, 2002			
	020857 001	LAMIVUDINE;COMBIVIR	6180639	JAN 30, 2018	U-248		
	020564 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
	020596 001	LAMIVUDINE;EPIVIR	6180639	JAN 30, 2018	U-248		
	021281 001	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	021281 002	LANSOPRAZOLE;PREVACID				I-316	NOV 30, 2003
						M-1	JUL 06, 2002
						D-42	JUL 20, 2001
	020905 001	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 002	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020905 003	LEFLUNOMIDE;ARAVA	4284786	DEC 13, 2001			
	020726 001	LETROZOLE;FEMARA	4978672	JUN 03, 2011	U-203		
	021088 001	LEUPROLIDE ACETATE;VIADUR	6235712	JUN 13, 2017			
>ADD>	021226 001	LOPINAVIR;KALETRA	6284767	FEB 14, 2016	U-401		
			6232333	NOV 07, 2017			
>ADD>	021251 001	LOPINAVIR;KALETRA	6284767	FEB 14, 2016	U-401		
	020386 001	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	020386 002	LOSARTAN POTASSIUM;COZAAR	5608075	MAR 04, 2014			
	019643 002	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 003	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	019643 004	LOVASTATIN;MEVACOR	4231938	JUN 15, 2001		I-250	MAR 11, 2002
			4231938*PED	DEC 15, 2001		PED	SEP 11, 2002
	075671 001	MEGESTROL ACETATE;MEGESTROL ACETATE				PC	JAN 12, 2002
	020357 001	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 002	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 003	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 004	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	020357 005	METFORMIN HYDROCHLORIDE;GLUCOPHAGE				M-6	APR 19, 2004
	021121 001	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 002	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372		
	021121 003	METHYLPHENIDATE HYDROCHLORIDE;CONCERTA	4783337	SEP 16, 2003	U-372	NP	AUG 01, 2003
	019962 001	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 002	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 22, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 003	METOPROLOL SUCCINATE;TOPROL-XL	4927640	MAY 27, 2007		I-194	FEB 05, 2004
			5246714	SEP 21, 2010			
	019962 004	METOPROLOL SUCCINATE;TOPROL-XL	4957745	SEP 18, 2007	U-107	NS	FEB 05, 2004
			5001161	MAR 19, 2008	U-107	I-194	FEB 05, 2004
			5081154	JAN 14, 2009	U-107		
			4927640	MAY 22, 2007			
			5246714	SEP 21, 2010			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021308 001	MICONAZOLE NITRATE;MONISTAT 1 COMBINATI	6153635	NOV 28, 2020			
			5514698	MAR 21, 2014			
>ADD>	019436 001	MILRINONE LACTATE;PRIMACOR	4313951	NOV 26, 2001			
>ADD>			4313951*PED	MAY 26, 2002			
>ADD>	020343 001	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
>ADD>			4313951*PED	MAY 26, 2002			
>ADD>	020343 002	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
>ADD>			4313951*PED	MAY 26, 2002			
>ADD>	020343 003	MILRINONE LACTATE;PRIMACOR IN DEXTROSE	4313951	NOV 26, 2001			
>ADD>			4313951*PED	MAY 26, 2002			
	021208 001	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 002	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	021208 003	MIRTAZAPINE;REMERON SOLTAB	5178878	JAN 12, 2010		NCE	JUN 14, 2001
	019297 001	MITOXANTRONE HYDROCHLORIDE;NOVANTRONE	4617319	JUN 13, 2005	U-390	I-324	OCT 13, 2003
	020829 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 001	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	020830 002	MONTELUKAST SODIUM;SINGULAIR	5565473	FEB 03, 2012	U-228		
	021085 001	MOXIFLOXACIN HYDROCHLORIDE;AVELOX				I-329	APR 27, 2004
>ADD>	075179 001	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
>ADD>	075189 001	NABUMETONE;NABUMETONE				PC	FEB 16, 2002
>ADD>	075189 002	NABUMETONE;NABUMETONE				PC	FEB 23, 2002
>ADD>	019583 001	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
>ADD>			4420639*PED	JUN 13, 2003			
>ADD>	019583 002	NABUMETONE;RELAFEN	4420639	DEC 13, 2002			
>ADD>			4420639*PED	JUN 13, 2003			
	021204 001	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	021204 002	NATEGLINIDE;STARLIX	RE34878	MAR 28, 2006			
			5463116	OCT 21, 2012			
			5488150	JAN 30, 2013			
	020920 001	NESIRITIDE;NATRECOR	5114923	MAY 19, 2009		NCE	AUG 10, 2006
			5674710	OCT 07, 2014			
	020165 004	NICOTINE;NICODERM CQ	6165497	JUN 14, 2008	U-388		
			5633008	JUN 14, 2008	U-389		
	020165 005	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		
	020165 006	NICOTINE;NICODERM CQ	5633008	JUN 14, 2008	U-389		
			6165497	JUN 14, 2008	U-388		
	075269 001	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
	075269 002	NIFEDIPINE;NIFEDIPINE				PC	JUN 05, 2001
>ADD>	019667 001	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
>ADD>	019667 002	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
>ADD>	019667 003	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>	019667 004	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
>ADD>	019667 005	OCTREOTIDE ACETATE;SANDOSTATIN	5753618	JUL 08, 2008			
	021008 001	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 002	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	021008 003	OCTREOTIDE ACETATE;SANDOSTATIN LAR	5753618	JUL 08, 2008			
	020799 001	OFLOXACIN;FLOXIN	5401741	MAR 27, 2012			
	020592 001	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 002	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 003	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 004	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	020592 005	OLANZAPINE;ZYPREXA	5229382	APR 23, 2011	U-149	NCE	SEP 30, 2001
			5605897	FEB 25, 2014	U-176		
			6251985	SEP 23, 2017			
	020592 006	OLANZAPINE;ZYPREXA	6251895	SEP 23, 2017			
	021086 001	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 002	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 003	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
	021086 004	OLANZAPINE;ZYPREXA ZYDIS	6020487	SEP 23, 2017			
			6251895	SEP 23, 2017			
>ADD>	020688 001	OLOPATADINE HYDROCHLORIDE;PATANOL	5641805	JUN 06, 2015	U-184		
	019810 001	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
	019810 002	OMEPRAZOLE;PRILOSEC	6150380	NOV 10, 2018		PED	DEC 29, 2001
			6147103	OCT 09, 2018			
			6166213	OCT 09, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014			
			5629305*PED	AUG 04, 2014	U-166		
			6147103*PED	APR 09, 2019	U-188		
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019810 003	OMEPRAZOLE;PRILOSEC	6191148*PED	APR 09, 2019			
			4508905	APR 02, 2002			
			6150380	NOV 10, 2018		I-229	JUN 29, 2001
			6147103	OCT 09, 2018		PED	DEC 29, 2001
			6166213	NOV 10, 2018			
			6191148	OCT 09, 2018			
			4255431*PED	OCT 05, 2001	U-108		
			4636499*PED	JAN 30, 2006			
			4786505*PED	OCT 20, 2007	U-108		
			4853230*PED	OCT 20, 2007	U-108		
			5093342*PED	AUG 02, 2010	U-166		
			5599794*PED	AUG 04, 2014	U-166		
			5629305*PED	AUG 04, 2014	U-188		
			6147103*PED	APR 09, 2019			
			6150380*PED	MAY 10, 2019			
			6166213*PED	APR 09, 2018			
			6191148*PED	APR 09, 2019			
	021246 001	OSELTAMIVIR PHOSPHATE;TAMIFLU	4508905	APR 02, 2002			
			5763483	DEC 27, 2016	U-376	I-317	NOV 17, 2003
	020897 001	OXYBUTYNIN CHLORIDE;DITROPAN XL	5866601	FEB 02, 2016		NDF	DEC 14, 2003
	020897 002	OXYBUTYNIN CHLORIDE;DITROPAN XL	5952375	FEB 02, 2016		NCE	OCT 27, 2004
			6124355	MAY 22, 2015	U-378		
			6262115	MAY 22, 2015	U-393		
	020897 003	OXYBUTYNIN CHLORIDE;DITROPAN XL	6124355	MAY 22, 2015	U-378		
			6262115	MAY 22, 2015	U-393		
	020553 004	OXYCODONE HYDROCHLORIDE;OXYCONTIN	6124355	MAY 22, 2015	U-378		
			6262115	MAY 22, 2015	U-393		
			4861598	AUG 29, 2006			
			4970075	NOV 13, 2007			
			5266331	FEB 05, 2008			
	020553 005	OXYCODONE HYDROCHLORIDE;OXYCONTIN	5549912	FEB 05, 2008			
			4861598	AUG 29, 2006			
			4970075	NOV 13, 2007			
			5266331	FEB 05, 2008			
			5549912	FEB 05, 2008			
			5508042	APR 16, 2013			
			5656295	FEB 05, 2008			
			6096331	FEB 22, 2013			
>ADD>	020262 001	PACLITAXEL;TAXOL	6150398	MAY 08, 2011	U-380		
						D-68	AUG 20, 2004
	020036 001	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
	020036 003	PAMIDRONATE DISODIUM;AREDIA				D-68	AUG 20, 2004
	020036 004	PAMIDRONATE DISODIUM;AREDIA				I-330	JUN 12, 2004
	020987 001	PANTOPRAZOLE SODIUM;PROTONIX	4758579	JUL 19, 2005		NDF	MAR 22, 2004
	020988 001	PANTOPRAZOLE SODIUM;PROTONIX IV				NCE	FEB 02, 2005

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020031 001	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 002	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 003	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 004	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020031 005	PAROXETINE HYDROCHLORIDE;PAXIL				I-326	APR 13, 2004
	020936 003	PAROXETINE HYDROCHLORIDE;PAXIL CR	4721723	DEC 29, 2006			
			4839177	JUN 13, 2006			
			5422123	JUN 06, 2012			
			5789449	JAN 06, 2009	U-286		
			5872132	MAY 19, 2015			
			5900423	MAY 19, 2015			
			6063927	APR 23, 2019			
			6080759	MAY 19, 2015			
			6121291	MAR 17, 2017	U-286		
			6133289	MAY 19, 2015	U-286		
			6172233	JAN 15, 2018			
>ADD>	021064 001	PERFLUTREN;DEFINITY	5527521	APR 05, 2011		NCE	JUL 31, 2006
>ADD>			5547656	APR 05, 2011			
>ADD>			5769080	JUL 20, 2010			
	020667 005	PRAMIPEXOLE DIHYDROCHLORIDE;MIRAPEX	4886812	MAR 25, 2011			
	019627 002	PROPOFOL;DIPRIVAN				I-322	FEB 20, 2004
	020973 002	RABEPRAZOLE SODIUM;ACIPHEX	5045552	SEP 03, 2008	U-385		
			5035899	APR 04, 2009	U-385		
	020815 001	RALOXIFENE HYDROCHLORIDE;EVISTA	4418068	APR 03, 2002			
	019901 001	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 002	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 003	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	019901 004	RAMIPRIL;ALTACE	5061722	OCT 19, 2008			
	020741 001	REPAGLINIDE;PRANDIN	6143769	MAR 24, 2009			
	020741 002	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
	020741 003	REPAGLINIDE;PRANDIN	6143769	MAR 14, 2009			
>ADD>	020903 001	RIBAVIRIN;REBETOL	6063772*PED	JUL 23, 2016	U-375	PED	JUN 09, 2002
			5767097	JAN 23, 2016	U-235	PED	DEC 03, 2001
			5914128	DEC 22, 2017			
			6051252	DEC 22, 2017			
			6063772	JAN 23, 2016	U-375		
			6172046*PED	MAR 21, 2018	U-377		
			6172046	SEP 21, 2017	U-377		
			5767097*PED	JUL 23, 2016	U-235		
			5914128*PED	JUN 22, 2018			
			6051252*PED	JUN 22, 2018			
>ADD>	018859 001	RIBAVIRIN;VIRAZOLE	6150337	NOV 21, 2017	U-400		
	020945 001	RITONAVIR;NORVIR	6232333	NOV 07, 2017			
	021042 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
			6239173	JUN 24, 2013			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	021042 002	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
			5691374	NOV 25, 2017			
	021042 003	ROFECOXIB;VIOXX	6239173	JUN 24, 2013			
			6239173	JUN 24, 2013			
	021052 001	ROFECOXIB;VIOXX	5474995	JUN 24, 2013	U-266		
	021052 002	ROFECOXIB;VIOXX	5691374	NOV 25, 2017			
	020692 001	SALMETEROL XINAFOATE;SEREVENT	6239173	JUN 24, 2013			
>ADD>	020828 001	SAQUINAVIR;FORTOVASE	6239173	JUN 24, 2013			
	019839 001	SERTRALINE HYDROCHLORIDE;ZOLOFT	5290815	MAR 01, 2011	U-386		
	019839 002	SERTRALINE HYDROCHLORIDE;ZOLOFT	5196438	NOV 19, 2010			
	019839 005	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
	020990 001	SERTRALINE HYDROCHLORIDE;ZOLOFT				M-11	AUG 06, 2004
	020632 001	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				M-11	AUG 06, 2004
						M-11	AUG 06, 2004
	020632 002	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
						M-9	FEB 16, 2004
	020632 003	SIBUTRAMINE HYDROCHLORIDE;MERIDIA				D-65	FEB 16, 2004
						M-9	FEB 16, 2004
	020280 006	SOMATROPIN RECOMBINANT;GENOTROPIN				D-65	FEB 16, 2004
	020280 007	SOMATROPIN RECOMBINANT;GENOTROPIN				M-9	FEB 16, 2004
	020280 001	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
	020280 002	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
	020280 003	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
	020280 004	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
	020280 005	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
	020280 008	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
	020280 009	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
	020280 010	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT	6152897	JUN 11, 2018		I-334	JUL 25, 2004
	020280 011	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
	020280 012	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
	020280 013	SOMATROPIN RECOMBINANT;GENOTROPIN PRESERVAT				I-334	JUL 25, 2004
	021151 001	SOTALOL HYDROCHLORIDE;BETAPACE AF				I-334	JUL 25, 2004
						NP	FEB 22, 2003
	021151 002	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
						NP	FEB 22, 2003
	021151 003	SOTALOL HYDROCHLORIDE;BETAPACE AF				PED	AUG 22, 2003
						NP	FEB 22, 2003
	020412 001	STAVUDINE;ZERIT				PED	AUG 22, 2003
			4978655	JUN 24, 2008	U-94		
	020412 002	STAVUDINE;ZERIT	4978655*PED	DEC 24, 2008	U-94		
			4978655	JUN 24, 2008	U-94		
	020412 003	STAVUDINE;ZERIT	4978655*PED	DEC 24, 2008	U-94		
			4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020412 004	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008	U-94		
	020412 005	STAVUDINE;ZERIT	4978655	JUN 24, 2008	U-94		
			4978655*PED	DEC 24, 2008	U-94		
>ADD>	019964 001	TERCONAZOLE;TERAZOL 3	4358449	NOV 09, 2001			
	020898 001	THYROTROPIN ALFA;THYROGEN	5674711	AUG 31, 2010			
			5602006	FEB 11, 2014			
			5658760	AUG 19, 2014			
			5240832	AUG 31, 2010			
			6114144	NOV 24, 2015			
			5840566	NOV 24, 2015			
	020330 001	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
	020330 002	TIMOLOL MALEATE;TIMOPTIC-XE	4861760	SEP 25, 2006			
>ADD>	020505 001	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
>ADD>						I-335	AUG 28, 2004
>ADD>	020505 002	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
>ADD>						I-335	AUG 28, 2004
>ADD>	020505 003	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
>ADD>						I-335	AUG 28, 2004
>ADD>	020505 004	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
>ADD>						I-335	AUG 28, 2004
>ADD>	020505 005	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
>ADD>						I-335	AUG 28, 2004
>ADD>	020505 006	TOPIRAMATE;TOPAMAX				ODE	AUG 28, 2008
>ADD>						I-335	AUG 28, 2004
>ADD>	020844 001	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
>ADD>						I-335	AUG 28, 2004
>ADD>	020844 002	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
>ADD>						I-335	AUG 28, 2004
>ADD>	020844 003	TOPIRAMATE;TOPAMAX SPRINKLE				ODE	AUG 28, 2008
>ADD>						I-335	AUG 28, 2004
	020528 001	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020528 002	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020528 003	TRANDOLAPRIL;MAVIK	4933361	JUN 12, 2007			
	020591 001	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 002	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 003	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	020591 004	TRANDOLAPRIL;TARKA	5721244	FEB 24, 2015			
	021257 001	TRAVOPROST;TRAVATAN	6011062	DEC 22, 2014	U-382	NCE	MAR 16, 2006
			5631287	DEC 22, 2014	U-382		
			5849792	DEC 22, 2014	U-383		
			5889052	AUG 03, 2013	U-383		
			6235781	JUN 15, 2019	U-382		

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	019963 001	TRETINOIN;RENOVA					
	021108 001	TRETINOIN;RENOVA	RE36068	JUL 29, 2003	U-131		
			RE36068	JUL 29, 2003	U-131		
	020475 001	TRETINOIN;RETIN-A MICRO	4603146	JUL 29, 2003	U-131		
	020468 001	TRIAMCINOLONE ACETONIDE;NASACORT AQ	5955109	SEP 21, 2016	U-134		
>ADD>	021288 001	TRIPTORELIN PAMOATE;TRELSTAR	6143329	JUL 03, 2016			
>ADD>			5225205	JUL 20, 2010		NP	JUN 29, 2004
	020715 001	TRIPTORELIN PAMOATE;TRELSTAR DEPOT	5192741	MAR 09, 2010		NCE	JUN 15, 2005
	020759 001	TROVAFLOXACIN MESYLATE;TROVAN	5776885	JUL 07, 2015			
	020759 002	TROVAFLOXACIN MESYLATE;TROVAN	6187341	JAN 20, 2019			
	020550 001	VALACYCLOVIR HYDROCHLORIDE;VALTREX	6187341	JAN 20, 2019			
	020550 002	VALACYCLOVIR HYDROCHLORIDE;VALTREX				D-67	JUN 25, 2004
	021304 001	VALGANCICLOVIR HYDROCHLORIDE;VALCYTE				D-67	JUN 25, 2004
>ADD>	021283 001	VALSARTAN;DIOVAN	6083953	JUL 28, 2014	U-384	NE	MAR 29, 2004
>ADD>	021283 002	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
>ADD>	021283 003	VALSARTAN;DIOVAN	5399578	MAR 21, 2012		NCE	DEC 23, 2001
>ADD>	020151 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5399578	MAR 21, 2012		NCE	DEC 23, 2001
>ADD>			6274171	MAR 20, 2017		I-325	MAY 02, 2004
>ADD>	020151 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5916923	JUN 28, 2013	U-398		
>ADD>			6274171	MAR 20, 2017		I-325	MAY 02, 2004
>ADD>	020151 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5916923	JUN 28, 2013			
>ADD>			6274171	MAR 20, 2017		I-325	MAY 02, 2004
>ADD>	020151 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5916923	JUN 28, 2013	U-398		
>ADD>			6274171	MAR 20, 2017		I-325	MAY 02, 2004
>ADD>	020151 005	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5916923	JUN 28, 2013	U-398		
>ADD>			6274171	MAR 20, 2017		I-325	MAY 02, 2004
>ADD>	020151 006	VENLAFAXINE HYDROCHLORIDE;EFFEXOR	5916923	JUN 28, 2013	U-398		
>ADD>			6274171	MAR 20, 2017		I-325	MAY 02, 2004
>ADD>	020699 001	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	5916923	JUN 28, 2013	U-398		
>ADD>			6274171	MAR 20, 2017		I-325	MAY 02, 2004
>ADD>	020699 002	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	5916923	JUN 28, 2013	U-398		
>ADD>			6274171	MAR 20, 2017		I-325	MAY 02, 2004
>ADD>	020699 003	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	5916923	JUN 28, 2013	U-398		
>ADD>			6274171	MAR 20, 2017		I-325	MAY 02, 2004
>ADD>	020699 004	VENLAFAXINE HYDROCHLORIDE;EFFEXOR XR	5916923	JUN 28, 2013	U-398		
>ADD>			6274171	MAR 20, 2017		I-325	MAY 02, 2004
>ADD>	021119 001	VERTEPORFIN;VISUDYNE	5916923	JUN 28, 2013	U-398		
	020547 001	ZAFIRLUKAST;ACCOLATE				I-325	MAY 02, 2004
	020547 003	ZAFIRLUKAST;ACCOLATE				I-336	AUG 22, 2004
	020859 001	ZALEPLON;SONATA				I-328	SEP 17, 2002
	020859 002	ZALEPLON;SONATA				I-328	SEP 17, 2002
	020825 001	ZIPRASIDONE HYDROCHLORIDE;GEODON				M-8	FEB 22, 2004
			4831031	MAR 02, 2007		M-8	FEB 22, 2004
	020825 002	ZIPRASIDONE HYDROCHLORIDE;GEODON	5312925	SEP 01, 2012		NCE	FEB 05, 2006
			4831031	MAR 02, 2007			
			5312925	SEP 01, 2012		NCE	FEB 05, 2006

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA
*PED and PED represent Pediatric Exclusivity

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT/PED EXCL EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	020825 003	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
	020825 004	ZIPRASIDONE HYDROCHLORIDE;GEODON	4831031	MAR 02, 2007		NCE	FEB 05, 2006
			5312925	SEP 01, 2012			
	021223 001	ZOLEDRONIC ACID;ZOMETA				NCE	AUG 20, 2006
						ODE	AUG 20, 2008
>ADD>	021231 001	ZOLMITRIPTAN;ZOMIG-ZMT				NDF	FEB 13, 2004

PATENT AND EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE PATENT AND EXCLUSIVITY COLUMNS, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 21ST EDITION FOR A FULL LISTING OF PATENT AND EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). THE CUMULATIVE SUPPLEMENT WILL LIST NEW CODES ADDED SINCE THE LAST ANNUAL EDITION.

ABBREVIATIONS

REFERENCES

NEW DOSING SCHEDULE

D-47	PREVENTION OF HEARTBURN SYMPTOMS WHEN ADMINISTERED FROM 15 MINUTES UP TO, BUT NOT INCLUDING, 1 HOUR PRIOR TO A PROVOCATIVE MEAL
D-65	CHANGE DOSING AND ADMINISTRATION TO INDICATE MAINTENANCE OF WEIGHT LOSS OVER AN 18 MONTH PERIOD THUS EXTENDING THE USE OF THIS DRUG FROM ONE TO TWO YEARS
D-66	DOSING RECOMMENDATIONS FOR PATIENTS UNDERGOING PCI
D-67	SHORTER TREATMENT COURSE OF THREE DAYS IN THE TREATMENT OF RECURRENT EPISODES OF GENITAL HERPES
D-68	CHANGE OF ADMIN RATE FOR INFUSION OF AREDIA FOR TREATMENT OF MODERATE AND SEVERE HYPERCALCEMIA OF MALIGNANCY FROM 24 HOURS TO 2 HOURS UP TO BUT NOT INCLUDING 24 HOURS

NEW INDICATION

I-321	JUVENILE RHEUMATOID ARTHRITIS
I-322	USE OF DIPRIVAN IN PATIENTS 3 MONTHS TO 16 YEARS
I-323	COLORECTAL CANCER
I-324	REDUCING NEUROLOGIC DISABILITY AND/OR FREQUENCY OF CLINICAL RELAPSES IN PATIENTS WITH SECONDARY (CHRONIC) PROGRESSIVE, PROGRESSIVE RELAPSING, OR WORSENING RELAPSING-REMITTING MULTIPLE SCLEROSIS
I-325	PREVENTION OF RELAPSE AND RECURRENCE OF DEPRESSION
I-326	GENERALIZED ANXIETY DISORDER
I-327	SYMPTOMATIC RELIEF OF RHINOORRHEA ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS IN PATIENTS 5 YEARS AND OLDER
I-328	PROPHYLAXIS AND CHRONIC TREATMENT OF ASTHMA IN PATIENTS 5-6 YEARS OF AGE
I-329	UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS
I-330	MAINTENANCE OF HEALING OF EROSIVE ESOPHAGITIS AND CONTROL OF DAYTIME AND NIGHTTIME HEARTBURN SYSTOMS IN PATIENTS WITH GERD
I-331	TREATMENT OF MODERATE ACNE VULGARIS
I-332	EMPIRIC THERAPY IN FEBRILE NEUTROPENIC PATIENTS WITH SUSPECTED FUNGAL INFECTIONS (ETFN)
I-333	TOPICAL TREATMENT OF TINEA (PITYRIASIS) VERSICOLOR DUE TO MALASSEZIA FURFUR (FORMERLY PITYROSPORUM ORBICULARE)
I-334	LONG-TERM TREATMENT OF GROWTH FAILURE IN CHILDREN BORN SMALL FOR GESTATIONAL AGE WHO FAIL TO MANIFEST CATCH-UP GROWTH BY TWO YEARS OF AGE
I-335	ADJUNCTIVE THERAPY IN PATIENTS TWO YEARS AND OLDER WITH SEIZURES ASSOCIATED WITH LENNOX-GASTAUT SYNDROME
I-336	EXPANSION OF INDICATION TO INCLUDE THE TREATMENT OF PATIENTS WITH PREDOMINATELY CLASSIC SUBFOVEAL CHOROIDAL NEOVASCULARIZATION DUE TO PATHOLOGIC MYOPIA OR PRESUMED OCULAR HISTOPLASMOSIS

PATENT AND EXCLUSIVITY TERMS

REFERENCES

MISCELLANEOUS EXCLUSIVITY CODES

M-6	ADDITIONAL INFORMATION REGARDING CLINICAL STUDIES DONE WITH GLUOPHAGE/GLYBURIDE COMBINATION ADDED TO CLIN PHARM AND DOSING AND ADMIN
M-7	CLINICAL PHARMACOLOGY IN PEDIATRIC PATIENTS; DOSAGE AND ADMINISTRATION INFORMATION
M-8	ADDITIONAL INFORMATION FOR THE USE OF SONATA CAPSULES FOR UP TO 5 WEEKS (35 NIGHTS) OF TREATMENT IN A CONTROLLED TRIAL SETTING
M-9	ADDITION TO THE CLINICAL STUDIES SECTION OF THE LABELING OF TEXT AND TWO TABLES CONTAINING INFORMATION FOR THE PRESCRIBING PHYSICIAN ON BLOOD PRESSURE, HEART RATE, AND HEART RATE VARIABILITY
M-10	INFORMATION REGARDING MAINTENANCE OF AN ANTIDEPRESSANT EFFECT UP TO 1 YEAR OF DOSING
M-11	USE FOR LONG-TERM TREATMENT OF POSTTRAUMATIC STRESS DISORDER

PATENT USE CODES

U-267	PREVENTING HEARTBURN EPISODES FOLLOWING INGESTION OF HEARTBURN-INDUCING FOOD/BEVERAGE, COMPRISING ADMIN TO PT, 30 MIN PRIOR TO CONSUMPTION BY THE PT THE FOOD/BEVERAGE, A COMPOSITION COMPRISING 10MG FAMOTIDINE
U-372	METHOD FOR ADMINISTERING A BENEFICIAL DRUG TO THE GI TRACT OF AN ANIMAL, WHICH METHOD COMPRISES ADMITTING AN OSMOTIC DEVICE ORALLY INTO THE ANIMAL...
U-373	GENERAL USE CLAIM SUBMITTED FOR 12 NEXIUM PATIENTS STATING "PERTINENT TO THE CAPSULE FORMULATION FOR NEXIUM AND ITS INDICATIONS FOR THE TREATMENT OFGERD AND ERADICATION OF H.PYLORI TO REDUCE THE RISK OF DUODENAL ULCER RECURRENCE
U-374	KIT ADAPTED AND DESIGNED TO PROVIDE BOTH DATA ON THE CURRENT REPRODUCTIVE STATUS OF A PATIENT AND CONTRACEPTION FOR THOSE WHO ARE NOT PREGNANT, BUT RECENTLY ENGAGED IN UNPROTECTED SEX
U-375	METHOD OF USING RIBAVIRIN FOR TREATING A DISEASE RESPONSIVE TO RIBAVIRIN, E.G. HEPATITIS C
U-376	TREATMENT OF INFLUENZA
U-377	METHOD OF TREATING PT WITH CHRONIC HEPATITIS C HAVING HCV GENOTYPE 1 AND VIRAL LOAD GREATER THAN 2 MILLION COPIES/ML TO ERADICATE DETECTABLE HCV-RNA BY ADMIN COMBINATION OF RIBAVIRIN AND INTERFERON ALFA-2B FOR A LEAST 24 WEEKS
U-378	METHOD FOR TREATING INCONTINENCE
U-379	METHOD OF TREATING ONYCHROMYCOSIS
U-380	COMBINATIONS OF TAXOL (PACLITAXEL) AND CISPLATIN WHICH ARE SUITABLE FOR THE TREATMENT OF OVARIAN AND NON-SMALL CELL LUNG CARCINOMAS
U-381	TREATMENT OF HYPERPHOSPHATEMIA
U-382	METHOD OF STABLIZING PROSTAGLANDIN
U-383	METHOD FOR TREATING GLAUCOMA AND OCULAR HYPERTENSION
U-384	TREATMENT OF CMV RETINITIS
U-385	TREATMENT OF PEPTIC ULCERS
U-386	TREATMENT OF PATIENTS SUFFERING FROM A LATE ASTHMATIC REACTION OR LATE PHASE ASTHMA
U-387	TREATMENT OF PATIENTS WITH RESPIRATORY DISORDERS
U-388	SMOKING CESSATION AID APPLIED TO THE SKIN
U-389	SMOKING CESSATION AID APPLIED TO THE SKIN ON WAKING AND REMOVED PRIOR TO SLEEP AFTER ABOUT 16 HOURS
U-390	METHOD OF USING THE DRUG TO TREAT NEUROIMMUNOLOGIC DISEASES (INCLUDING MULTIPLE SCLEROSIS)
U-391	USE OF CASODEX IN COMBINATION WITH LHRH AGONISTS FOR THE TREATMENT OF PROSTATE CANCER
U-392	TREATMENT OF PATIENTS FOR INFLAMMATION
U-393	MANAGEMENT OF INCONTINENCE, MGT OF HORMONE REPLACEMENT THERAPY, TREATMENT OF INVOLUNTARY INCONTINENCE, MGT OVERACTIVE BLADDER AND INCREASING COMPLIANCE IN SUCH PT
U-394	METHOD OF USE OF ALPHAGAN
U-395	METHOD OF USE OF ALPHAGAN P
U-396	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION
U-397	METHOD OF TREATING PEOPLE SUFFERING FROM DEPRESSION WITHOUT AN INCREASE IN NAUSEA
U-398	TREATMENT OF GENERALIZED ANXIETY DISORDER

PATENT AND EXCLUSIVITY TERMS

REFERENCES

PATENT USE CODES

U-399	IN-THE-EYE USE OF CHLORINE DIOXIDE CONTAINING COMPOSITIONS
U-400	USE OF RIBAVIRIN TO INCREASE TYPE 1 CYTOKINE RESPONSE AND SUPPRESS TYPE 2 CYTOKINE RESP0NSE TO LYMPHOCYTES, INCLUDING METHODS THAT TAKE ADVANTAGE OF SUCH MODULATION TO TREAT INFECTIONS AND INFESTATIONS
U-401	USE OF LOPINAVIR IN COMBINATION WITH REVERSE TRANSCRIPTASE INHIBITORS FOR TREATING HIV INFECTION AND IN COMBO WITH OTHER HIV PROTEASE INHIBITORS
U-402	TREATMENT OF ACTINIC KERATOSES
U-403	ANTI-ALLERGIC FOR VARIOUS ALLERGIC DISEASES
U-404	TREATMENT OF ALLERGIC CONJUNCTIVITIS
U-405	METHOD OF USE OF LOTRONEX

*U.S. Government Printing Office: 2001 — 491-214/40002

New 21st Edition



APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

21ST EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 8367

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** enter my subscription as follows:

_ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $101.00 per year.

The total cost of my order is $_____. Price includes regular shipping and handling and is subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐-☐

☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

_____
Company or personal name

_____
Additional address/attention line

_____
Street address

_____
City, State, ZIP Code

(____)_____
Daytime phone including area code

_____
Purchase Order No. (optional)

_____
(Credit card expiration date)

Thank you for your order!

_____
(Authorizing Signature)

(10/00)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2250.
To charge your subscription call (202) 512-1800.

Approved drug products with therapeutic equivalence